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Abstract
The development of pulmonary delivery is an attractive prospect for biologically active 
peptides and proteins, which are generally delivered invasively by injection. The large 
surface area for absorption and relatively low metabolic activity of the respiratory tract 
renders the lung as a potential target for local and systemic delivery of such agents.
There is no standard method currently available to assess drug release from the novel 
area of controlled release powders for inhalation. Thus, an attempt was made to address 
this issue by the development of an in vitro testing method that may be used to assess 
drug release profiles of such systems. The twin stage impinger (TSI; Apparatus A, BP 
1998) was modified to enable the development of a suitable piece of apparatus for 
routine use. Stage 1 and stage 2 of the TSI were modified individually and tested. The 
modified stage 1 TSI apparatus was found capable of distinguishing between release 
rates from controlled release particles greater than 6.4 /xm in size, and the modified 
stage 2 TSI apparatus from those less than 5 /xm.
This study investigated the utilisation of spray drying technology to manufacture 
particles for inhalation delivery. As there has been limited research to date in the area 
of controlled release pulmonary delivery of biotherapeutics, the preparation of protein 
inhalation powders and those potentially capable of affording controlled release were of 
particular interest. To this end, the potential of processing model gel-forming 
excipients, with known capacity to afford controlled release, by spray drying was 
investigated. Initial investigations were performed using salbutamol as a model drug. 
In the latter part of the study, insulin powders were prepared by spray drying from 
aqueous suspension and by co-spray drying with model excipients; these powders were 
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Inhalation therapy has been used for many hundreds of years, yet only recently has it 
received full recognition of its potential as a route of administration of 
pharmacologically active agents. The most common use of inhaled drugs for local 
actions is in the treatment of reversible airways obstruction, particularly in asthma. 
However, inhalation therapy has many other applications, for example, to achieve local 
anaesthesia before bronchoscopy, or to deliver antimicrobial drugs to infected 
bronchioles or alveoli. The lung, with its large surface area for absorption, is also a 
potential target for delivery of locally and systemically active nucleic acids, proteins 
and peptides. Several limitations are associated with the delivery of such agents, 
however, including low membrane permeability, poor stability, relatively short half- 
lives and potential safety issues (Smith, 1997).
Due to their poor oral bioavailability, injection is the normal mode of delivery of 
proteins and peptides (Johnson, 1997), often resulting in a lack of compliance as 
patients do not look forward to the pain and inconvenience of injections, particularly 
when required repeatedly for the treatment of chronic disease (Patton, 1997). 
Alternative delivery approaches are needed, the developments of which are currently 
being pursued by many pharmaceutical companies, in particular to enhance patient 
compliance and increase the benefits obtained from these drugs.
The potential for nasal delivery of macromolecules has been subject of recent research. 
However, although this route offers many advantages over the oral route, most polar 
molecules have a low bioavailability when administered to the nasal cavity (Davis, 
1998). Co-administration of ‘penetration enhancers’ is usually required to achieve 
reasonable bioavailabilities, however, they may have toxicity issues and often cause 
damage to the nasal epithelium (Mackay et al., 1994).
The development of pulmonary delivery is an attractive prospect for new protein drugs; 
especially since many large-molecule agents are naturally absorbed from the lung, 
relatively well (Smith, 1997; Niven, 1995; Patton, 1996) without the need of penetration
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enhancers (Johnson, 1997). The respiratory tract has a large surface area that can be 
exposed to the biotherapeutic drug almost simultaneously if administered via inhalation; 
there is relatively less metabolic activity, and it also has a large blood supply which 
avoids direct exposure to liver enzymes (Smith, 1997). Also, locally acting therapeutic 
aerosols for respiratory diseases will usually require smaller doses, as they reach the site 
of action directly, reducing the incidence of unwanted side effects (Johnson, 1997).
Advances in genetic engineering and biotechnology have allowed the commercial 
production of proteins for pharmaceutical purposes. Some examples of recombinant 
biological products used as therapeutic agents are deoxyribonuclease (DNase) for cystic 
fibrosis (Cramer and Bosso, 1996; Liberti et al., 1994; Shack et al., 1990); 
erythropoietin for kidney disease and anaemia (Goodnough et al., 1997); human growth 
hormone for hypopituitary dwarfism (Shao and Mitra, 1996); insulin for diabetes 
(Saffran et al., 1997; Sato et al, 1983); a-Interferon for hairy cell leukaemia and AIDS- 
related Kaposi’s sarcoma (Cirelli and Tyring, 1995); and tissue plasminogen activator 
for acute myocardial infarction (Holmes et al., 1997).
While aerosols have many advantages for the delivery of biotherapeutics, consistently 
depositing a high percentage of the dose in the alveolar region is a significant 
pharmaceutical and technological challenge. There is, to date, only one approved 
biotherapeutic agent for administration to the lungs (recombinant DNase) for achieving 
a local effect of liquefying viscous mucus in patients with cystic fibrosis, and there are 
no biotherapeutics approved for systemic delivery via the pulmonary route of 
administration.
The following sections review some of the important factors governing the formulation 
and development of proteins and peptides for pulmonary delivery. The potential for 
controlled release pulmonary delivery is also considered, together with the in vitro 
evaluation of dry powder inhalation systems.
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1.2 Considerations in the Development of Bio therapeutics
for Pulmonary Delivery
Smith (1997) has described various factors of which an understanding is required in 
order to achieve successful development of pulmonary delivery of biotherapeutics:
• absorption barriers posed by the respiratory tract
• approaches for evaluating pulmonary delivery, and potential limitations of these
• formulation development, with regard to the inherent instability of these agents
• development of device design to improve device reproducibility and efficiency, 
thereby optimising absorption
These factors will briefly be considered individually, with particular emphasis on the 
relevance to peptide and protein drug delivery by inhalation.
1.2.1 Barriers to Absorption
Efficient delivery of biotherapeutics to the respiratory tract requires that a number of 
barriers must first be overcome. These include the geometry of the airways, lung 
morphology, and the clearance mechanisms normally present in the respiratory tract 
(Smith, 1997).
1.2.1.1 Distribution in the Airways
In addition to patient factors such as breath-holding, dead space volume and vital 
capacity, the size of inhaled particles (aerodynamic diameter), size distribution, particle 
shape and density are important parameters governing subsequent deposition in the 
airways (Gupta and Hickey, 1991). Electrostatic forces, particle size growth due to 
hygroscopicity and drug concentration may also affect deposition (Vidgren, 1994).
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The deposition of aerosolised drug in the lung involves inertial impaction, 
sedimentation and diffusion processes. Particles greater than 8 /xm will largely be 
deposited in the oropharynx and the bifurcations between the large central airways 
(Smith, 1997). Inhaled particles of a certain momentum will not change direction when 
they encounter a bend in the airway, resulting in impaction on the airway wall 
(Livingstone and Livingstone, 1988); particles in the size range of about 5 /im are 
thought to be critically affected by this process (Gupta and Hickey, 1991). Inertial 
impaction of particles is of less importance in the lower airways as the continual 
divisions of the bronchial tree reduce the velocity of the air stream (Livingstone and 
Livingstone, 1988). Particles of less than 3 /xm in diameter are generally deposited in 
the lower airways and alveolar region by sedimentation (Smith, 1997), and much 
smaller particles of 0.5 /xm diameters or less are subject to Brownian motion - they may 
be exhaled, or deposited by diffusion (Gupta and Hickey, 1991; Smith, 1997).
For optimal deep alveolar deposition (as is targeted for the systemic delivery of 
biotherapeutic agents), the aerosol cloud should enter the patient’s mouth during a slow, 
deep breath (Gonda, 1994; Patton et al., 1999). Slow inspiration can reduce impaction 
in the oropharynx, while breath-holding after each inspiration allows time for particles 
(< 0.5 /xm) to deposit by diffusion and sedimentation rather than being exhaled.
1.2.1.2 Morphology of the Airways and Natural Clearance Mechanisms
A number of dynamic barriers must also be overcome before a biotherapeutic drug can 
be absorbed from the airways into the blood stream. These barriers have been described 
in detail in a review by Patton (1996), and will be outlined below:
Lung surfactant
This is a molecular monolayer that spreads at the air-water interface. It can cause 




This lies over the epithelium and acts as a reservoir for lung surfactant. As well as 
containing many of the components of plasma, it also contains mucous, which flows 
toward the mouth by the action of cilia beating. Mucociliary clearance within the 
tracheal-bronchial tree provides another barrier to the efficient delivery of 
biotherapeutics to the lung (Niven, 1995; Patton, 1997).
Pulmonary epithelium
Within the alveolar region (the site of absorption of biotherapeutics), the epithelial cells 
are probably the most significant barrier. Permeation across the alveolar epithelium is 
rate limiting, even the movement of injected solutes into the interstitium (the 
extracellular space inside tissues) being more rapid (Smith, 1997).
Interstitium and basement membrane
The role of these in macromolecule absorption is uncertain. The basement membrane is 
a tough, thin layer of interstitial fibrous material attached to epithelial and endothelial 
cells.
Vascular endothelium
This is the monolayer of cells that make up the walls of small blood and lymph vessels. 
The permeability of the vascular endothelium to macromolecules is variable depending 
on the type of blood vessel, but is greater than that of the epithelium.
Enzymes
Although peptidase activity is lower in the lung than in the gut (Hoover et al., 1992), the 
potential for degradation of biotherapeutics by peptidases and proteases that exist in the 
lung should be considered (Smith, 1997). Endogenous peptides (less than about 30 
amino acid chains) are susceptible to hydrolysis by peptidases, enzymes that are 
anchored to the plasma membranes of all cells. Endogenous proteins (more than about 
30 amino acid chains), however, are usually poor substrates for these peptidases. 
Proteins are hydrolysed by proteases, which are a more strictly defined class of 
enzymes, and their digestion usually only occurs in cells like macrophages; immune 
cells usually only release proteases into the lung fluids during infection and chronic
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inflammation. Bodily fluids (except for gastrointestinal fluids) contain protease 
inhibitors that inhibit the enzymatic breakdown of proteins (Patton et al., 1998).
1.2.2 Protein Instability
Unique difficulties in the purification, separation, formulation, storage and delivery of 
peptides and proteins are posed to the pharmaceutical industry, as a result of their 
complex chemical and physical properties. Protein degradation is likely to be the major 
obstruction encountered by formulators.
In order to maintain biological functions, protein molecules must be in their native state, 
that is, they must maintain their conformation. Normally, both physical and chemical 
reactions are involved in protein degradation by disturbing the physical and chemical 
forces that maintain their conformational stability (Chen, 1992). However because of 
their polymeric nature and ability to adopt some form of superstructure, proteins can 
undergo a variety of structural changes independent of chemical modification (Manning 
et al., 1989). Chemical degradation involves modification of the protein via covalent- 
bond formation or cleavage, resulting in a new chemical entity. This process is not 
usually reversible. In contrast, physical degradation is caused by changes in the non- 
covalent interactions, in which no change in the chemical nature of the protein occurs. 
These include denaturation, aggregation, precipitation, and adsorption to surfaces 
(Manning et al., 1989). Physical degradation may be reversible.
1.2.2.1 Physical Instability
The physical properties of a protein do not change continuously with respect to changes 
in environmental conditions, such as pH or temperature for example, instead they tend 
to be controlled by an ‘all-or-nothing’ law; that is, they exhibit little or no change until a 
point is reached where there is a dramatic change in physical properties, probably 
leading to a loss of biological function (Chen, 1992).
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Denaturation
Denaturation refers to loss of protein globular structure, that is disruption of tertiary and 
sometimes secondary structure. Protein denaturation may be reversible or irreversible 
(Wetzel et al., 1988), and can be caused by a variety of conditions including increase in 
temperature, decrease in temperature, extremes of pH, addition of solvents or other 
denaturants. If reversible denaturation occurs, the unfolded protein can reform back to 
its native state if the environment becomes favourable once more.
Surface Adsorption
An unfolded polypeptide chain can undergo further inactivation by association or 
adsorption with surfaces. Adhesion of proteins to surfaces is a well-known 
phenomenon that has been greatly studied with regard to the behaviour of insulin 
(Manning et al., 1989). This polypeptide adsorbs onto the surfaces of solution 
containers, to infusion devices (Sato et al., 1983), and to the inside of intravenous 
infusion bags (Manning et al., 1989). The addition of albumin to insulin solutions can 
counteract this adsorption (Brange and Langkkjcer, 1993), or alternatively, some of the 
insulin solution can be run through the tubing before beginning the infusion, as in 
practice, losses by adsorption are thought to be of little clinical importance (Sanson and 
Levine, 1989).
Aggregation and Precipitation
A partially unfolded intermediate may also be further inactivated by aggregation with 
other intermediates/ protein molecules, which can in turn lead to precipitation due to the 
formation of macroscopic ensembles of aggregates. Referring to insulin as an example 
once again, substantial shear rates can be developed during infusions that can influence 
insulin self-association and macromolecular aggregation (Sato et al., 1983). Such 
effects are obviously important considerations in the development of protein delivery 
systems, especially with nebulisers.
1.2.2.2 Chemical Instability
Conformational denaturation of proteins will usually accelerate the chemical reactions 
that affect proteins, resulting in inactivation or a change in activity of a protein. These
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reactions can involve hydrolysis, including both cleavage of peptide bonds as well as 
deamidation, and also oxidation, leading to disulfide bond formation and exchange. 
Other decomposition reactions include (3-elimination and racemization.
1.2.3 Formulation Development
There are many potential degradation pathways likely to be encountered in the 
manufacture of a protein formulation, involving changes in temperature, pH, salt, 
pressure, shear and interfaces (Chen, 1992). Possible mechanisms of protein 
denaturation, which may be induced during formulation development, are outlined 
below.
1.2.3.1 Thermal Denaturation
Changes in temperature, both increase and decrease alike, may result in conformational 
instability of proteins, although different degradation pathways are involved.
Heat Denaturation
Not only can high temperatures be encountered during manufacture, but also this is 
additionally important as high temperatures are used in accelerated stability studies, and 
could result in inactivation (reversible or irreversible). Multiple degradation pathways 
may take place in the heat-denatured protein (Gu et al., 1991).
Cold/Freeze Denaturation
Freezing, as encountered in formulation processes such as freeze-drying (Pikal, 1990), 
or if employed as a means of preservation of biologically active materials (Seguro et al.,
1990), may result in conformational changes occurring. This appears to be inevitable 
when dealing with low protein concentrations (Seguro et al., 1990). A concentration 
effect is observed during freezing; that is, local concentrations of all the solutes are very 
high when ice separates from the mixture, possibly being the causative factor (Chen, 
1992). Furthermore, pH changes, the degree of supercooling, and ice crystal formation
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may also influence freeze denaturation. Cryoprotection may be afforded by the 
inclusion of various additives; for example, some amino acids, polyalcohols such as 
glycerol, and some carbohydrates (Chen, 1992; Ford and Dawson, 1993; Prestrelski et 
a l, 1993). Stabilization is achieved by an exclusion effect. At low concentrations of 
the additive, the protein is preferentially hydrated by water molecules, and the more 
hydrophobic additive is excluded (Chen, 1992; Manning et al., 1989).
1.2.3.2 pH Denaturation
Proteins are most stable and least soluble at the pH of their isoelectric point (Chen, 
1992). With biotherapeutics, solubility is rarely a challenge as product concentration is 
very low. However, amino acid residues in the formulation may contribute to protein 
stability, therefore it is necessary to establish customary pH-rate profiles for protein 
drugs. Proteins will denature outside of their optimal pH range, leading to aggregation 
or chemical degradation. In a pharmaceutical formulation effects of pH on additives 
should also be considered.
1.2.3.3 Salt Denaturation
The term ‘salting-in’ refers to an increase in solubility, and generally salting-in ions 
enhance the stability of the native state of a protein. In contrast, ‘salting-out’ ions cause 
a decrease in solubility and subsequent denaturation. Solubility properties of proteins 
depend greatly upon the nature of the salt (Chen, 1992).
1.2.3.4 Pressure and Shear Denaturation
Shear denaturation is a function of both shear rate and exposure time. It may be 
observed during mixing, or may result from pushing protein through the tiny holes of a 
filter during sterile filtration or ultrafiltration (Chen, 1992). Application of pressure, for 
example to increase rate of filtration, is used in manufacturing processes. Extremely 
high pressure may cause protein denaturation, although this is also dependent on the
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rate of pressurization (Buchet et al., 1990). Thus, denaturation induced by high shear 
rate and pressure during filtration is unlikely if exposure time is short and only 
moderate pressure is used (Hsu et al., 1988; Pikal et al., 1991). Of greater concern is 
the loss of protein by surface denaturation at the air-liquid interface, created during the 
process of sterile filtration, for example (Hsu et al., 1988).
1.2.3.5 Surface Denaturation
This usually occurs at solid-liquid and air-liquid interfaces. Most likely sources of 
surface-induced denaturation (or, surface adsorption) of biotherapeutic agents are the 
container and the administration set-up (Sato et al., 1983), and the agitation that may 
occur during manufacture (Chen, 1992). In general, surface denaturation depends on 
the nature of protein-protein interactions, time, temperature, pH, and ionic strength of 
the medium (Chen, 1992).
1.2.4 Devices for Protein Delivery
There are many devices available for delivery of non-biological drugs that can be 
explored for the possibility of delivering proteinacious drugs to the lungs. These 
devices, and an indication of their potential use to deliver formulations containing 
biopharmaceuticals, are outlined below:
1.2.4.1 Nebulisers
One method of administering protein formulations to the lungs is to aerosolise the 
protein solution via a nebuliser to generate an inhalable aerosol, the method currently 
adopted for the administration of DNase (Cramer and Bosso, 1996; Shack et al., 1990) 
as well as many other non-biopharmaceuticals.
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Formulations for nebulisation require an external power source to generate an aerosol. 
Jet nebulisers use compressed gas while ultrasonic nebulisers use ultrasonic vibration to 
break the fluid up into droplets for aerosolisation. Ultrasonic nebulisers often have a 
higher output than jet nebulisers, but are generally more expensive (Livingstone and 
Livingstone, 1988).
Nebuliser drug delivery is cumbersome, inefficient, time-consuming and expensive, and 
the reproducibility of dosing is also poor (Patton and Platz, 1994). Thus, the 
development of biotherapeutic agents for nebulisation requires several important 
considerations, as have been described by Niven (1995). These include:
• protein stability after aerosolisation
• possibility of partial denaturation during nebulisation
• potency and therapeutic index
• output and particle size
• containment of the drug
• waste
• construction/materials
• nebuliser performance and intra-device variability
Since dosing solutions for nebulisers are packaged in sterile vials or sachets (unit-dose), 
the development of these as such should not differ greatly from that of any injectable 
formulation. However, problems are still likely to be encountered, which have also 
been described by Niven (1995):
• many proteins cannot be formulated in solution
• many proteins may not be stable to aerosolisation
• excipients may not be suitable, or not approved, for inhalation
• unit-dose requirements for inhalation may be very different from those used for
injections
• proteins may adhere to container walls during nebulisation and thus container
materials will need consideration, to minimise losses of the biotherapeutic drug
by adsorption
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The role of protectants for stabilization of proteins to nebulisation has been investigated. 
It has been shown that air-jet nebulisation induces the loss of enzymatic activity of 
lactate dehydrogenase (LDH) and human granulocyte-stimulating factor (G-CSF), but 
that the addition of polyethylene glycol (PEG) 1000 can have a marked stabilizing 
effect (Niven et al., 1994a). Tween 80 has also been shown to be effective in reducing 
the aggregation and degradation of G-CSF (Niven et al., 1996). In addition, the 
incorporation of biotherapeutic agents into liposomes has been demonstrated to 
suppress inactivation during nebulisation (Kanaoka et al., 1999).
Nonetheless, due to their inefficiency and size, nebulisers are unpopular for use in 
ambulatory care. Furthermore, they cannot be used readily in emergency situations 
(Gupta and Adjei, 1997). Thus there is still a need for the development of more efficient 
and convenient aerosol delivery devices for the administration of biotherapeutics.
1.2.4.2 Metered-Dose Inhalers (MDIs)
The main advantages of MDIs are that they are cheap to manufacture, easy to use (by 
patients with adequate co-ordination), compact and portable, and low inspiration flow 
rates achieve adequate deposition in the lung (O’Byrne, 1995). The drug contents are 
packaged under pressure, which allows them to be contained within a sealed, compact 
environment as a concentrated suspension or solution, from which metered doses can be 
dispensed.
The chlorofluorocarbon (CFC) propellants used in these types of devices are currently 
being subjected to legislation, aiming now to ban their use in MDIs after the year 2005 
(Elvecrog, 1997). CFCs are known to destroy the Earth’s protective ozone layer and as 
a result of the Montreal Protocol (an international treaty drawn up in 1987 by the United 
Nations Environment Program), the production of CFCs was banned from January 1996 
in the developed world, and from January 1995 in the European Union. Exceptions 
were made for few essential uses, such as in MDIs, which are allowed an annual 
exemption until a suitable alternative is available (Elvecrog, 1997). Individual 
companies are now developing their products using new propellants,
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hydrofluoroalkanes (HFAs), which are less damaging to the environment. However, 
HFAs contribute to global warming, and may require to be replaced in the future.
Thus, the future of the MDI would appear to be limited, although not only due to the use 
of CFC propellants. Other disadvantages of MDI drug delivery include:
• the relatively large size and high initial velocity of the delivered droplets leading 
to considerable drug loss in the oropharynx (Vidgren, 1994)
• the need for the patient to synchronise discharge from the device with 
inspiration (Ganderton and Kassem, 1992)
• the dimensions of the metering valve and the actuator orifice are such that the 
maximum amount of dose that can be delivered is relatively limited (Ganderton 
and Kassem, 1992)
The use of spacer devices (O’Byme, 1995), and breath-actuated MDIs can reduce some 
of these problems for established MDI formulations; however, if peptides and proteins 
were to be delivered to the lungs via MDIs, several formulation problems are likely to 
arise, in the first instance, as the dispersion and stabilization of proteinacious materials 
in a non-aqueous or co-solvent environment is complex (Niven, 1995). Technical 
challenges associated with the development of MDI formulations of peptides and 
proteins include (Gupta and Adjei, 1997):
• inter- and intramolecular reactivity
• charge
• aggregate formation
• destabilisation during product manufacture
Delivery via an MDI has been shown to be feasible with leuprolide acetate (Adjei and 
Garren, 1990), but the aerosol formulations used in this study were prepared with CFC 
propellants. More recently, it has been demonstrated that the structural integrity and 
activity of model proteins, lysozyme (Quinn et al., 1999), and deoxyribonuclease I 
(DNase I) (Oliver et al., 2000; Quinn et al., 2000) can be maintained in the newer HFA 
propellants. Nevertheless, the development of proteins for pulmonary delivery using 
MDIs is the most complex in terms of formulation development and, additionally,
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would not be suitable for the more expensive biotherapeutic agents due to the inherent 
inefficiency of the MDI (Niven, 1995).
1.2.4.3 Dry Powder Inhalers (DPIs)
The main advantages of DPIs are that they are portable, environmentally acceptable and 
are more user friendly than MDIs as they do not require co-ordination between 
actuation and inhalation by the patient (O’Byrne, 1995). Also, they can deliver much 
higher doses than MDIs (Broadhead et al., 1996).
There are many DPIs in use today whose performance, as characterized by emitted dose 
and repeatability, is highly variable (Niven, 1995). As a consequence of this and other 
factors such as the phasing out of CFCs, the increasing number of drugs being 
attempted via the inhalation route and the advances in plastics, there is much 
development in progress to improve on existing inhaler devices.
DPI formulations consist of micronised drug and very often a considerably coarser 
carrier material (usually lactose), to minimise the impact of inherent surface charge and 
poor flowability (Timsina et al., 1994). Powder formulations are packaged in unit-dose 
capsules, in blisters, or in a multi-dose reservoir. Marketed DPIs do not require 
epropellants but instead rely on the airflow from the patient’s inhalation to aerosolise 
the drug (Johnson, 1997). Although this aids in co-ordinating inhalation with aerosol 
generation, the respirable fraction attained is influenced by the airflow through the 
device (Clark and Hollingworth, 1993). Flow rate through a device is a function of 
device resistance, patient effort and pathophysiology of the patient’s respiratory tract 
(Clark and Hollingworth, 1993). Slow inhalation does not disperse the powder 
formulation adequately and thus can enhance upper airway deposition, whereas higher 
inspiratory flow rates achieve better deagglomeration of the powder (Newman et al.,
1991). However, increases in pressure drop across the device, as a result of higher flow 
rates, can reduce the respirable fraction of the powder as a result of impaction. Thus, 
DPI devices require optimisation whereby an adequate pressure drop is achieved that 
provides a good dispersion but yet limits impaction losses, in the device or in the 
oropharynx, during dosing (Adjei and Gupta, 1997).
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Many improvements in the operation of DPIs are required if to be developed for use 
with biotherapeutics. Improvements in performance may be achieved by consideration 
of the following criteria for DPIs, as described by Niven (1995):
• complete fluidisation and emission of total dose from device
• device-controlled dispersion and deaggregation of powder
• thorough deaggregation of powder
• ability to alter the packaged number of doses
• drug sealed from moisture
• easy-to-clean units
• compact size with few moving parts
• easy-to-use
Komada and co-workers (1994) have observed that the rate of transpulmonary 
absorption following intratracheal administration of model biotherapeutic agents 
(human chorionic gonadotrophin (HCG), follicle stimulating hormone (FSH), thyroid 
stimulating hormone (TSH) and insulin) was slower when given as a dry powder than as 
an aqueous solution. This was attributed to the fact that drug in a dry powder must first 
dissolve at the site before it can be absorbed. Bioavailabilities of the same agents after 
administration as neutral solutions were about twice the results obtained with the dry 
powder presentations. Aggregation of powder drug resulting in decreased dissolution 
was suggested as a possible reason for these reduced bioavailabilities. Niven and co­
workers (1994b) demonstrated, however, that dry powder aerosolised recombinant 
human granulocyte colony-stimulating factor (rhG-CSF) was well absorbed from the 
lung of rabbits and that the dissolution of the drug was not rate-limiting; bio availability 
of the powdered aerosol formulation was less than the intratracheal solution formulation 
control.
Such animal studies have their limitations, as bioavailabilities of peptides and proteins 
following pulmonary administration to different animals are not consistent (Farr and 
Taylor, 1997; Patton et al., 1999). In addition, the modes of administration that have 
been used to compare pulmonary delivery of powder and solution formulations are 
different, resulting in differences in bioavailabilities due to inefficient dosing of powder 
formulations after the insufflation via an endotracheal tube compared with the
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intratracheal instillation of solution formulations (Niven et al., 1994b). It is true that the 
efficiency of aerosol insulin, for example, is lower than subcutaneous injection due to 
losses of the hormone that do not occur with the latter method of administration. 
However, results from human pulmonary studies, using a novel inhaled dry powder 
insulin delivery system that has been developed by Inhale Therapeutic Systems (section 
1.2.4.4), indicate that inhaled insulin provides equivalent glucose control when directly 
compared to subcutaneous injection (Patton et al., 1999).
The use of a gelatin capsule as a dosage container for a proteinacious powder is not 
altogether feasible, as in these capsules moisture retention is quite high and, over time, 
the drug or the carrier may extract some of this moisture. This in turn can affect 
stability and/or dispersion and deaggregation properties of the powder (Niven, 1995).
Hiller and co-workers (1980) observed the increase in particle size at high RH to be 
relatively greater for droplet aerosols than for powder aerosols. Nevertheless, 
hygroscopicity associated with dry powders can also result in apparent particle size 
changes if they are exposed to humid environments (Jashnani et al., 1995). 
Hygroscopic substances absorb water vapour in the warm, humid environment of the 
respiratory tract during their passage through the airways; changes in size and density of 
hygroscopic aerosols following inhalation can result in differences in deposition sites of 
such particles compared to non-hygroscopic particles of identical pre-inspired physical 
features (Hickey and Martonen, 1993).
Deposition of spray dried p-galactosidase from a dry powder inhaler device has been 
investigated by Broadhead and co-workers (1996). In this study, the spray dried protein 
was found to be extremely sensitive to humidity; large reductions in respirable fraction 
in vitro were noted after storage at 43% RH. In this case, the presence of a non- 
hygroscopic carrier (mannitol) in the formulation had no effect on the moisture uptake 
of the spray dried protein. The effect of this moisture sorption on the stability of the 
protein formulation was not determined.
In vitro deposition characteristics of spray dried powders of recombinant human 
deoxyribonuclease (rhDNase) has been investigated (Chan et al., 1997). Pure spray
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dried rhDNase powders were found to be cohesive, and respirable fractions were greatly 
improved by co-spray drying rhDNase with suitable excipients, varying the protein- 
excipient compositions, and through the manufacture of physical blends consisting of 
fine particles of rhDNase with suitable coarse carriers.
Similarly, in vitro deposition of model protein particles, bovine serum albumin (BSA) 
particles co-spray dried with maltodextrin, has also been successfully demonstrated 
(Lucas et al., 1998). In this instance, fine particle excipients were used as performance 
modifiers; enhancement of performance was proposed to result from a redistribution of 
protein particles from coarse carrier particles to the fine particle component in the 
ternary mix, achieved by modification of the micromeritic properties of the carrier 
lactose. Louey and co-workers (2000) have recently confirmed this. Pre-formulation 
characterisation of powder micromeritic properties, that is, particle size, shape and 
morphology, relative humidity and electrostatic properties can provide a basis for 
designing more efficient DPI formulations, for use in any DPI device (Staniforth, 1996).
Dry powder formulations have advantages over liquid equivalents for proteins and 
peptides, as most are far more stable in a solid state than in a liquid state (Berressem, 
1999). In addition, this technology addresses the concerns associated with protein 
denaturation during nebulisation (Niven et al., 1994a). The development of protein 
powders for inhalation is described further in section 1.4.
1.2.4.4 Novel Aerosol Delivery Systems
Recent developments in aerosol delivery systems may in the future provide means for 
delivery of proteins and peptides. Examples include the Aerodose™ inhaler 
(Gopalakrishnan and Xia, 2000; Simon and Gopalakrishnan, 2000a; Simon and 
Gopalakrishnan, 2000b) and the HaloLfre™ (Denyer and Nikander, 1998) and AERx™ 
(Schuster et al., 1997; Schuster et al., 1998) delivery systems that are based on liquid 
drug delivery, and Inhale Therapeutic Systems’ new device, which is currently being 




This system contains a novel, battery-powered aerosol generator that is electronically 
controlled (Simon and Gopalakrishnan, 2000a). The core technology is the aerosol 
generator that atomises liquids to generate a slow velocity aerosol (Gopalakrishnan and 
Xia, 2000), enabling breath-actuated, controlled administration to targeted sites in the 
lungs (Simon and Gopalakrishnan, 2000a). Several delivery platforms have been 
created with the coupling of the aerosol generator to various liquid dispensing 
mechanisms. Those available include (a) the multi-dose inhaler -  a canister which 
allows discrete volumes to be dispensed, (b) the SLV -  a pre-filled single-dose cartridge 
and (c) the SLV Multi which allows the patient to dial-a-dose as required from the pre­
filled cartridge (Simon and Gopalakrishnan, 2000a).
Protein solutions, lipid dispersions and microsphere suspensions have all been 
aerosolised efficiently using the Aerodose™ inhaler (Simon and Gopalakrishnan, 
2000b).
HaloLite™ Aerosol Delivery System
This system uses adaptive aerosol delivery to target aerosol delivery during the first 
50% of each inhalation and continues to adapt throughout the treatment. The system 
reacts to the patient’s breathing pattern, and targets the aerosol delivery to maximise 
lung deposition by ensuring that aerosol is only delivered during the initial phase of the 
patient’s inhalation. It is a hand-held device that is operated by compressed air, which 
can deliver a precise, pre-set dose from a unit dose vial (Denyer and Nikander, 1998).
AERx™ Aerosol Delivery System
This system has been described as a mains powered system (Schuster et al., 1997) and 
as a battery-powered hand-held system (Schuster et al., 1998). It consists of a unit-dose 
disposable blister pack, aerosol generation hardware and electronics associated with 
breath actuation and compliance monitoring -  it visually guides the patient to inhale in 
the optimum range of inspiratory flow rates and the aerosol bolus is only delivered at a 
pre-programmed inspired volume, and in addition has a timer for assisting the patient 
with the breath-holding manoeuvre. A mechanical actuator forces the liquid dose in the 
blister container through a multi-orifice nozzle, thereby producing an aerosol.
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The AERx™ system has been shown to be highly suited and compatible for the delivery 
of gene-based biotherapeutics to the lung (Sorgi, et al., 1998). More recently, 
Mudumba and co-workers (2000) have reported the efficient aerosolisation of 
recombinant human deoxyribonuclease (rhDNase); two inhalations using the AERx™ 
system results in a delivered dose that is comparable to conventional nebulisation. The 
AERx™ has also been demonstrated as being more convenient and efficient than 
conventional nebulisers for the delivery of high dose drugs to the lung (Cipolla et al., 
2000).
Inhale Deep Pulmonary Drug Delivery System
This device is actuated independently of the force of the patient’s inhalation (Patton,
1997). The inhalation device supplies enough extra energy to break apart any powder 
agglomerates that may be present. Gripping or squeezing the handle primes the unit, 
which compresses air in the device. When the air is released, it travels through a centre 
channel at sonic velocity, collecting powdered drug on the way. A standing cloud of 
captured aerosolised particles is created in a holding chamber, ready for the patient to 
inhale and there is no requirement to co-ordinate triggering the device with inhalation. 
As drug is inhaled through the mouthpiece, it is followed by a large volume of air which 
pushes the drug down to the alveoli in the deep lung region (Berressem, 1999).
Many biotherapeutic agents are in human clinical trials using this delivery system with 
reproducibility of delivery to the bloodstream being equivalent to that of subcutaneous 
injection.
1.3 Controlled Release Pulmonary Drug Delivery
Sustaining the release of drugs in the lung, thereby prolonging drug action is an 
attractive prospect for many local and systemic therapies (Zeng et al., 1995a). 
Presently, many medications in aerosol form require inhalation at least three to four 
times a day because of the relatively short duration of subsequent clinical effects
20
(Byron, 1986). Controlled release of inhaled therapeutics has the potential to reduce the 
frequency of dosing and so increase patient compliance (Zeng et al., 1995a; Gonda, 
1988).
Many methods of producing potential pulmonary controlled release systems have been 
investigated. These include incorporating drugs into liposomes; the use of other 
biodegradable microspheres; the modification of chemical structure, for example by 
producing long-acting prodrugs or macromolecule conjugates; the production of 
sparingly soluble forms which will be absorbed more slowly, or by co-precipitating 
relatively insoluble materials with aqueous soluble drugs (Zeng et al., 1995a).
More recently, a number of new technologies have been developed. For example, 
unusually large and porous particles have been shown to provide an advantage as 
sustained release vehicles of inhaled therapeutics (Edwards et al., 1997; Edwards et al., 
1998; Vanbever et al., 1999). Sustained release pulmonary delivery has also been 
achieved using a new technique that involves the post application of dry-coatings 
(Talton et al., 2000), achieved by directing laser-induced high-energy pulses of 
ultraviolet light on to the polymer. Such particles have resulted in sustained dissolution 
following administration to rats, when compared to uncoated particles (Talton et al., 
2000).
There has been limited research to date in the area of controlled release pulmonary 
delivery of biotherapeutics. Those systems that may have potential in the formulation 
of such agents will be discussed.
1.3.1 Liposomes
Liposomes (drug-lipid vesicle systems) have been extensively investigated for 
controlled delivery of drugs to the lung (Colthorpe et al., 1992; Farr et al., 1985; Saari et 
al., 1999). Liposomes can be produced over a wide range of sizes and can incorporate 
both hydrophilic and hydrophobic drugs. In addition, they can be prepared from 
phospholipids that are endogenous to the lung as surfactants (Zeng et al., 1995a),
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minimising toxicity concerns. Residence time of encapsulated drug in the respiratory 
tract can be controlled by appropriate selection of the chain length and the degree of 
saturation of the phospholipid acyl groups, and also by the addition of other components 
like cholesterol (McCalden, 1990).
Liposomes have been used to stabilise protein drugs (Kanaoka et al., 1999), and have 
been shown to prolong pulmonary absorption of insulin in rats following intratracheal 
instillation (Lui et al., 1993). However, poor storage stability (Niven, 1992) and the 
possible detrimental effects encountered by liposomal formulations during nebulisation 
(Taylor et al., 1990), are major concerns in their development for pulmonary drug 
delivery.
1.3.2 Microspheres
A microsphere can be defined as a solid, spherical particle ranging from 1 -  1000 fim  in 
diameter (El-Baseir et al., 1997). They are porous, microparticulate drug delivery 
systems promoting the controlled release of drug, which is uniformly distributed 
throughout a polymeric matrix (Pavanetto et al., 1992). In recent years, work has been 
focused on the use of microspheres for inhalation delivery (of a suitable size for 
aerosolisation) and the use of biodegradable polymers have enabled controlled release 
formulations to be investigated.
Synthetic polymers and co-polymers such as poly(lactide and/or glycolide) (Conte et al., 
1994; Coombes et al., 1998; El-Baseir and Kellaway, 1998; El-Baseir et al., 1997; 
Evora et al., 1998), as well as natural polymers such as albumin (Haghpanah et al., 
1994; Zeng et al., 1995b) have been most widely used in the production of microspheres 
for potential sustained drug delivery to the lung. More recently, formulation of the 
therapeutic agent with a select group of lipophilic oligosaccharide ester derivative glass- 
formers has been described, as the novel SoliDose® technology (Blair et al., 2000). 
When polymeric microparticles are used as drug carriers, the extent and rate of release 
is influenced by factors such as the rate of biodegradation of the polymer, its
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wettability, surface area and related physicochemical parameters (Gupta and Hickey, 
1991).
Traditional methods for the preparation of microspheres utilise the techniques of 
emulsion formation followed by solvent evaporation or solvent extraction (Pavanetto et 
al., 1992). Techniques such as supercritical fluid precipitation (Falk et al., 1997), freeze 
drying (Sato, et al., 1988) and spray drying (Conte et al., 1994; Haghpanagh et al., 
1994; Pavanetto et al., 1992) have also been investigated for the preparation of 
microparticulate drug delivery systems. These methods are detailed in section 1.4.
In contrast to liposomes, microspheres may be more physico-chemically stable both in 
vitro and in vivo; thus drugs entrapped in biodegradable microspheres have a potentially 
slower release rate and a longer duration of action than those incorporated in liposomes 
(Zeng et al., 1995a).
1.3.3 Large Porous Particles
Edwards and co-workers (1997) have described a new type of inhalation aerosol that 
was characterised by porous particles of low mass density (< 0.4 g/cm3) and large size 
(> 5 /xm), for the delivery of inhaled biotherapeutics into the systemic circulation. 
Relatively large particles with high porosity are said to have the same aerodynamic 
diameter as smaller, nonporous particles. Since particle mass dictates where an aerosol 
is deposited in the lung, these large particles may be deposited in the alveolar region, 
resulting in increased systemic bioavailability of an inhaled drug due to the increased 
aerosolisation efficiency of such large and light particles. In addition, by virtue of their 
geometric size, relatively large particles may avoid phagocytic clearance from the lung 
until the therapeutic dose has been delivered.
Large porous particles of limited water solubility can be made as controlled release 
carriers using biodegradable polymers or nonpolymeric lipophlic materials by methods 
such as solvent evaporation and spray drying (Edwards et al., 1998), incorporating
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drugs for both local (Ben-Jebria et al., 1999; Hrkach et al., 2000) and systemic (Elbert, 
2000; Vanbever et al., 1999) delivery via the respiratory tract.
Dellamary and co-workers (2000) have described an alternative approach whereby 
hollow and porous powders, with potential application in both MDI and DPI 
formulations (Tarara et al., 2000), have been prepared. The PulmoSpheres™ 
technology involves a two-step manufacturing process: preparation of a submicron oil- 
in-water emulsion by high-pressure homogenisation, which is combined with an 
aqueous phase containing the active agent and then spray dried. During the spray 
drying step, the oil phase in the emulsion droplets serves as a ‘blowing agent’ or 
‘inflation agent’; this retards shrinkage of the droplets and, at the same time, creates 
pores in the particle surface (Tarara et al., 2000).
1.4 Manufacture of Protein Powder Formulations for
Inhalation
The development of a proteinacious powder for inhalation requires the transformation 
of the protein from a liquid to a solid, usually involving several process steps in 
between that need to be successfully completed. Apart from stability, the physical 
properties of the final powder should be appropriate for inhalation; thus, the methods 
used to reach this final stage are important, in that they will determine the resultant 
characteristics of the powder. Figure 1.1 illustrates possible steps involved in 
translating a protein solution into a stable powder formulation suitable for inhalation.
1.4.1 Milling
Micronisation of coarse powders for inhalation can be carried out in ball mills, colloid 
mills, hammer mills and jet or fluid-energy mills, with the majority being prepared with 
a jet mill (Johnson, 1997).
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Salt buffers/sugars may be 
used to provide tonicity 
Surfactants may be used to 
stabilize the protein
May be necessary to adjust prior to drying since the final 
formulated protein concentration is usually relatively low
May be necessary to remove excipients previously 
added to bulk formulation prior to drying
Materials suited to 
a particular drying 
process may be 
needed
Not widely used in the 
pharmaceutical industry 
Avoids ‘freezing’ stage, 
unlike lyophilisation 
Minimises time of existence
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required for inhalation drying cyc e^
Figure 1.1 Possible steps involved in translating a protein solution into a stable powder formulation suitable for inhalation 
(adapted from Niven, 1995).
Size reduction in a jet mill is achieved as a result of particle collision and attrition. 
Unmilled particles are introduced into the jet mill by, and suspended in, a turbulent gas 
stream moving at a very high velocity in a spherical or elliptical path. The gas stream is 
usually compressed air but inert gases such a nitrogen, superheated steam and liquid 
nitrogen might also be used (Phillips et al., 1998). Particles fracture into smaller ones 
as a result of inter-particle collisions in the gas stream. Larger particles are propelled to 
the periphery of the mill, for further size reduction, by the centrifugal force in the 
milling chamber while fine particles exit near the mill’s centre with the gas stream 
(Johnson, 1997; Phillips et al., 1998).
Although a number of proteins have been milled successfully for subsequent 
formulation as powders for inhalation delivery (Phillips et al., 1998), there are a number 
of drawbacks with this method of particle size reduction. Milling requires two stages of 
operations to prepare fine particles of a drug that is in solution; that is, a drying stage, 
followed by jet milling (Johnson, 1997). This is both time-consuming, and introduces a 
larger scope for degradation or denaturation of biotherapeutics to occur. Also, the heat 
generated during inter-particle collisions can cause changes in the solid state of the 
material and surface charging (York and Hanna, 1996), and chemical decomposition of 
heat-sensitive molecules has been observed (Johnson, 1997). The collection efficiency 
of jet milling is also often questioned, especially since proteins and peptides are 
generally expensive pharmaceutical ingredients.
1.4.2 Supercritical Fluid Precipitation
A supercritical fluid is one whose temperature and pressure are both above the critical 
point; that is, the temperature and pressure where the gas and liquid phases have the 
same density and the fluid appears as a single phase. In the supercritical region, the 
fluid exhibits very high rates of change with respect to temperature and pressure; small 
changes can result in large changes in solvent power. Supercritical fluids have liquid­
like densities with very high compressibilities, allowing solvent power to be 
manipulated and controlled with the use of pressure (Debenedetti et al., 1993; Sacchetti 
and Van Oort, 1996). The most common uses of supercritical fluids in the generation of
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particles are as a solvent (rapid expansion of supercritical fluid solutions) or as an 
antisolvent (gas antisolvent precipitation, or supercritical antisolvent precipitation).
1.4.2.1 Rapid Expansion of Supercritical Solutions (RESS)
With this technique, the solute is dissolved in the supercritical fluid. Particles are 
formed as a result of the rapid expansion of the fluid, causing the solvent to flash off 
and the solute to precipitate (Sacchetti and Van Oort, 1996). RESS can produce fine 
particles in a single processing-step, avoiding the use of liquid organic solvents, 
surfactants, and heat (when low critical temperature solvents are used) (Debenedetti et 
al., 1993). However, processing is dependent on finding an appropriate solvent system 
in which the compound of interest is soluble; the supercritical fluid must also be 
nonreactive with the solute, and the apparatus must be able to withstand the high 
pressures and temperatures that may be used (Sacchetti and Van Oort, 1996). Other 
disadvantages of RESS are low product yields as a result of the low solubility of many 
drugs, and difficulty in collecting the product (York and Hanna, 1996).
1.4.2.2 Supercritical Antisolvent (SAS) Techniques
Here, a supercritical fluid is used as an antisolvent to cause the precipitation of solids. 
More commonly, the antisolvent is added to a solution of the compound of interest thus 
causing it to precipitate, or alternatively, the solution is added to the antisolvent in order 
to precipitate the compound (Sacchetti and Van Oort, 1996). The supercritical fluid is 
required to have a low solvent power with respect to the solid, but should be miscible 
with the liquid (Debenedetti et al., 1993).
SAS is useful for processing of solids that are difficult to solubilise in supercritical 
fluids, or are sensitive to mechanical handling, as are many peptides and proteins 
(Debenedetti et al., 1993; Yeo et al., 1993). Organic protein solutions have been 
sprayed into supercritical carbon dioxide, resulting in precipitation of dry, 
microparticulate protein powders of 1-5 jLtm (Winters et al., 1996; Yeo et al., 1993). 
Changes in secondary structure, which were protein-specific, were observed in the
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protein precipitate samples; upon reconstitution, however, minimal loss of biological 
activity was exhibited indicating that conformal changes occurring as a result of the 
SAS precipitation technique were reversible upon reconstitution.
Limitations of SAS arise due to the solubility of the supercritical fluid into the drug 
solution (York and Hanna, 1996); the partitioning of drugs into the external carbon 
dioxide phase has caused problems of low drug loading of microspheres (Bodmeier et 
a l, 1995; Falk et al., 1997). Problems are also encountered with product and solvent 
recovery each time the apparatus is depressurised (York and Hanna, 1996).
1.4.3 Freeze Drying
Freeze drying (lyophilisation) is a process in which the solvent, usually water, is first 
frozen and then removed by sublimation in a vacuum environment. An aqueous 
solution of the protein is frozen, the ice is removed by sublimation at low pressure 
during ‘primary drying’, and then most of the unfrozen water is removed from the 
amorphous protein phase during ‘secondary drying’ (Pikal, 1990).
Proteins often present unique stability problems, the main one being potential 
conformational instability during the freeze drying process. In addition, aggregation 
during the process often leads to insoluble protein, and degradation may occur during 
storage of the dried product. Problems with stability can be improved upon by varying 
the formulation, for example, the addition of excipients (Franks, 1997). Such excipients 
may also improve the stability of the dried product and provide mechanical strength and 
‘body’, as biologically active materials are usually only present at very low 
concentrations.
Carbohydrate additives such as lactose and trehalose have been shown to protect model 
proteins during freeze-drying (Ford and Dawson, 1993; Prestrelski et al., 1993). Sugars 
turn glassy as they dry, pulling the protein into a stable state (Fox, 1995) and thus 
maintaining its activity. Sugar solutions stay liquid well below their expected freezing 
point unlike pure water. Rapid cooling causes tiny ice crystals to be formed, which
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results in an increase in the proportion of sugar to water in the solution. As it cools 
further, a thick syrup is created in which molecular motion is greatly slowed. 
Eventually, the syrup forms a hard, amorphous glass that can keep proteins, peptides 
and other drugs in a state of suspended animation (Crystall, 1997). Human serum 
albumin has also been successfully used to afford protection during the freeze drying 
process (Ford and Allahiary, 1993).
After freeze drying, a single manufacturing stage of milling usually remains in order to 
produce particles of inhalable size (Niven, 1995). However, this micronisation stage 
may also pose problems as the nature of the container materials, the quality of the gas 
and its moisture content may all influence stability; problems associated with jet milling 
have been previously discussed in section 1.4.1.
1.4.4 Spray Drying
Spray drying is a one-step process where a liquid (solution or suspension) can be 
transformed directly into particles of an appropriate size for inhalation. By definition, it 
is the transformation of feed from a fluid state into a dried particulate form by spraying 
the feed into a hot drying medium (Masters, 1985).
Spray drying has a wide range of applications, being commonly used to process milk, 
eggs, coffee, ceramics, fertilizers and several chemicals. The applications of spray 
drying in the pharmaceutical industry include long established uses such as the 
production of excipients, or as an alternative to wet granulation for tablet formulations 
that cannot be directly compressed; formulation techniques such as complexation and 
microencapsulation can be accomplished in a single step in a spray dryer (Broadhead et 
al., 1992). In addition, some more novel pharmaceutical applications of spray drying 
are currently under investigation, including that of dry powder aerosol formulations, 
with particular interest in the spray drying of enzymes and pharmaceutical proteins.
Spray dried powders are often hollow particles of a narrow size distribution. Particles 
are not, however, always spherical and they may have convoluted surfaces, asperities,
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holes and voids (Masters, 1985). The powder will normally have a low particle density 
due to the hollow nature of the particles. Properties such as appearance, particle size and 
size distribution, bulk density, particle density, porosity, moisture content, flowability, 
stability and retention of activity can be altered and controlled by modifying the spray 
drying process. The end product should ideally be active and stable, and with physical 
characteristics that promote dispersion and deaggregation of particles. These factors are 
influenced by the atomisation, heating and drying steps occurring during spray drying. 
As the effects of each step on the final product are difficult to predict, development has 
largely been based on a trial and error approach (Niven, 1995).
Advantages of spray drying over freeze drying include a shorter processing time, low 
energy input and relatively low cost of capital equipment (Mathias et al., 1991). 
Furthermore, spray drying offers the possibility for a continuous operation, co-spray 
drying with excipients and has the capability for aseptic production (Foster and 
Leatherman, 1995). Disadvantages of the spray drying process are exposure of labile 
drugs to high temperatures and the shear stress encountered as a result of spraying 
through a nozzle, low product yields, undesirably high residual moisture levels and 
variation obtained when changing process conditions and equipment (Foster and 
Leatherman, 1995).
1.4.4.1 Preparation of Controlled Release Powders
Synthetic and natural polymers, as mentioned previously, can be co-spray dried with 
drug to produce potential controlled release particles for pulmonary delivery.
The structure of the microparticles obtained by spray drying is dependent on whether 
the drug is dispersed or dissolved in the polymeric solution to be spray dried (Conte et 
al., 1994). When drug is spray dried from suspension in a solution of the polymeric 
coating, microcapsules (reservoir structure) are obtained, whereas if a solution of drug 
and polymer is spray dried, microspheres are obtained, represented by polymeric 
matrices in which the drug is embedded. Dissolution profiles of micro spheres prepared 
by spray drying have been shown to promote a more gradual release than those prepared 
by traditional methods (Pavanetto et al., 1992), in addition to higher drug entrapment
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efficiency and a shorter processing time for preparation of microspheres by spray drying 
(Haghpanah et al., 1994; Pavanetto et al., 1992).
1.4.4.2 Preparation of Proteinacious Powders
Spray drying is a logical choice for the development of biotherapeutic powders for 
inhalation. It is a one-step process where the liquid protein solution can be transformed 
directly into particles of an appropriate size for inhalation, usually with no further 
modification being required. Despite the high temperatures of the drying air, spray 
drying can be used to prepare powder from heat-sensitive materials as the cooling effect 
caused by rapid solvent evaporation means that the temperature of the dried product 
does not rise above its wet bulb temperature and remains relatively low (Broadhead et 
al., 1992; Masters, 1985). Dried powder is removed rapidly from the drying zone and 
thus protected from overheating, and the final product is separated from the air stream 
by cyclones or filters (Johnson, 1997).
Activity losses can be reduced or minimized by incorporating additives, such as sugars 
and salts, as protectants/stabilizers. Researchers have used their experience in freeze 
drying to assist in the selection of potential stabilizers (Broadhead et al., 1992). The 
effectiveness of different stabilizers, in terms of their ability to preserve enzymatic 
activity during the spray drying process, and in some cases also during long-term 
storage, have been studied using different models. For example, mannitol, sucrose, 
arginine hydrochloride and trehalose have all been shown to have a stabilizing effect 
when spray dried with P-galactosidase (Broadhead et al., 1994). Loss of alkaline 
phosphatase activity has been reported to be prevented when the enzyme was spray 
dried along with lactose, trehalose and sucrose, but not with mannitol, in a study 
looking at spray drying and electrostatic precipitation of different protein-sugar 
solutions (Naini et al., 1996).
Although thermal degradation can be avoided, some biotherapeutics may encounter 
degradation during the atomisation process. High shear rates required by the 
atomisation process can denature proteins (Johnson, 1997). Insoluble aggregates may
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also be formed by surface-induced denaturation of proteins at the air-liquid interface 
during atomisation (Maa and Hsu, 1997), the extent of which appears to be protein- 
specific (Mumenthaler et al., 1994). These effects can be reduced or prevented by the 
presence of a surfactant in the formulation, in which instance it has been postulated that 
the surface concentration of protein may be reduced due to surfactant adsorbing 
preferentially at the air-liquid interface of the spray droplets (Millqvist-Fureby et al., 
1999). The addition of a known stabiliser for a particular protein can also minimise 
protein degradation at the air-liquid interface; for example, zinc ions can stabilise 
recombinant human growth hormone by forming a dimer complex that can resist the 
formation of soluble protein aggregates (Maa et al., 1998b).
1.5 Characterisation of Dry Powder Aerosol Performance
Pulmonary deposition and clearance of drug delivery systems can be assessed by 
looking at in vivo performance, which may, for example, involve studying the pattern of 
deposition and clearance of radiolabelled particles from the lungs of healthy human 
volunteers using gamma-scintigraphy (Farr et al., 1985; Newman and Wilding, 1998).
Animal studies with rats and guinea pigs have been used to assess in vivo performance 
(Edwards et al., 1998). Larger animal species such as dogs and monkeys are potentially 
more useful as animal models to assess efficacy and safety of inhaled biotherapeutics, as 
they are relatively similar to humans physiologically and their biological responses are 
generally predictive of those that would be observed in humans (Wolff et al., 2000). 
However, such in vivo studies are expensive, and time-consuming (Zeng et al., 1995a), 
and significant differences in distribution profiles are likely as a consequence of the 
differences in size and aerodynamic properties of human airways compared to those of 
small animal models (Zeng et al., 1995a).
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1.5.1 In Vitro Evaluation of Inhalation Aerosols
There has recently been a global interest with respect to the harmonisation of inhaler 
testing (Ganderton and Byron, 1996) and compendial specifications for inhaled drugs 
(Byron, 1998). In vitro tests are of particular significance in the development process of 
products for pulmonary delivery as pharmacokinetic, pharmacodynamic and clinical 
assessments are imprecise because circulating blood levels are too low for straight 
forward analysis (Ganderton and Byron, 1996), thus there is a tendency to extrapolate in 
vitro data to lung deposition (Hickey and Dunbar, 1997). The most crucial in vitro 
comparators for inhaled products are considered to be the delivered dose and the 
aerodynamic size distribution (Byron, 1998), the standards and methods of assessment 
of which are set out in the major pharmacopoeias.
The current BP (1998) and EP (1996) advocate the use of any one of four specified 
methods for the aerodynamic assessment of fine particles. These include the single 
stage (Metal Impinger, Apparatus B), twin stage (Glass Impinger, Apparatus A), and 
multistage (Multistage Liquid Impinger, Apparatus C and Multistage Cascade Impactor, 
Apparatus D) sizing methods. The current USP (1995) requires that the aerodynamic 
size distribution be determined using either Apparatus 1 (Multistage Cascade Impactor), 
Apparatus 2 or Apparatus 3 (referred to as Single Stage Impactors) - Apparatus C of the 
BP and EP is not included in the current USP, and there are considerable revisions of 
the existing procedures for aerosols being made for the next edition (Burnell et al.,
1998).
1.5.1.1 Cascade Impaction
This method of aerosol characterisation provides information on the aerodynamic 
particle size distribution by inertial differentiation of particles (Hickey and Dunbar,
1997). The relationship between mass and velocity is utilised: large particles with 
sufficient inertia are impacted on the upper stages and finer particles penetrate to the 
lower stages of the separator (Timsina et al., 1994). An increase in the velocity of the 
air stream, as it passes through the stages of the impactor, is achieved by successively
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decreasing the jet sizes at each stage (Milosovich, 1992). The mass of material 
deposited on each impaction plate can be determined by weighing the plates before and 
after sampling, or alternatively, the plates can be washed with a suitable solvent for 
subsequent determination of drug content (Milosovich, 1992), allowing the drug mass 
distribution as a function of the aerodynamic diameter to be calculated.
Of the impactors available for aerodynamic size determination of inhalation aerosols, 
none is ideal (Olsson et al., 1998), and consideration of parameters such as size range, 
flow range, inter-stage losses, particle re-entrainment, incidence of particle bounce and 
blow-off need to be taken in to account before a rational choice of impactor is made.
1.5.1.2 Impinger Methods
Liquid impingement methods size aerosols using a technique similar to impaction 
(Phillips et al., 1990). Multistage liquid impingers are similar to cascade impactors. 
The collection surfaces, on which the particles impact following aerosolisation, consist 
of wet sintered-glass plates and the liquid impinger (the penultimate stage) consists of a 
jet/nozzle, tangential to the surface of the solvent (Gonda, 1994), which traps the 
remaining drug.
Simple two-stage inertial separation devices that could be used to divide an aerosol into 
a coarse oropharyngeal fraction and a fine pulmonary fraction were developed for 
routine use as simpler, reproducible alternatives to the slow and laborious cascade 
impactors (Hallworth and Westmoreland, 1987; Atkins, 1992). Such methods do not 
provide size distributions, but are simple techniques that can be used for initial 
screening of devices and/or formulations (Hindle and Byron, 1996).
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1.5.2 Drug Release from Controlled Release Inhalation Aerosols
Despite the diversity of in vitro aerosol characterisation methods that exist, there is no 
standard method presently available to assess drug release from potential controlled 
release inhalation delivery systems.
In vitro deposition patterns of potential sustained release systems have been evaluated 
using the twin stage impinger (Farr et al, 1985; Zeng et al., 1995b), and the Anderson 
cascade impactor (Ben-Jebria et al., 1999; Sakagami, et al., 1998; Vanbever et al., 1998) 
but in vitro drug release studies to date are not satisfactory with respect to dry powder 
formulations. Studies have been performed using calorimetric procedures (Zeng et al., 
1995b), and by other methods that involve agitating a suspension of the drug and carrier 
in buffer, and centrifuging and sampling the supernatant at timed intervals (Farr et al., 
1985; Kawashima et al., 1999). Methods such as these cannot, however, be correlated 
with the mechanism of drug release following deposition of a controlled release dry 
powder in the lungs as the powder will typically be deaggregated, thus with probable 
differing release characteristics to the bulk formulation.
Drug release rates from metered dose inhaler (MDI) formulations have been assessed, 
where controlled release was achieved as a result of spontaneous liposome formation 
following actuation of the device (Dalby and Byron, 1988). In this study, a ‘dynamic 
dialysis’ testing apparatus was used, in which the liposomes were freely suspended after 
being collected in buffer following the actuation of the MDI into a vertically mounted 
evaporation chamber. This method also has drawbacks, in that the sampled dose is not 
representative of, say, the respirable fraction, but includes the complete dose discharged 
from the inhaler.
None of the methods described would enable drug release from a gel-forming polymer 
to be evaluated as a potential means of controlled release drug delivery to the lung.
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1.6 Aims of the Study
There is currently no approved dry powder formulation for pulmonary delivery of any 
biotherapeutic agent, mainly due to the difficulties with regard to the pharmaceutical 
development of such agents, as has been described.
Studies were initiated to first investigate the potential of spray drying methods to 
produce controlled release formulations of a non-biological drug (salbutamol was 
chosen due to ease and sensitivity of fluorescence assay of this established inhalation 
therapeutic) for delivery to the lungs using model gel-forming excipients, with the view 
to extend the use of this technology for the manufacture of protein particles, and 
subsequently to manufacture controlled release protein particles for pulmonary delivery.
In vitro evaluation of dry powder aerosols is an important part of their development 
process, yet there is no standard testing method presently available for the novel area of 
controlled release powders for inhalation, with respect to drug release rates. An attempt 
was made to address this issue by the development of an in vitro testing method that 
may be used to assess drug release profiles of such systems.
Gel-forming polymers have been investigated as controlled release carriers for 
parenteral formulations (Joshi et al., 1998) and for nasal drug delivery as an alternative 
to parenteral administration (Dohi et al., 1997; Dohi et al., 1998; Witschi and Mrsny,
1999). In the latter case, reduced mucociliary clearance of drugs due to the formation of 
a gel in situ has been suggested. The feasibility of employing such a gel-forming 
mechanism to achieve controlled release inhalation delivery was investigated as part of 
this study, by considering the effect of particle size on gel formation and subsequent 
release characteristics obtained in vitro following aerosolisation.
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CHAPTER 2
Materials and General Methods
2.1 Materials
2.1.1 Analytical Materials
Acetonitrile, cyclohexane and methanol were HPLC grade (Fisher Scientific Ltd., 
Loughborough, UK).
Lecithin (Epikuron 100P), Nonidet P-40 (NP-40), sodium dodecyl sulphate (SDS) and 
sodium hydroxide ConvoL® (approx. 7 moll'1 solution for dilution) were from BDH 
Laboratory Supplies (Poole, UK).
Acrylamide/bisacrylamide (30:0.8), Bio-Rad Protein Assay Dye Reagent Concentrate 
and 2-mercaptoethanol were from Bio-Rad Laboratories (Hemel Hempstead, UK).
Bovine serum albumin (BS A) was from Boehringer Mannheim (Lewes, UK).
P-Nitrophenyl phosphate (PNPP) was obtained as Calbiochem® disodium hexahydrate 
from Calbiochem-Novabiochem Corp. (La Jolla, CA, USA).
Bromophenol blue, glycine, sodium azide and Tris-HCl (Tris 
(hydroxymethyl)methylamine hydrochloride), were from Fisons Scientific Equipment 
(Loughborough, UK).
Glutamine, fetal bovine serum, Hank’s buffered saline solution (lOx), penicillin, RPMI 
1640 growth medium and streptomycin were from Gibco BRL (Life Technologies Inc., 
Scotland, UK).
Ammonium persulphate (APS), apoprotein, deuterium oxide, ethylenediamine tetra 
acetic acid (EDTA), glycerol, leupeptin, magnesium chloride, ovalbumin, pepstatin A, 
phenylmethylsulphonyl fluoride (PMSF), Ponceau S, potassium bromide, sodium 
chloride, sodium fluoride, sodium molybdate, sodium vanadate, soyabean trypsin 
inhibitor, N \ N \ N ’, N’-tetramethylethylenediamine (TEMED), Trizma® Base
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(Tris(hydroxymethyl)aminomethane) Electrophoresis Reagent and zinc chloride were 
from Sigma Chemical Company (Poole, UK).
All solutions, standards, and reagents were prepared using purified Milli-Q® Water 
(Compact Milli-Q® Water System, Millipore (UK) Ltd., Watford, UK) when working 
with proteins.
2.1.2 Model Drugs and Excipients
Model drugs used in the course of this study are listed in Table 2.1 and excipients are 
listed in Table 2.2.
Table 2.1
Details o f the Model Drugs Used in the Course o f this Study.
Supplier
Alkaline phosphatase, Sigma Chemical Company, Poole, UK.
LOT 75H7051, 43H7185
and 72H70351.
Insulin, from bovine pancreas (USP Sigma Chemical Company, Poole, UK.
grade), LOT 128H0485 and 88H1307.
Trypsin, Sigma Chemical Company, Poole, UK.
LOT 93H0698.




Details o f the Excipients Used in the Course o f this Study.
Supplier
Dextrose, Penwest Pharmaceuticals Company, Patterson,
LOT 980305.EXP. NY, USA.
Hetastarch, Geistlich Pharma, Chester, UK.
Batch R096JK3, R024LB2 and 61913.
Lactose, Meggle Crystalc 40, Meggle, Wasserburg,Germany.
Batch 196.
Locust bean gum, Penwest Pharmaceutical Company, Patterson,
LOT 97802.EXP. NY, USA.
Maltodextrins, Cerestar UK Ltd., Manchester, UK.
C*Pur 01908 (DE = 8-10),
C^Pur 01910 (DE = 14), and
C*Pur 01925 (DE = 22-25).
Mucin, Type II Crude, Sigma Chemical Company, Poole, UK.
from porcine stomach, LOT 48H0596.
Polyvinylpyrrolidones: I.S.P. Technologies Inc., New Jersey, USA
Plasdone C-15, Batch TX50527,
pyrogen-free excipient grade,
K-value = 16-18.
Plasdone C-30, Batch TX60111,
pyrogen-free excipient grade,
K-value = 29-32.
Plasdone K-29/32, Batch TX60125,
excipient grade, K-value = 29-32.
Plasdone K-90, Batch A60409,
excipient grade, K-value = 85-95.
Trehalose, Forum Products Ltd., Surrey, UK.
Batch 198.
Xanthan gum, Penwest Pharmaceuticals Company, Patterson,
LOT 97801.EXP and 970303.EXP. NY, USA.
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2.2 Spray Drying
Powders were manufactured using both a bench-scale spray dryer and a pilot-scale 
spray dryer, during the course of this study.
2.2.1 Bench-Scale Manufacture of Spray Dried Powders
The Buchi Mini Spray Dryer, Model B-191 (Buchi Labortechnik AG, Switzerland), was 
used for all bench-scale operations, as supplied with a standard 0.7 mm nozzle). The 
Mini Spray Dryer (Figure 2.1; hereafter referred to as a bench-scale spray dryer) 
operates on the principle of nozzle spraying in parallel flow, i.e. the sprayed product and 
the drying air both flow in the same direction. The feed is directed to the nozzle by 
means of a peristaltic pump. There are essentially 4 process stages:
1. Atomisation of feed into a spray. The feed concentrate and the atomising air are 
passed separately to the nozzle head. High air velocities are generated within the nozzle 
for effective feed contact, which breaks up the feed into a spray of fine droplets.
2. Spray-air contact (mixing and flow). The air stream is rotated within the nozzle and 
feed is contacted as the liquid emerges from the nozzle orifice (external mixing).
3. Drying of spray (moisture evaporation). As soon as the droplets of the spray come 
into contact with the drying air, evaporation takes place from the saturated vapour film 
at the droplet surface. The temperature at the droplet surface corresponds to the wet- 
bulb temperature of the drying air. Spray evaporation is rapid, takes a very short time, 
and the product temperature is low during the time that the bulk of the evaporation takes 
place. Particle temperature does not rise substantially; the drying air also cools rapidly 
and thus each particle is almost immediately in contact with much cooler air.
4. Separation of dried product from the air. The dried product remains suspended in 
the air and passes into the cyclone where it is separated from the air stream. The 










Aspirator --------  w ^ ______ |_ _ _  Product
Vessel
Figure 2.1 The Buchi Mini Spray Dryer, Model B-191. Controls: a) Main switch; 
b) Regulator and indicator for spray flow; c) Keyboard and display for pump; d) 
Keyboard and display for aspirator; e) Keyboard and display for heater; f) Digital 
indicator for inlet temperature (T in iet); g) Digital indicator for outlet temperature ( T outiet)-
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2.2.1.1 Spray Drying of Model Drugs
Salbutamol
For characterisation, salbutamol base was spray dried at an inlet temperature (Tiniet) of 
110°C and also at the maximum Tiniet of 220°C to induce decomposition, or, yellowing 
of the salbutamol (as was observed during pilot-scale spray drying, section 4.4). Spray 
conditions employed for both temperatures are detailed in Table 2.3. The spray dryer 
was allowed to equilibrate under the experimental conditions for 60 minutes (to attempt 
to reach thermal equilibration irrespective of operating conditions employed), with 
Milli-Q water, before spray drying of salbutamol was commenced.
Decomposed salbutamol was required for investigation as to whether or not the 
salbutamol in the powders that were produced in the pilot-scale spray dryer had indeed 
undergone a degree of decomposition (section 2.5.6). In order to collect any product at 
220°C, other spray conditions, namely the feed concentration and flow-rate, required to 
be changed from the conditions used to spray dry salbutamol at an Tiniet of 110°C.
Proteins
To investigate the effect of spray drying on model protein drugs at different 
temperatures, each was spray dried keeping all the spray conditions the same, with the 
exception of the Tiniet. The Tiniet is the temperature at which the feed solution enters the 
dryer; the outlet temperature (Toutiet) automatically adjusts and is dependent upon the 
settings of the Tiniet and other controls, the settings of which are shown in Table 2.4. 
Thus, as all other parameters were kept constant, an increase in Tiniet resulted in an 
increase in Toutiet-
Protein feed solutions were prepared in Milli-Q water, with slow-speed stirring using a 
Heidolph™ MR3000 magnetic stirrer (Heidolph™ Elecktro GmbH & Co. KG, 
Kelheim, Germany) if necessary to enable complete solubilisation. The feed 
concentrations spray dried were 3% (w/w) solutions of alkaline phosphatase (AP) and 
trypsin, and 1% (w/w) suspension of insulin, which is practically insoluble in water (BP,
1998). Both solutions, but not the suspension, were filtered under vacuum (Sartorious®
3.0 pm  cellulose nitrate filter, Sartorious GmbH, Germany), prior to spray drying. As 
before, the spray dryer was thermally equilibrated before drying was commenced.
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Table 2.3
Spray Conditions Employed for the Bench-Scale Spray Drying o f Salbutamol at Inlet
Temperatures o f 110°C and 220°C.
Tiniet’ 110°C 220°C
Toutiet:* 73°C 137°C
Airflow: 600 1/hr 6001/hr
Aspirator: 100% 100%
Feed flow rate (pump): 5 ml/min 10 ml/min
Feed concentration: 1% (w/w) 5% (w/w) (suspension)
*As recorded during the spray drying process.
Table 2.4
Spray Conditions Employed fo r  the Bench-Scale Spray Drying o f Model Proteins. 
Airflow: 6001/hr
Aspirator: 100%
Feed flow rate (pump): 5 ml/min
Feed concentration: 3% (w/w) AP and trypsin
1% (w/w) insulin (suspension)
Table 2.5
Spray Conditions Employed fo r  the Bench-Scale Spray Drying o f the Majority 
o f Excipients Used in the Course o f this Study.
Tiniet: 120°C
Toutiet:* 80 ± 2°C
Airflow: 6001/hr
Aspirator: 1 0 0 %
Feed flow rate (pump): 5 ml/min
Feed concentration: 1 % (w/w)
*As recorded during the spray drying process.
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2.2.1.2 Spray Drying of Excipients
Spray drying conditions were kept constant as much as possible in order to enable direct 
comparison of the resulting spray dried excipient properties. The spray dryer was 
allowed to equilibrate under the experimental conditions for 60 minutes, with Milli-Q 
water, before spray drying of each of the excipient solutions was commenced. For the 
majority of the excipients, a good product yield (42-69%) was obtained when spray 
dried under the conditions detailed in Table 2.5. Exceptions included lactose, trehalose, 
xanthan gum (XG) and locust bean gum (LBG). Product yield was determined on a 
weight basis in terms of the relative mass of powder collected from the product vessel 
(Figure 2.1) compared to the initial mass of powder that was spray dried.
Lactose and trehalose failed to produce any significant amount of spray dried product 
under the spray conditions detailed in Table 2.5. Both were re-sprayed under conditions 
described by Sebhatu and co-workers (1994), Table 2.6. These conditions resulted in a 
better product yield (32% for lactose and 39% for trehalose, section 4.2.2) enabling 
further characterisation work to be carried out. When spray drying XG and LBG, feed 
concentration was decreased as 1% (w/w) solutions of both were very difficult to attain 
due to their viscous nature, and also to avoid the possibility of causing the spray dryer 
nozzle to become blocked. The pump was also increased, as a larger volume per batch 
was required to be spray dried due to the low feed concentrations. Table 2.7 details the 
conditions that were used to spray dry XG and LBG. 0.25% (w/w) feeds of XG, LBG 
and XG:LBG were prepared as follows:
Xanthan gum
1.25 g was weighed and made up to 500g with distilled water. The mixture was stirred 
using a Eurostar digital overhead stirrer (Type Euro-ST D S2, IKA Labortechnik, 
Staufen, Germany) at 500 rpm for 90 minutes.
Locust bean gum
1.25 g was weighed and made up to 500g with distilled water. The mixture was 
covered and preheated at an elevated temperature (80-85°C) in a water bath (Grant 
Water Bath, Type JB1, Grant Instruments (Cambridge) Ltd., UK) for 2 hours, set at 
104°C. This step was included to obtain a solution of the LBG in preference to a
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suspension which sediments rapidly when prepared at room temperature. The mixture 
was made up to weight again when cool, then left overnight to set. Finally, it was 
stirred, using the Eurostar digital overhead stirrer, for 30 minutes prior to spray drying.
Xanthan gum: Locust bean gum (50:50)
250g each of 0.125% (w/w) XG and 0.125% (w/w) LBG were prepared as described in the 
respective methods above and then combined. The LBG was gradually added to the XG 
solution, while stirring at 500 rpm, with the Eurostar digital overhead stirrer. Mixing 
was continued for a further 30 minutes, after which the mixture was left to stand 
overnight to allow bubbles to dissipate prior to spray drying.
2.2.1.3 Co-Spray Drying of Model Drugs with Excipients
When co-spray drying drug with excipient, each of the components were solubilised 
together prior to spray drying.
Salbutamol
Salbutamol was co-spray dried with polyvinylpyrrolidone (PVP) (Povidone K-90), 
mucin, XG and XG:LBG, at different drug: excipient ratios in order to afford controlled 
release. SalbutamohPVP solutions and salbutamol:mucin solutions were prepared as 
1 % (w/w) total solids, and then spray dried as before, under the conditions detailed in 
Table 2.5.
Various spray conditions were investigated when co-spray drying with XG and 
XG:LBG in an attempt to achieve good product yields. Feed solutions were prepared 
by mixing salbutamol with XG using the overhead stirrer, as described in section 2.2.1.2 
above. Salbutamol:XG was combined with preheated LBG when co-spray drying 
salbutamol:XG:LBG.
Protein
Insulin was co-spray dried with lactose and with XG under the conditions outlined in 
Table 2.8. Insulin:excipient ratios of 1:10 and 1:100 were spray dried at inlet 
temperatures of 110°C, 140°C and 170°C each.
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Table 2.6
Spray Conditions Employed fo r  the Bench-Scale Spray Drying o f Lactose and 
Trehalose, Based on the Method ofSebhatu and Co-Workers (1994).
Tiniet- 185°C
T outiet’ * 106 ± 2°C
Airflow: 6001/hr
Aspirator: 1 0 0 %
Feed flow rate (pump): 1 0  ml/min
Feed concentration: 12.5% (w/w)
*As recorded during the spray drying process.
Table 2.7
Spray Conditions Employed fo r  the Bench-Scale Spray Drying ofXG  and LBG.
XG LBG XG:LBG (50:50)
Tiniet- 120°C 120°C 120°C
T ou tiet:* 54 ± 2°C 57 ± 2°C 48 ± 2°C
Airflow: 6001/hr 600 1/hr 6001/hr
Aspirator: 1 0 0 % 1 0 0 % 1 0 0 %
Feed flow rate (pump): 1 0  ml/min 1 0  ml/min 15 ml/min
Feed concentration: 0.25% (w/w) 0.25% (w/w) 0.25% (w/w)
*As recorded during the spray drying process.
Table 2.8
Spray Conditions Employed fo r  the Bench-Scale Co-Spray Drying o f Insulin with 
Lactose and with XG. Each Spray Dried as 1:10 and 1:100, Insulin:Excipient Ratios.
Tiniet: 110°C 140°C 170°C
T ou tiet:* 73 ± 2°C 97 ± 2°G 117 ± 2°C
Airflow: 6001/hr 6001/hr 6001/hr
Aspirator: 1 0 0 % 1 0 0 % 1 0 0 %
Feed flow rate (pump): 5 ml/min 5 ml/min 5 ml/min
Feed concentration: 1 %  ( w/ w) 1 %  ( w/w ) 1 %  ( w/w )
*As recorded during the spray drying process.
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2.2.2 Pilot-Scale Manufacture of Spray Dried Powders
Pilot-scale spray drying operations were carried out at Penwest Pharmaceutical 
Company, Patterson, NY, USA, using the Niro Production Minor, Serial No. 9019 (Niro 
Atomiser, Copenhagen, Denmark). The Production Minor is a laboratory-sized unit 
(internal chamber diameter 2  metres) that may be found in a pilot-plant test station 
(Masters, 1985), hereafter referred to as a pilot-scale spray dryer. This pilot-scale spray 
dryer (Figure 2.2) incorporates a co-current rotary atomiser, which is considered to be 
suitable for the manufacture of a fine-particle heat sensitive product (Masters, 1985).
Only co-spray dried powders of salbutamol with either xanthan gum (XG), or with 
xanthan gum and locust bean gum (XG:LBG) were manufactured using the pilot-scale 
spray dryer, at different drug:excipient ratios of 1:10, 1:50 and 1:100. The ratio of 
XG:LBG was always 50:50. Each of the powders was manufactured under the same 
conditions, as detailed in Table 2.9. High operation temperatures were necessary 
overcome detection of moisture condensate in the collection vessel, which was thought 
to be the result of inefficient drying as a consequence of the viscous nature of the feeds. 
The LBG was not preheated as when spray dried in the bench-scale spray dryer as this 
was not practical. All of the powders were weighed individually and then made up to 
final weight with water; 40 to 50 kg batches of feed were spray dried during each 
session, which was left stirring overnight to ensure thorough mixing and solubilisation 
of each of the components prior to spray drying.
Table 2.9
Details o f the Spray Conditions Employed fo r  the Pilot-Scale Spray Drying of 
Salbutamol with XG and with XG:LBG.
Tiniet* 240-250°C
T ou tie t'* 120-125°C
Airflow: approx. 400 kg/hr
Atomiser speed: 600 Hz (approx. 24000 rpm)
Feed flow rate (pump): 6.5-8
Feed concentration: 0.25% (w/w)
*As recorded during the spray drying process.
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Figure 2.2 The Niro Production Minor, Serial No. 9019.
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2.3 Wet Granulation
Granulation (the process of adhering powder particles together to form larger particles 
called granules) can be used to prevent segregation of the constituents in a powder mix 
and to improve the flow properties of a mix (Summers, 1988). Wet granulation 
involves the use of a volatile, non-toxic solvent to cause massing of the powder mix, 
which can be removed by drying. The solvent may be used alone or may contain a 
binding agent to promote particle adhesion.
Powders for potential delivery to the upper airways were manufactured by wet 
granulation followed by milling, as an alternative method of manufacture, which 
produced particles of a larger size distribution than those produced by spray drying.
2.3.1 General Method for Manufacture of Granules
Three blends were prepared at drug:excipient ratios of 1:100. The amount of each of 
the excipients, dextrose (DEX) and xanthan gum (XG), was varied to produce three 
blends having different characteristics. Ratios of DEX:XG used were 75:25, 50:50 and 
25:75. A control blend of 1:100 salbutamol:lactose was prepared in the same way as the 
test blends.
Materials and Method
1.0 g of salbutamol base was dissolved into 40 ml of 95% ethanol. A total of 100 g of 
excipient(s), making up the required ratio, was weighed into the mixing bowl of a high 
shear mixer (Magimix™ Cuisine System 2000™, Montceau-Enbourgogne Cedex, 
France), and mixed briefly. While mixing, the ethanolic salbutamol solution was added 
slowly by 1 ml increments to the bowl, over a period of approximately 1 0  minutes. 
This was followed by 20 ml of distilled water, also added slowly in 1 ml increments. 
During addition of the liquids, mixing was stopped and the walls of the Magimix™ 
bowl were scraped with a flexible polyethylene spatula for every 1 0  ml of liquid added. 
The granules were then transferred to a metal tray for drying overnight in an oven, at 
60°C (Model IH-150, Gallenkemp, UK).
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2.3.2 Particle Size Reduction of Granules
Granules were pre-milled using a Retsch ZM1000 ultra-centrifugal mill (Glen-Creston 
Instruments, Middlesex, UK) set at 14000 rpm with a 24-tooth rotor, no retaining mesh 
and an internal collecting pan.
The free flowing off-white powders produced, with a particle size of approximately 100 
mm, were then milled using a Gem-T air pulveriser (Glen Creston Limited, Middlesex, 
UK). Opposing jet pressures were set to 90 psi at the O-inlet, and 65 psi at the P-inlet. 
The resulting fine powder was analysed for particle size distribution using a Malvern 
Mastersizer X (see section 2.4.1, below).
2.4 Physical Characterisation of Powders
2.4.1 Particle Size Analysis
Particle size distribution of both the raw materials and the spray dried materials was 
determined using the technique of low angle laser light scattering (LALLS), as 
employed by the Malvern Mastersizer X (Malvern Instruments Ltd., Malvern, 
Worcestershire, UK).
The pattern of scattering depends on the wavelength of the light, and the intensity of 
scattering from small particles is low, as particles scatter progressively much less light 
as they become smaller (Malvern Instruments Diffraction Training Manual). These 
factors are accounted for by using a helium-neon laser beam (X = 633 nm), which emits 
essentially monochromatic light and allows sensitive measurements of all sizes and of 
relatively low concentrations. The scattered light from a system of particles is measured 
via an optical arrangement to a series of detectors, which record a current proportional 
to the intensity of the scattered light falling upon them. The Mie scattering theory is 
applied in making the link between the light scattered and recorded in the computer,
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resulting in a distribution by volume of a range of particle sizes, representative of the 
sample being measured. The Mie theory accounts for the optical properties of particles 
(Zhang and Xu, 1992), which becomes especially important when sizing very small 
particles (< 5 /im) (Nathier-Dufour and Bougeard, 1993).
Materials and Method
All particles were sized using the Malvern Mastersizer X. The small volume stirred cell 
( 1 2  ml) was filled with dispersant and the stirrer switched on before taking a 
background reading, a measure of the diffracted light with no sample present. The 100 
mm lens was used, enabling particle sizes between 0.5 to 180 fxm to be measured. 
Representative powder samples of approximately 1 mg were suspended using 0.1% (w/v) 
lecithin in cyclohexane as the dispersing medium (Lucas et al., 1998), and sonicated for 
1 to 3 minutes, as required to break-up agglomerates, prior to measurement (Decon® 
ultrasonic bath, UK). The powder dispersion was added to the cell using a pipette until 
an obscuration level of 15 to 20% was reached. Three separate samples of each powder 
were dispersed and analysed in the same way.
Size distributions were expressed in terms of equivalent volume diameters, d(0.1), 
d(0.5) and d(0.9), with, respectively, 10%, 50% and 90% of particles in the distribution 
being smaller than the value obtained for each. The value obtained for d(0.5) represents 
the volume median diameter (VMD) for the sample, under which half of the distribution 
lies.
2.4.2 Morphology
Surface morphology of pharmaceutical formulations has been characterised using the 
scanning electron microscope (SEM) for many years, providing high-resolution images 
with a good depth of field (D’Emanuele and Gilpin, 1996). Spray dried particles in 
particular are very often characterised in this way (Conte et al., 1994; Maa et al., 1996; 
Maa et al., 1997; Pavanetto et al., 1992). The specimen usually requires a thin metal 
coating in order to generate surface contrast and to prevent electrostatic charging 
(Robards and Wilson, 1993).
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Materials and Method
Particles were viewed using a Jeol JSM-T330 Scanning Electron Microscope (Japanese 
Electron Optics Ltd., Tokyo, Japan). Powder samples were mounted on aluminium 
stubs using double-sided adhesive carbon tape, and then coated with a thin conductive 
layer of gold (Sputter Coater, Model S150B, Edward’s High Vacuum, Sussex, UK). 
Heat generated during the coating process sometimes caused melting and charring of 
sensitive samples. This was overcome by coating the sample for short successive 
periods of 1 minute, until a total of 4 minutes of coating had been achieved. SEM 
imaging was carried out using an accelerating voltage of 1 0  kv in all cases.
2.4.3 Moisture Content
Moisture loss on drying of the individual raw excipients and the respective spray dried 
excipients was determined using a Mettler LP16 Infrared Dryer (Mettler Toledo AG, 
Switzerland), and a Mettler PM 2500 Delta Range Balance (Mettler Toledo AG, 
Switzerland). This instrument uses infrared radiation to penetrate the material, heating 
it from the bottom.
Approximately 1 g samples of each of the excipients were dried at 100°C to constant 
weight (for 60 minutes). Spray dried excipients were tested immediately after 
collection from the spray dryer wherever possible, to avoid encountering any possible 
moisture-gain from the environment by these samples. Limited quantities of spray dried 
material were available, thus it was only possible for one determination to be made.
2.4.4 Drug Incorporation
Drug incorporation efficiency, also referred to as entrapment efficiency (Haghpanah et 
al., 1994), encapsulation efficiency (Pavanetto et al., 1992), or loading efficiency (Wang 
and Wu, 1998) was determined as a measure of how much, and how efficiently, 
salbutamol had been incorporated with the respective excipients during the co-spray 
drying process. Drug incorporation efficiency was calculated using Equation 2.1:
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^  r . v Actual Drug Incorporation , _ _Drug Incorporation Efficiency (%) = ----------------------------------------- xlOO
Theoretical Drug Incorporation
Equation 2.1
Actual drug incorporation was determined experimentally by reconstituting samples of 
the spray dried powders (0 .1% (w/v) total solids) and diluting each one to an appropriate 
concentration for analysis of salbutamol by fluorescence (section 2.5.2). Theoretical 
drug incorporation was calculated from the nominal ratios of the formulation, assuming 
incorporation of the entire drug that was present. The mean and standard deviation of 
five (bench-scale) or ten (pilot-scale) individual determinations were calculated.
2.5 Analytical Techniques
2.5.1 Mathematical Representation of Analytical Data
Throughout this study, linear regression analysis carried out with respect to analytical 
work was performed using MicroCal® Origin v2.94, Scientific and Technical Graphics 
in Windows (MicroCal Software Inc., MA, USA).
Where the use of a Student’s t-Test or Chi-squared test (Bartlett test) (Richardson, 
1973) was required, values for t and with the calculated degrees of freedom at p =
0.05, were obtained from Statistical Tables for Biological, Agricultural and Medical 
Research (Fisher and Yates, 1963). Both tests are detailed in Appendix A.
2.5.2 Fluorescence Spectrometric Assay of Salbutamol
Fluorescence spectrometry (fluorimetry) was chosen for the assay of salbutamol base as 
it is an exquisitely sensitive analytical procedure and nanogram amounts of 
fluorophores can usually be assayed fluorimetrically (Harris and Bashford, 1987).
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Fluorescence is the emission of light by a sample that absorbs light (of higher energy) at 
a lower wavelength (Harris and Bashford, 1987). Two types of spectra are obtained for 
the characterisation of a fluorescent substance:
1. Excitation spectra. The excitation spectrum determines the best wavelength for 
raising the substance to an activated state and is governed by both the absorbance of a 
compound and the intensity of the radiant energy.
2. Emission spectra. The emission spectrum is a characterisation of the light emitted 
when the activated substance returns to its ground state.
It follows that the spectral properties of the fluorescence excitation of a substance 
should be identical with the absorption spectrum, which enables use of the wavelength 
of maximum absorption as a starting point when determining the excitation wavelength 
(Xex) and emission wavelength (A,em) of a substance.
The BP (1998) identifies an absorption maximum for salbutamol at 276 nm. This value 
was used as the Xex for salbutamol to attain an emission spectrum using an F-2000 
Fluorescence Spectrophotometer (Hitachi Instruments, Japan). The Pre-Scan function 
was used in Emission Mode; that is, Xem scanning of a sample of salbutamol in distilled 
water was carried out. Emission start wavelength was selected as 220 nm and emission 
stop wavelength was selected as 400 nm. A peak was detected at 305 nm, subsequently 
utilised as the for salbutamol for all assays carried out using this specific apparatus. 
Peak detection at 305 nm was confirmed using the Wavelength Scan function to obtain 
excitation/emission spectral measurements of salbutamol in distilled water.
2.5.2.1 Quantitation of Fluorescence
There is no absolute scale of fluorescence intensity, thus fluorescence intensities reflect 
the apparatus in which they are recorded as much as the nature of the sample, as a 
consequence of the lack of an equivalent relationship to the Beer-Lambert Law for 
absorbance spectroscopy (Harris and Bashford, 1987). Fluorescence spectrometers 
register relative fluorescence, which may vary from apparatus to apparatus, thus
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measurements made with a specific apparatus only should be compared with each other, 
unless fluorescence spectra corrected for instrument variables are being compared. 
Corrected excitation spectra are corrected for changes in lamp output and should 
correspond to the absolute absorbance spectrum of the fluorescent material, while 
corrected emission spectra are corrected for the non-linearity of the photodetector 
(Harris and Bashford, 1987).
The least arbitrary parameter of fluorescence that can be measured is the quantum yield 
(Qf): the fraction of photoexcited molecules that lose their excess energy as 
fluorescence. Qf values range from 0  (for non-fluorescent molecules) to 1 , and these 
values depend very strongly on environmental factors such as temperature, solvent 
composition, local polarity and the presence of quenching agents (Harris and Bashford, 
1987).
The theoretical dependence of fluorescence on chromophore concentration can be 
derived from the Beer-Lambert Law, where absorbance, A, is given by:
A =  £ . s . I
Equation 2.2
where e is the molar absorptivity (or, extinction co-efficient), a constant whose value 
characterises the particular solute, s, and / is the length of the path of light through the 
sample (usually 1 cm). The molar absorptivity is the absorbance of a 1 M solution 
measured in a 1 cm pathlength cell.
Equation 2.2 can be rewritten as:
i , = i0. i c f**'1
Equation 2.3
where I0 and It are the intensities of the incident and transmitted light beams, e is the 
molar absorptivity, s the molar concentration of solute, / the path length, and where la is 
the intensity of absorbed light, given by:
56
Ia =  I o ~ I ,
Equation 2.4
Equations 2.3 and 2.4 can be combined to give:
l a =  Ia . ( l - 1 0 ' £'s l)
Equation 2.5
The intensity of fluorescence (//) is given by:
If =  la - Q f
Equation 2.6
If Ia is substituted in Equation 2.6 using the value given in Equation 2.5, and the 
exponential term is expanded, ignoring the higher order terms (a reasonable assumption 
when e.s.l < 0.05), the intensity of fluorescence is then given by:
If =  2.303 . IQ. Qf. £. s. I
Equation 2.7
Thus in dilute solutions (with absorbance values of less than 0.05), fluorescence is 
proportional to: (a) the incident intensity; (b) the absorptivity; and (c) the quantum 
yield, and fluorescence intensity is directly proportional to the concentration of 
fluorophores.
2.5.2.2 Measurement of Fluorescence Values
The F-2000 Fluorescence Spectrophotometer (Hitachi Instruments, Japan) was used for 
all fluorescence analysis. The light source was allowed to stabilize for at least 30 
minutes prior to making the first measurement.
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Manual Sampling
Distilled water was used to zero the instrument, filled in a clean, 1 cm quartz cell 
(Merck, Poole, UK). The Photometry function was used for sample concentration 
measurement under pre-determined, specified conditions that are detailed in Table 2.10. 
A new calibration curve was measured each time the fluorimeter was switched on in 
preference to using stored calibration curve data. The curve-type was selected as first- 
order so that the computer would apply the least squares method in generating a 
calibration curve, which it used to carry out a concentration calculation when the 
standard and analyte samples were measured.
Stock solutions of 100 jLtg/ml salbutamol base in distilled water (diluted to prepare 
calibration standards), were stored in a refrigerator for up to one month, then discarded 
and a fresh stock prepared. Calibration standards were kept at room temperature for one 
week, and then discarded. The stock solution was allowed to equilibrate to room 
temperature before each new dilution series (DS) was prepared. A working calibration 
range of 0-4 /tg/ml was used for most analysis; however, it was necessary to use a 
narrower range of 0 - 1  /xg/ml for some work to achieve more accurate results. 
Concentrations greater than 5 /Jg/ml appeared to cause a curving of the calibration line 
and poor correlation as a result. This curving observed at higher concentrations could 
be due to the effect of quenching of fluorescence, for example by collisional 
mechanisms, resulting in deactivated excited-state molecules, thus quenching their 
fluorescence (Harris and Bashford, 1987).
Typical linear regression data obtained are summarised in Table 2.11 and Table 2.12, 
and a typical calibration plot is shown in Figure 2.3.
Automated Sampling
The F-2000 spectrophotofluorimeter was fitted with a 90 p\ flow through-cell and a 
contact closure timing device, which enabled automated measurements to be taken 
using the apparatus at varying (pre-set) intervals. A continuous loop of water was set 
up with either the reservoir of the modified stage 1 , or that of the modified stage 2 , and 
the flow through cell using a peristaltic pump (Watson-Marlow, Cornwall, UK) fitted 
with 0.5 mm bore Neoprene™ tubing and polyethylene tubing (1.5 mm internal and 1.8 
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Figure 2.3 Example of a typical fluorescence calibration curve for salbutamol in 
distilled water.
Table 2.10
Photometry Conditions Employed Quantitative Analysis o f Salbutamol Using the
F-2000 Fluorescence Spectrophotometer.
Excitation wavelength (kex): 276 nm
Emission wavelength (Aem): 305 nm
Response time: 0.5 seconds
Bandpass width (excitation): 1 0  nm
Bandpass width (emission): 1 0  nm
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Table 2.11
Linear Regression Data Obtained fo r  the Fluorimetric Assay o f Salbutamol Calibration 
Standards in Distilled Water (n-6; 0-4 fig/ml)
DS 1 DS2*
Day 1 Day 5 Day 1 Day 5
Gradient 47.748 46.108 46.532 46.926
Standard Deviation 0.4155 0.6482 0.5812 0.5068
Y-Axis Intercept 4.2558 4.9364 4.3567 4.2403
Correlation 0.9999 0.9996 0.9997 0.9998
Table 2.12
Linear Regression Data Obtained fo r  the Fluorimetric Assay o f Salbutamol Calibration
Standards in Distilled Water (n-6; 0-1 fig/ml)
DS 1 DS 2*
Day 1 Day 5 Day 1 Day 5
Gradient 55.024 54.974 54.725 54.604
Standard Deviation 0.2264 0.1266 0.1178 0.0980
Y-Axis Intercept 3.1162 3.0365 3.0899 2.9637
Correlation 0.9999 0.9999 0.9999 0.9999
*DS 2 was prepared from the same stock solution as DS 1, after the stock solution had 
been stored in a refrigerator fo r  a period o f one month.
Table 2.13
Linear Regression Data Obtained fo r  Salbutamol Calibration Standards (0-4 pg/ml), 
With and Without the Presence o f Various Formulation Excipients (0-400 pg/ml); n=6.
No
Excipient
Lactose XG LBG XG: LBG 
(50:50)
Gradient 54.702 53.480 53.308 54.031 53.716
Standard Deviation 0.4402 0.7002 0.5814 0.7173 0.3583
Y-Axis Intercept 4.8818 5.7261 8.2264 6.7755 5.8888
Correlation 0.9999 0.9997 0.9998 0.9997 0.9999
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A Student’s t-Test (section 2.5.1) was used to determine whether or not there was a 
significant difference between the values of the slopes obtained on day 1 and on day 2 , 
for each DS in Table 2.11 and Table 2.12. Values obtained for tsiope when considering 
day 1 compared with day 2, were 0.511 and 0.195 for DS 1, and 1.094 and 0.792 for DS 
2 for the data in Table 2.11 and Table 2.12 respectively; thus, the slopes were not 
significantly different. The values for tsiope obtained when considering the curve 
obtained on day 1 for DS 1 and day 1 for DS 2 (prepared after one month), were 1.702 
(Table 2.11) and 1.172 (Table 2.12); again, not significant at the 5% level.
A Chi-squared test (section 2.5.1) was also carried out with the same data in both tables 
to test the hypothesis that there was no significant difference between the slopes of any 
of the calibration graphs obtained for the respective concentration ranges of salbutamol. 
The values of %2 siope obtained were 4.923 (Table 2.11) and 5.313 (Table 2.12). Thus, it 
was concluded that there was no significant difference between the slopes of any of the 
curves detailed in Table 2.11, and also between any of the curves detailed in Table 2.12 
rendering both the assay and the protocol for the storage of calibration standards 
suitable over the concentration range of 0-4 /xg/ml and 0-1 /xg/ml of salbutamol.
2.5.2.3 Effect of Formulation Excipients
It was necessary to determine the effect that the presence of dextrose, lactose, PVP 
(Plasdone K-90), mucin, xanthan gum (XG) and locust bean gum (LBG) might have on 
the fluorescence measurements that were being obtained, as one or more of these 
excipients was usually present in the formulation being analysed for salbutamol content. 
The worst-case scenario was considered for each, whereby in a 1:100 
salbutamol:excipient formulation, we would expect there to be approximately 1 0 0  times 
more excipient than salbutamol.
Materials and Method
2 0 0  /xg/ml samples were prepared in distilled water for spectral measurements of each 
of the excipients. This concentration was chosen as 2 /xg/ml salbutamol is the mid-point 
of the broad calibration range, corresponding to 200 /xg/ml of excipient. When excited
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at 276 nm, all of the excipients except for dextrose and PVP, appeared to fluoresce 
slightly in the 300 to 400 nm region, and a peak was observed for lactose at 305 nm. 
These measurements could have been due to the excipients themselves, having the 
ability to fluoresce under the experimental conditions employed or, more likely, due to 
impurities or contaminants that may have been present, as fluorescence is particularly 
sensitive to contaminating substances (Harris and Bashford, 1987). As a result of these 
observations, it was necessary to assess whether or not the presence of lactose, XG and 
LBG in particular, made a difference to the slopes of the calibration curves obtained.
Calibration standards for each excipient were prepared from the same salbutamol stock 
solution (100 /xg/ml) over the concentration range of 0-4 /-ig/ml of salbutamol. 500 ml 
solutions of each of the excipients under investigation was prepared to a concentration 
of 50 mg/ml with distilled water, and appropriate amounts then titrated into each 
calibration standard, to a final concentration of salbutamol:excipient of 1 :1 0 0 . 
Fluorescence intensity of each solution was measured in the same way as outlined 
above, in section 2.5.2.2.
Results and Discussion
Linear regression data obtained for salbutamol calibration standards with and without 
the presence of the various formulation excipients are summarised in Table 2.13.
The Student’s t-Test (section 2.5.1) was used to compare each of the curves in Table 
2.13, obtained with excipients(s) against that obtained without the presence of any 
excipient. Values for tsi0pe when compared with the slope obtained with no excipient 
were 1.477 for lactose, 1.910 for XG, 0.796 for LBG and 1.737 for XG:LBG. None of 
the curves were significantly different, at the 5 % level, to the original calibration curve 
without any excipient.
A Chi-squared test (section 2.5.1) was also carried out with the same data to test the 
hypothesis that there was no significant difference between the slopes of any of the 
calibration graphs obtained. The value of %2si0pe obtained was 0.507. There was no 
significant difference, at the 5% level, in the calibration curves obtained, with or 
without the presence of excipient(s).
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2.5.3 Spectrophotometric Assay of Proteins
2.5.3.1 UV Absorption
Ultraviolet (UV) absorption measurement is often used as a convenient method for the 
assay of proteins as most exhibit wavelengths of maximum absorbance in the UV region 
due to the presence of aromatic amino acids (Jones, 1993). For example, alkaline 
phosphatase (AP) has can be assayed for routine determination of protein concentration 
by absorbance measurements at 278 nm (Fosset et al., 1974). In the case of insulin, 
however, it has been demonstrated that insulin concentrations below 2.85 units/ml have 
a very low absorbance (Kumar, 1986); thus, UV detection was not thought to be 
sensitive enough for the determination of insulin concentrations that were likely to be 
used during the course of this study.
Materials and Method
A sample of AP (in 10 mM Tris buffer, pH 8 ) was scanned over the wavelength range 
190 to 750 nm (Lambda 3 Spectrophotometer, Perkin-Elmer, Connecticut, USA). An 
absorbance peak was observed at 277 nm and was subsequently utilised as the 
wavelength of maximum absorbance.
Solutions of AP were prepared over the range 0-3 mg/ml and a calibration curve was 
obtained by measuring the absorbance at 277 nm of each one, versus Tris blank 
(Spectronic Spectrophotometer, Model 601, Milton Roy Company, USA).
Results and Discussion
Figure 2.4 illustrates a typical result obtained for the UV calibration of AP (0-3 mg/ml). 
Although linear over the test range of 0-3 mg/ml of AP, absorbance of concentrations 
below 0.5 mg/ml was found to be very low and variable. This method was thus 
considered unsuitable, in terms of sensitivity, for the determination of actual 
concentrations of the majority of test samples of alkaline phosphatase that would 
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Figure 2.4 An example of a typical UV calibration curve for AP in 10 mM Tris 
buffer, pH 8 .
Table 2.14
Linear Regression Data Obtained fo r  the UV Calibration 







The Bio-Rad Protein Assay was used, which is a dye-binding assay based on the 
differential colour change of a dye in response to various concentrations of protein. The 
principle is based on the binding of Coomassie Brilliant Blue G-250 to protein that 
causes a shift in the absorption maximum of the dye from 465 to 595 nm. The increase 
in absorption at 595 nm is monitored (Bradford, 1976).
The extinction co-efficient of a dye-albumin complex solution has been shown to be 
constant over a ten-fold concentration range (Spector, 1978). Thus, an appropriate ratio 
of dye volume to sample concentration can be selected to allow accurate quantification 
of protein by applying Beer’s Law. Over a broad range of protein concentrations, an 
accurate but not entirely linear response is achieved by the dye-binding method (Bio- 
Rad Protein Assay, 1994). However, for the purposes of this work, this method of 
determining the concentration of an unknown sample was found to be more sensitive 
and accurate when compared to UV analysis, over the low and narrow concentration 
range of protein that was generally under investigation.
Materials and Method
The Microassay procedure was followed (Bio-Rad Protein Assay, 1994), suitable for 
analysis of 1-20 fig protein; < 25 /xg/ml. A standard calibration curve was prepared 
each time the assay was performed.
A stock solution of known concentration (approximately 40 mg/ml) of the protein 
(alkaline phosphatase or insulin) to be analysed was prepared in 10 mM Tris buffer, pH 
8 . The stock solution of protein standard was then diluted appropriately in five 
individual microcentrifuge tubes (Elkay Products, Inc., Shrewsbury, MA, USA) over 
the range of 0 to 10 /tg/ml, to a total volume of 800 /xl with Tris buffer. A 200 [i\ aliquot 
of Dye Reagent Concentrate was added to each sample, after which the sample was 
inverted five times to ensure thorough mixing. Each sample was transferred to a clean, 
disposable 1 ml cuvette (Elkay Products, Inc., Shrewsbury, MA, USA) just prior to 
analysis.
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Absorbance, at 595 nm (A595) was measured versus Tris blank, after a period from 5 
minutes to one hour, allowing sufficient time for the complex-formation to take place 
(Spectronic Spectrophotometer, Model 601, Milton Roy Company, USA). The OD595 
value obtained for zero protein concentration was plotted as the first point on the 
calibration curve and was not used as the blank since the reading was found to fluctuate. 
Results obtained after 10 minutes and after 20 minutes were compared initially to 
determine the time period after which A595 should be measured.
Two series of dilutions for each of three stock solutions (A, B and C) were prepared to 
assess the integrity of protein stock solutions and of the assay, in terms of 
reproducibility and accuracy. Dilution series (DS) 1 and 2 were performed on 
consecutive days; the stock solution was stored in a refrigerator overnight and allowed 
to equilibrate to room temperature before analysis on the following day.
Results and Discussion
Table 2.15 summarises the linear regression data obtained from the calibration plots for 
alkaline phosphatase (AP) when measurements were made after 10 minutes and after 20 
minutes. Table 2.16 summarises the linear regression data obtained for three separate 
stock solutions of AP. Five dilutions of each stock were prepared over the 
concentration range of 0-10 /xg/ml for each DS. A595 measurements were made after 10 
minutes.
From the results obtained, it was decided that all measurements would be taken after 
allowing 1 0  minutes for complex-formation to take place, and that a new protein 
standard stock solution should be prepared and appropriately diluted to obtain a 
calibration curve on each new day that the Bio-Rad protein assay was to be performed. 
A typical plot is shown in Figure 2.5.
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Table 2.15
Linear Regression Data fo r  AP Analysed by the Bio-Rad Protein Assay at Time 
Intervals o f 10 and 20 minutes, (n = 5; 0-10 pg/ml).
DS 1 DS 2*
1 0  minutes 2 0  minutes 1 0  minutes 2 0  minutes
Gradient 0.0099 0.0096 0.0099 0 .0 1
Standard Deviation 0.0003 0.0003 0.0003 0.0005
Y-Axis Intercept 0.2799 0.2839 0.2826 0.2844
Correlation 0.9987 0.9986 0.9986 0.9958
*DS 2 was prepared from the same stock (A) as DS 1, on consecutive days.
Table 2.16
Linear Regression Data fo r  Three Stock Solutions, and Respective Dilution Series’ 
Prepared on Consecutive Days, o f AP Analysed By the Bio-Rad Protein Assay,
(n = 5; 0-10 pg/ml).
Stock A Stock B Stock C
DS 1 DS 2 DS 1 DS 2 DS 1 DS 2
Gradient 0.0099 0.0099 0.0098 0.0088 0.0103 0 .0 1 0 0
SD 0.0003 0.0003 0.0004 0 .0 0 0 1 0 .0 0 0 1 0.0003
Intercept 0.2799 0.2826 0.2858 0.2884 0.2828 0.2880
Correlation 0.9987 0.9986 0.9974 0.9999 0.9999 0.9989
A Student’s t-Test (section 2.5.1) was used to determine whether or not there was a 
significant difference between the values of the slopes obtained after 1 0  minutes and 
after 20 minutes, for each DS in Table 2.15. Values obtained for tsiope when considering 
the curves obtained after 10 minutes compared with after 20 minutes, were 0.829 for DS 
1 and 0.657 for DS 2, thus the slopes were not significantly different at the 5% level.
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The value for tsiope obtained when considering results obtained for two sets of dilutions 
prepared from the same stock solution of protein were 0.0479 for measurements taken 
after 1 0  minutes and 0.662 for measurements taken after 2 0  minutes; again, not 
significant.
Thus it was found that there was no significant difference, at the 5% test level, in the 
values of the slopes obtained after 1 0  minutes and after 2 0  minutes, either from the 
same set of dilutions or when comparing two sets of dilutions prepared from the same 
stock solution of protein, rendering either method suitable.
A Student’s t-Test was also used to determine whether or not there was a significant 
difference between the values of the slopes obtained after 1 0  minutes and after 2 0  
minutes, for each DS in Table 2.16. Values obtained for tsi0pe when considering 
measurements taken from two dilutions of the same stock solution were 0.0479 for 
stock A, 2.3823 for stock B and 1.0935 for stock C, thus the slopes were not 
significantly different at the 5% level.
A Chi-squared test (section 2.5.1) was carried out to assess whether or not there was a 
difference in the values of the slopes obtained for all six sets of data in Table 2.16. The 
value of %2 with 5 degrees of freedom, at p = 0.05 is 11.070. In this case, it was found 
that there was a significant difference at the 5% level as the value of %2si0pe obtained was 
19.638.
Though a more sensitive assay than the UV absorbance assay, there is much scope for 
error when using the Bio-Rad Protein Assay, thus it was decided that a new protein 
standard stock solution should be prepared and appropriately diluted to obtain a 
calibration curve on each new day that assay was to be performed.
Effect of Formulation Excipients
Both lactose and xanthan gum were found not to interfere with the Bio-Rad Protein 
Assay at concentrations that were employed in this study, when assessed using the same 
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Figure 2.5 An example of a typical standard calibration curve obtained for the 
estimation of protein concentration by the Bio-Rad Protein Assay.
2.5.4 Protein Aggregation
The degree of aggregation occurring as a result of spray drying proteins at different 
temperatures was investigated by assessing turbidity, measured spectrophotometrically 
as optical density (OD) in the 340-360 nm range, as has been described by Eckhardt and 
co-workers (1994). Measurement of turbidity as OD in the 340-360 nm region presents 
a practical approach to quantification of a protein solution’s visual clarity as this will be 
outside the region of chromophoric absorption, yet still sensitive enough to distinguish 
between individual suspensions (Eckhardt et al., 1994). An increase in optical density 
would indicate an increase in turbidity, and thus protein aggregation.
Solutions of known concentration (approximately 1 mg/ml) of standard protein and 
spray dried protein were prepared with 10 mM Tris buffer and the OD of each was 
measured at 340, 350 and 360 nm, both as reconstituted samples and following filtration
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(Whatman® 0.2 fim  Cellulose Nitrate Membrane Filters, Whatman International Ltd., 
Maidstone, UK) of the reconstituted samples. OD/mg was calculated to standardise the 
results. The difference between the OD of the unfiltered sample and that of the filtered 
sample was considered to be due to turbidity. The degree of aggregation was 
determined by calculating mean OD/mg due to turbidity over the range of 340-360 nm 
and the data for each spray dried sample was normalised by dividing by the value 
obtained for the respective raw material.
2.5.5 Determination of Protein Activity
2.5.5.1 Alkaline Phosphatase Activity Assay
Phosphatases such as alkaline phosphatase (AP), the model enzyme used in this study, 
catalyse the hydrolysis of monosubstituted phosphate esters; that is, the hydrolysis of 
various ROPO32' species to ROH + Pi (Walsh, 1979). The determination of AP activity 
can thus be made colorimetrically with suitable substrates that liberate a coloured 
species upon hydrolysis. The use of p-nitrophenyl phosphate (PNPP) as a substrate for 
kinetic determination of AP has been previously described (Etzel, et al., 1996), where 
the rate of increase in absorbance at 405 nm (A^snm) was directly proportional to AP 
activity of the sample.
The Sigma Quality Control Test Procedure for the Enzymatic Assay of Alkaline 
Phosphatase (Glycine and Zinc Assay), based on the method of Bergmeyer and co­
workers (1983), was used during this study to determine loss of activity, observed as a 
result of spray drying AP at different temperatures, by continuous spectrophotometric 
rate determination.
Assay Principle
p-Nitrophenyl Phosphate + H20  —— ^ ^ p . h°si*af^-----„ p-Nitrophenol + Pi
where Pi = inorganic phosphate.
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Conditions
pH 10.4; temperature = 37°C; A405nm, light path = 1 cm.
The activity is measured in units, where it is defined that 1 unit will hydrolyse 1.0 
/-imole of PNPP per minute at pH 10.4, at 37°C.
Materials and Method
The following reagents were required to perform the assay:
A. 50ml of 100 mM glycine buffer with 1.0 mM magnesium chloride (MgCk) and 1.0 
mM zinc chloride (ZnCb), pH 10.4 at 37°C; adjusted to pH with 1 M sodium 
hydroxide (NaOH) and prepared fresh.
B. 5.0 ml of 60 mM PNPP, prepared fresh.
C. 50 ml of 1.0 mM MgCk*.
D. Alkaline phosphatase enzyme solution, containing 0.1 - 0.2 unit/ml of AP in cold 
reagent C*, prepared immediately before use.
Fixed volumes, as shown in Table 2.17, of reagents A and B were pipetted into 3 ml 
plastic cuvettes (Elkay Products, Inc., Shrewsbury, MA, USA) and allowed to 
equilibrate to 37°C (Grant Water Bath, Type JB1, Grant Instruments (Cambridge) Ltd., 
UK), for at least 10 minutes. After equilibrating, either reagent C (Blank), or reagent D 
(Test) was added and the contents immediately mixed by inversion. The increase in 
A405 was then measured, at 30-second intervals, for 5 minutes (Shimadzu 
Spectrophotometer, Model UV-120-02, Shimadzu Corporation, Kyoto, Japan). The 
AAWminute for both the Test and the Blank was obtained by plotting the A405 against 
time. Linear regression was performed on the data obtained which was then used to 
calculate the units of enzyme present in the sample. The actual concentration of protein 
in the sample was obtained using the Bio-Rad Protein Assay (detailed in section 2.5.3.2) 
to calculate units/mg protein (Equation 2.3).
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Table 2.17
Volumes (ml) o f Reagents Required fo r  the Enzymatic Assay o f AP.
Test Blank
A (Buffer) 2.60 2.60
B (PNPP) 0.30 0.30
C (MgCl2)* - 0.10
D (AP Solution) 0.10 -
*Reagent C was replaced with 10 mM Tris buffer, pH  8. Alkaline phosphatase 
(particularly after spray drying) was not readily soluble in 1.0 mM MgCh, requiring up 
to 10 minutes sonification in an ultrasonic water bath.
Calculations
, (AA4os/tnin Test - AAws/min Blank) (3) (df)Umts/ml enzyme = --------------
(18.5) (0.1)
Equation 2.1
where 3 is the volume (ml) of assay, 
d f  is the dilution factor
18.5 is the millimolar extinction coefficient of p-nitrophenol at 405 nm 
0.1 is the volume (ml) of enzyme used
units/ml enzyme
Units/mg solid =
mg solid/ml enzyme Equation 2.2
units/ml enzyme
Units/mg protein =
mg protein/ml enzyme Equation 2.3
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Reproducibility of the enzymatic activity assay was assessed by comparing results 
obtained from separate assays.
Results and Discussion
Figure 2.6 and Table 2.18 summarise the activity assay linear regression data obtained 
for three samples of AP, each from a separate stock solution. Initial 2 mg/ml stock 
solutions were diluted xlOO to meet the requirements of the assay (AP raw material 
used was labelled as 10-20 units/mg, and the assay required the use of 0.1-0.2 units/ml 
of AP).
C/iz-squared analysis (section 2.5.1) of the data in Table 2.18 revealed a significant 
difference, at the 5% level, between the slopes of the activity assays for the three 
samples of AP, (x2sioPe = 34.571).
Figure 2.7 and Table 2.19 summarise the activity assay linear regression data obtained 
for three assays performed using the same sample of AP. A dilution of x250 of the 
initial 3 mg/ml stock solution was required for each assay. When the slopes of three 
assays from the same stock solution were compared, no significant difference was found 
at the 5% level, (x2si0pe = 0.3935).
It was decided that all AP activity assays would be carried out in triplicate and the mean 
result of three assays would be used to determine the true value for units/mg solid when 
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Figure 2.6 Enzymatic activity assay results for the determination of AAWminute of 
AP sample 1 (•) , sample 2 (A) and sample 3 (▼), and 10 mM Tris blank (■); xlOO 
dilutions of initial 2 mg/ml samples of AP were required for assay.
Table 2.18
Linear Regression Data fo r  the Enzymatic Activity Assay a Sample o f AP Taken From
Three Separate Stock Solutions o f AP
Blank 1 2 3
GradientCAAWminute) -0.0009 0.0916 0.0874 0.0938
Standard Deviation 0.0001 0.0007 0.0010 0.0006
Y-Axis Intercept 0.3697 0.4423 0.5551 0.4660
Correlation -0.9446 0.9998 0.9995 0.9998
Units/mg solid* - 6.6 6.3 6.9






5  0.2 -
0. 1 -
0.0
0 1 2 3 4 5
Time (minutes)
Figure 2.7 Enzymatic activity assay results for the determination of AAWminute of 
AP. Three assays performed with samples of AP taken from the same stock solution: 
assay number 1 (•), assay number 2 (▲), assay number 3 (T ), and 10 mM Tris blank 
(■); x250 dilutions of a 3 mg/ml stock solution of AP were required for assay.
Table 2.19
Linear Regression Data fo r the Enzymatic Activity Assay o f Three Samples o f AP Taken
from the Same Stock Solution.
Blank 1 2 3
Gradient(AA405/minute) -0.0041 0.0515 0.0516 0.0518
Standard Deviation 0.0002 0.0004 0.0004 0.0003
Y-Axis Intercept 0.3767 0.3985 0.4069 0.3871
Correlation Coefficient -0.9892 0.9971 0.9998 0.9998
Units/mg solid* - 6.8 6.8 6.9
*Calculated using Equation 2.2 and Equation 2.1.
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2.5.5.2 Insulin Activity Assay
Insulin activity before and after spray-drying was assessed qualitatively. 
Phosphorylated protein(s) which had been activated by the insulin signalling pathway 
were detected using the procedure of sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE).
Electrophoresis is one of the most common methods used for the analytical separation 
of mixtures of proteins (Jones, 1993), the acidic and basic groups of which means that 
they can carry an electric charge in response to an applied electric field by migration 
towards the anode or cathode. Most proteins denatured in sodium dodecyl sulphate 
(SDS) have a relatively uniform overall negative charge relative to their mass, due to 
the large number of negatively charged SDS molecules bound to the protein. As a 
result, proteins in SDS migrate according to mass differences when subjected to SDS- 
PAGE (Jones, 1993), whereby the smaller the protein, the more rapidly it will migrate. 
Proteins separated by SDS-PAGE can be transferred to a nitrocellulose membrane 
allowing the proteins of interest to be probed using specific antibodies.
Insulin acts by binding to its receptors in the plasma membrane of target cells, initiating 
receptor autophosphorylation and activation of intrinsic tyrosine kinase, thereby 
inducing phosphorylation of tyrosine residues on target proteins (Stryer, 1988). The 
ability of insulin to induce tyrosine phosphorylation of proteins can be assessed by 
immunoblotting with anti-phospho-tyrosine antibodies (Welham et al., 1995), which 
was one of the methods used in this study. The other was the detection of protein 
kinase B (PKB) activation and phosphorylation, triggered by insulin (Cross et al., 
1995), by immunoblotting with anti-phospho-PKB antibodies.
Preparation o f  Cell Extracts
Cells were cultured in humidified incubators at 37°C, 5% CO2 (v/v) in RPMI 1640 
medium, supplemented with 10% (v/v) fetal bovine serum, 20 pm  2-mercaptoethanol, 
100 units of penicillin/streptomycin and 2 mM glutamine. A myeloid cell line was used 
(FD-6), grown in the presence of interleukin-3 (IL-3). Cells were washed three times 
with Hanks’ buffered saline solution, and then re-suspended in serum-free RPMI, at 
37°C, to a final cell density of approximately 2 x 106/ml and incubated at 37°C for 1
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hour prior to stimulation. 0.5 ml aliquots of the cell suspension were added to 
microcentrifuge tubes ready for stimulation. Stimulations were carried out for 2 
minutes with various known concentrations of insulin and the cells were immediately 
pelleted by centrifugation (Biofiige Fresco, Heraeus Instruments, Germany), at 4°C for 
15 seconds at 13,000 rpm. The supernatant was aspirated, and the cell pellets were 
lysed in 40 /xl of solubilisation buffer (Table 2.20). The lysates were centrifuged for 2 
minutes at 13,000 rpm (Jouan A14 Centrifuge, Jouan SA, France) to pellet the debris, 
and the supernatants were removed to clean microcentrifuge tubes for analysis. The 
samples were denatured by boiling (Grant QB T2, Grant Instruments (Cambridge) Ltd., 
UK) for 2 minutes in 10 /xl of 5 x SDS-sample buffer (Table 2.20), and spun briefly 
before loading on to the gel.
Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE)
Glass plates were cleaned with 70% ethanol and the apparatus assembled (Bio-Rad 
Mini-Protean® II Gel System, Bio-Rad Laboratories GmbH, Germany). Running gels 
(7.5% acrylamide, Table 2.21) were pipetted between the assembled glass plates (~ 4.5 
ml per gel), avoiding bubbles. The gels were carefully overlaid with Milli-Q water after 
pouring and polymerisation allowed to take place for 20 to 30 minutes or until set, after 
which the Milli-Q water was aspirated. The stacking gel (5% acrylamide, Table 2.21) 
was poured on top of the running gel, and a 15-well comb was inserted to make the 
wells. Polymerisation was allowed to take place for 20 minutes or until set, after which 
the comb was removed and the wells washed out thoroughly with Milli-Q water. The 
wells were filled with SDS-PAGE running buffer (Table 2.20) and the samples were 
carefully loaded, each into an individual well. Electrophoresis was carried out at a 
constant voltage of 80 V for the stacking gel, and 180 V for the running gel (Bio-Rad 
Power Pac 300, Bio-Rad Laboratories GmbH, Germany). Following electrophoresis, 
the proteins were transferred to a nitrocellulose membrane by Western blotting.
Immunoblotting
The graphite electrodes of the blotting apparatus (Pharmacia LKB Multiphor II, and 
Electrophoresis Supply -  EPS 600, Pharmacia Biotech, Sweden) were dampened with 
semi-dry transfer buffer (Table 2.20) to ensure good contact. Appropriately sized 
squares of 3 MM chromatography paper (Whatman International Ltd., Maidstone, UK), 
soaked in semi-dry transfer buffer, were placed on the electrode, rolling gently with a
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plastic pipette to expel any bubbles; a four-paper stack was built up in this way. A 
piece of nitrocellulose membrane (BDH Laboratory Supplies, Poole, UK) was cut to the 
same size as the gel and 3 MM paper, wet in semi-dry transfer buffer, and placed on top 
of the paper stack, ensuring to expel any bubbles.
Next, the gel was wet in semi-dry transfer buffer and placed on top of the nitrocellulose, 
and another four-paper stack was built up on top of the gel with 3 MM paper soaked in 
semi-dry transfer buffer, rolling gently in between each layer. The upper electrode was 
dampened with Milli-Q water and the apparatus assembled. The proteins were then 
transferred electrophoretically to the nitrocellulose membrane for 1 hour at 0.8 mA per 
c m .
Following transfer, the nitrocellulose membrane was washed with Milli-Q water and 
stained with Ponceau S solution to check that transfer had been successful. The 
molecular weight standards were marked and the stain washed off with Tris-buffered 
saline (TBS) before transferring the membrane to blocking solution (TBS containing 
5% (7 V) bovine serum albumin (BSA), 1% (w/v) ovalbumin and 0.05% sodium azide). 
The non-specific binding sites on the membrane were blocked by incubation at room 
temperature, overnight on a rocking platform (3D Rocking Platform STR9, Stuart 
Scientific, UK). The blocking solution was then rinsed away with TBS and the 
membrane was incubated with primary antibody (monoclonal anti-phospho-tyrosine, 
4G10, used at 0.1 jLtg/ml and supplied by Upstate Biotechnology Ltd., NY, USA, or 
anti-phospho-PKB, rabbit anti-mouse polyclonal against phospho-Ser 473, antibody 
number 9270, used at 1/1000 and supplied by New England Bio labs) in a 1:5 dilution of 
blocking solution, for at least 3 hours at room temperature on a rocking platform. The 
membrane was then washed five times -  once with TBS, three times with TBSN (TBS 
with 0.05% NP-40) and again with TBS, allowing approximately 10 minutes per wash. 
Washing was followed by incubation with the anti-primary secondary antibody (anti­
mouse IgG for anti-phospho-tyrosine, or anti-rabbit IgG for anti-phospho-PKB, used at 
0.05 /xg/ml, both supplied by Dako, Cambridge, UK) (coupled to horseradish 
peroxidase) diluted in TBSN, for 1 to 2 hours at room temperature on a rocking 
platform. The membrane was finally washed again, five times, as before with an extra 
TBS wash at the end, and developed immediately.
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Table 2.20
Details o f the Compositions o f Buffers.
Tris-buffered saline: 
Solubilisation buffer:
5 x SDS-Sample buffer:
SDS-PAGE running buffer:
Semi-dry transfer buffer:
20 mM Tris-HCl; 150mM NaCl; pH 7.4.
50 mM Tris-HCl; 150 mM NaCl; 1% Nonidet P-40 
(NP-40); 10% glycerol; 5 mM ethylenediaminetetra- 
acetic acid (EDTA); 1 mM sodium vanadate;
1 mM sodium molybdate; 10 mM sodium fluoride;
40 jttg/ml. phenylmethylsulphonyl fluoride (PMSF);
0.7 jitg/ml pepstatin A; 10 /xg/ml aprotinin;
10 /zg/ml leupeptin; 10 jug/ml soyabean trypsin 
inhibitor; pH 7.5.
10% SDS; 50 % glycerol; 200 mM Tris-HCl; 
bromophenol blue; pH 6.8.
25 mM Tris base; 192 mM glycine; 0.1%.(w/v) SDS; 
pH >8.3.
39 mM glycine; 48 mM Tris base; 0.0375% (w/v) SDS; 
20% (v/v) methanol.
Table 2.21
Details o f the Gel-Constituents Used fo r  SDS-PAGE 
Running gel: 3.75 ml acrylamide/bisacrylamide (30:0.8); 5.6 ml Milli-Q water;
5.6 ml 1 M Tris-HCl, pH 8.8; 0.25 ml 10%(w/v) SDS;
50 /xl 10% (w/v) ammonium persulphate (APS)
Polymerisation was initiated by the addition of 20 /xl of 
N’ ,N* ,N* ,N’-tetramethylethylenediamine (TEMED).
Stacking gel: 1.67 ml acrylamide/bisacrylamide (30:0.8); 6.0 ml Milli-Q water;
1.25 ml 1 M Tris-HCl, pH 6.8; 0.15 ml 10%(w/v) SDS;
50 /xl 10% (w/v) APS.
Polymerisation was initiated by the addition of 20 /xl of TEMED.
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The proteins were visualised using the enhanced chemiluminescence (ECL) system 
(Amersham International, Bucks., UK). The horseradish peroxidase conjugated to the 
secondary antibody oxidises luminol in the presence of hydrogen peroxide, releasing 
chemiluminescent light, which is detected by autoradiography. A piece of film (Kodak 
X-AR-5, Kodak, Liverpool, UK) was overlaid on the developed blot for various times 
depending on the intensity of the chemiluminescent signal (1 to 5 minutes). The film 
was developed in an automated developing machine (RG II Fuji X-Ray Film Processor, 
Fuji Photo Film Co. Ltd., Japan).
2.5.6 Investigation of Salbutamol Decomposition
A yellow discolouration of spray dried powders produced in the pilot-scale spray dryer 
was observed, which was more noticeable in powders containing a higher concentration 
of salbutamol than those containing less salbutamol. It was thought that this might have 
been due to possible decomposition of the salbutamol, which melts at 155°C, with 
decomposition, according to the BP (1998), and the decomposition rate of which is 
enhanced by elevated drug concentration and elevated temperature, according to the 
Pharmaceutical Codex (Lund, 1994). Thus, the salbutamol may have decomposed as a 
result of the very high temperatures that were necessary to operate the pilot-scale spray 
dryer. The various analytical methods that were employed to investigate this yellowing 
phenomenon are described below.
2.5.6.1 Infrared Absorption Spectrophotometry
Test B, the examination by infrared (IR) absorption spectrophotometry and comparison 
with the spectrum obtained with salbutamol CRS, described in the BP (1998), is the first 
identification test for salbutamol.
Potassium bromide (KBr) discs were prepared by triturating 1 to 2 mg of each of the 
test samples individually with 0.3 to 0.4 g of dried, finely powdered KBr. The mixture 
was ground using a pestle and mortar, then compressed under vacuum in a die (Specac,
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Kent, UK), at a pressure of approximately 10 tons. IR spectra were obtained using a 
Perkin-Elmer 782-50 Hz Infrared Spectrophotometer (Perkin-Elmer Ltd., UK).
2.5.6.2 Nuclear Magnetic Resonance Spectroscopy
Approximately 10 mg of each test sample was dissolved separately in deuterium oxide 
(D2O) for the determination of its proton magnetic resonance spectrum. Samples were 
analysed by the University of Bath NMR Service, Dept, of Pharmacy and 
Pharmacology using a Jeol JNM-GX270 FT NMR Spectrometer.
2.5.6.3 High Performance Liquid Chromatography
Samples were analysed for the presence of decomposition product(s) using a reverse 
phase high performance liquid chromatography (HPLC) method. Chromatographic 
conditions as described by Bannon and co-workers (1988), were employed for this 
work, with the exception that a different column was used (see Table 2.22 for details). 
The BP (1998) method was first attempted, but peak separation was less than ideal, and 
the results were not reproducible.
Table 2.22
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The Wavelength Scan function (F-2000 Fluorescence Spectrophotometer, Hitachi 
Instruments, Japan) was used to obtain excitation/emission spectral measurements for a 
sample of 2 /xg/ml micronised salbutamol base and also for samples of 2 /xg/ml spray 
dried salbutamol (bench-scale) at inlet temperatures of 110°C and 220°C. Excitation 
spectra were obtained by scanning over the range 220 nm to 350 nm, Xem = 305nm, and 
emission spectra by scanning over the range 250 to 400 nm, A,ex = 276 nm. The spectra 
obtained were almost identical when super-imposed, with peaks and valleys observed at 
exactly the same wavelengths.
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CHAPTER 3
Development of an In Vitro Method for the Assessment 
of Potential Controlled Release Pulmonary Drug
Delivery Systems
3.1 Introduction
Apparatus A of the British Pharmacopoeia (BP) (1998), often referred to as the twin 
stage impinger (TSI), is shown in Figure 3.1. The aerosol cloud deposits on three 
impaction surfaces. Larger particles impact initially on the back of the glass throat; the 
rest of the cloud passes through the upper liquid impinger, which has an effective 
aerodynamic cut-off diameter (ECD50) of 6.4 /xm at the prescribed flow rate of 60 ± 5 
lmin' 1 (Hallworth and Westmoreland, 1987), and the remaining fine particles are 
trapped by the last impaction surface, the lower impinger.
107
45’
Figure 3.1 Apparatus A (BP, 1998). The throat and upper impinger are defined as 
stage 1 (A, B, C, D), and the lower impinger is defined as stage 2 (E, F, G, H). 
Dimensions are in mm.
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The TSI was considered as a favourable analytical tool that could be modified for the 
purpose of this study. It has been shown that the TSI is a valuable tool for routine 
quality assessment of aerosols during product development, for stability testing and for 
the quality assurance and comparison of commercial products (Hallworth et al., 1978). 
It is true that the TSI is considered to have limitations in that the total sample is only 
divided into two size categories, and that the separation between these two categories is 
not perfectly sharp (El-Baseir et al., 1998), however, multistage devices are slow and 
tedious as chemical and physical quantification of collected particles is very time- 
consuming (El-Baseir et al., 1998). The TSI was originally developed to overcome this 
problem as a simpler but reproducible method for routine use (Hallworth et al., 1978; 
Timsina et al., 1994), as was required for this study.
3.2 Modification of Stage 1
3.2.1 Rationale
The aim of this initial work was to develop an in vitro testing method capable of 
discriminating between different controlled release formulations. Xanthan gum (XG), a 
hydrogel, was chosen as a model excipient for preliminary work due to its known ability 
as a controlled release excipient in tablet formulations (Challinor, 1996; Talukdar et al., 
1998). The principles established by studying stage 1 deposition of controlled release 
powders were subsequently used to develop an in vitro method for studying deposition 
and release from fine particles (section 3.3).
Stage 1 deposition represents delivery to the bronchiolar regions of the respiratory tract. 
Though this is not the conventional approach for pulmonary delivery (which is 
generally aimed at the large surface area of the alveolar region), there is scope for drug 
deposition to these parts for local therapy, for example with bronchodilators and anti­
inflammatory steroids, as it is the smooth muscle in this region which is the primary 
target site for these drugs (Ruffin et al., 1977). The obvious concern with such an
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approach is that particulate material deposited in the upper airways will be subjected to 
rapid mucociliary transport, resulting in a short duration of residence of both drug and 
carrier (Niven, 1992; Xeng et al., 1995a), whereas for a sustained release carrier to be 
effective, it needs to be able to reside in the lung for a prolonged period of time so that 
the drug can be released and then absorbed. To overcome this, deposition should be 
directed to the deeper ciliated regions of the lung, the terminal bronchiole and 
respiratory bronchiole regions, as described by Weibel (1991), where the mucociliary 
escalator moves slower (Niven, 1992). In this instance, as the dose is carried up the 
mucociliary tract, the slow release of drug should occur within the vicinity of its site of 
action (Niven, 1992).
3.2.2 Design Aspects
Initial experiments were conducted using a standard twin stage impinger (TSI) 
(Apparatus A of the BP (1998); Figure 3.1), whereby potential sustained release dry 
powder formulations were fired into the TSI; the solvent from stage 1 was removed and 
diluted to a specific volume. From these studies, the amount of drug appearing in the 
solvent could be calculated and a release profile constructed based on the time elapsed 
between firing of the powder and removal of the solvent from stage 1. This technique 
proved unsatisfactory as the amount of drug detected was generally determined by the 
amount of powder impinging in stage 1, with no indication of how the drug was 
releasing from the gel that had formed. Subsequently, the stage 1 assembly was 
redesigned to provide information about the drug diffusion properties of sustained 
release dry powder blends with different excipient components. The basis for 
determining the effectiveness of a particular dry powder formulation in vitro was in 
terms of its release profile.
To construct release profiles of given powder blends, aspects which are known to 
influence apparent release rates in standard tablet dissolution procedures were 
investigated; namely, the dissolution volume and stirring rate. The round bottom flask 
of the stage 1 assembly was modified as shown in Figure 3.2 (University of Bath glass- 
blowing workshop, Bath, UK). A 300 ml reservoir was added to its base, providing a
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large enough volume for sink conditions to be present for in vitro release studies. Sink 
conditions are generally considered to be achieved when the saturated solubility of a 
drug in a medium is greater than ten times that of the maximum achievable 
concentration during the course of an experiment (Corbo et al., 1993). The solubility of 
salbutamol in water is 1 in 70 (Lund, 1994), thus even when the worst-case scenario is 
considered, whereby the complete dose ( 1 0 0 0  fig) is deposited in stage 1 , the solubility 
of salbutamol is over 4000 times the estimated maximum concentration.
A 1 mm brass mesh was fused between the reservoir and the round bottom flask. This 
size was chosen so that drug could easily diffuse across it without being restricted by 
the mesh size. Also the gel that formed was able to rest on the grid and not fall on to 
the stirrer situated at the bottom of the reservoir.
The standard ‘swan neck’ section of the coupling tube that connects stage 1 and stage 2 
of the TSI was lengthened by 20 cm (the lower jet assembly was unchanged). This 
enabled the magnetic stirrer and a laboratory jack to be placed under the modified stage 
1 assembly above the 250 ml conical flask of the stage 2 assembly. The flow rate, for 
the Rotahaler® device used, was set to 60 ± 5 lmin' 1 to maintain an effective 
aerodynamic cut-off diameter (ECD50) of 6.4 pm.
Beneath the modified stage one assembly a magnetic stirrer (MR 3002, Heidolf Elektro 
GmbH & Co. KG, Kelheim, Germany) was set to a constant stir rate of 100 rpm. An 
increase or decrease in the stir rate resulted in a respective increase or decrease in 
release rate from the same powders; thus, this parameter was required to be constant in 
order to obtain comparable results for different powder formulations. It was important 
that this speed was not set too high as the development of a vortex disturbed the 
formation of the gel above.
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aFigure 3.2 Modified stage 1 of the TSI.
a) Connection for stage 1 jet; b) Stage 1 impingement chamber; c) To 
spectrophotofluorimeter; d) To stage 2; e) 1 mm brass mesh; f) From peristaltic pump; 
g) Sampling ports; h) 300 ml water reservoir; i) Magnetic follower. Specifications: a) 
Quickfit™ 24/29 joint; b) Height 65.6 x width 65.3 mm; d) Quickfit™ 14/23 joint + 22 
mm side arm; e) External diameter 50 mm; h) Height 74 x width 83 mm; i) Length 20 x 
width 7 mm.
Figure 3.3 Full assembly of the modified stage 1 TSI apparatus, 
a) Silicone mouthpiece adapter; b) Throat adapter; c) Neck adapter (stage 1 jet); d) 
Modified stage 1 assembly; e) Stage 1 impingement chamber; f) 300 ml reservoir; g) 
Lengthened stage 2 coupling tube adapter; h) Stage 2 jet; i) Stage 2 impingement 
chamber; j) To vacuum pump.
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3.2.3 Validation of the Modified Stage 1 TSI
3.2.3.1 Manufacture of Powder Blends
The powder blends used to test the modified stage 1 were prepared by wet granulation 
as detailed in section 2.3. Salbutamol base (SB) was used as a model drug, and blends 
were prepared at drug:excipient ratios of 1:100 using dextrose (DEX) and xanthan gum 
(XG). The ratio of excipients was varied to produce three blends with differing 
characteristics. Formulation A, DEX:XG (75:25), contained 25% hydrogel; formulation 
B, DEX:XG (50:50), contained 50% hydrogel and formulation C, DEX:XG (25:75) 
contained 75% hydrogel. A control blend of salbutamol:lactose (SB:LAC) (1:100) was 
prepared in the same way as the test blends.
3.2.3.2 Diffusion Experiment Method
The F-2000 spectrofluorimeter was set up for automated sampling (see section 2.5.2.2).
The modified TSI apparatus was set up as in Figure 3.4 (shown schematically in Figure 
3.3), using the specifications set out in the BP (1998). The reservoir beneath the 
modified stage 1 assembly was filled with 300 ml of distilled water. A magnetic 
follower was placed in the reservoir and stirred at a constant rate of 100 rpm using a 
magnetic stirrer (Heidloph™ MR 3002, Heidolf Elektro GmbH & Co. KG, Kelheim, 
Germany) to ensure mixing throughout. A continuous loop of water was set up with the 
300 ml reservoir of the modified stage 1 and the flow-through cell. The fluorimeter was 
blanked and the magnetic stirrer was switched off.
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Figure 3.4 Full assembly of the modified stage 1 TSI apparatus.
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The fine powder produced after particle size reduction of granules (section 2.3.2) was 
weighed into size 3 hard gelatin capsules (Davcaps®, Herfordshire, UK), to a fill-weight 
of 20 ± 1 mg. A Rotahaler® device (GlaxoWellcome, Hertfordshire, UK) was used to 
discharge the contents of five gelatin capsules individually into the modified TSI at a 
rate of 60 ± 5 lmin'1 using an oil-less rotary vane pump model 1475 (Gast 
Manufacturing Company Limited, Buckinghamshire, UK). Each capsule was fired for 
4 seconds giving an inhaled volume of 4 litres of air per capsule. This gave a total dose 
weight of 100 mg, with a total drug content of 1000 jug.
After discharging all five capsules, the magnetic stirrer was switched on and the timing 
device was activated. Data points were collected at the set interval previously 
programmed into the timing device, to obtain the release profile of the powder blend in 




Figure 3.5 shows the release profile obtained for the control blend of 1:100 SB:LAC, 
and Figures 3.6 to 3.8 illustrate the release profiles obtained for each of the hydrogel- 
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Figure 3.5 Release profile for the control blend, SB:LAC (1:100), performed using 
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Figure 3.6 Release profiles for formulation A, SB:DEX:XG (1:75:25). Run 1 (■), 
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Figure 3.7 Release profiles for formulation B, SB:DEX:XG (1:50:50). Run 1 (■), 
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Figure 3.8 Release profiles for formulation C, SB:DEX:XG (1:25:75). Run 1 (■), 
and run 2 ( • )  performed using the modified stage 1 TSI.
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3.2.3.4 Discussion and Conclusions
Upon comparison of the results obtained from the different formulations tested, a wide 
variation in release profiles were obtained that could be distinguished between using the 
novel modified stage 1 of the TSI.
After firing 100 mg of the control blend into the modified stage 1, the powder was seen 
to pass through the 1 mm wire mesh and into the 300 ml reservoir as large aggregated 
particles. These quickly dispersed and began to dissolve. The modified TSI diffusion 
data for the SB:LAC (1:100) control blend indicated a quick diffusion rate across the 
sinter. With no polymer-based excipient in this particular formulation, total release of 
the SB occurred in 6 to 7 minutes, Figure 3.5.
Release rates for formulations A, B and C, each containing increasing amounts XG (the 
hydrogel component) can be seen to vary with respect to how much XG was present in 
the formulation, as would be expected. Formulation A (25% hydrogel, Figure 3.6) took 
30 to 35 minutes and Formulation B (50% hydrogel, Figure 3.7) took 180 minutes to 
reach 100% drug-release. Formulation C (75% hydrogel, Figure 3.8) did not achieve 
100% release of SB even after 400 minutes. After firing of the test blends, the powder 
could be seen on the surface of the 300 ml reservoir. Over time, the powder was seen to 
expand and form a hydrogel structure that rested on the top of the wire mesh above the 
reservoir. This was more visually apparent for formulations B and C, and was reflected 
in the release rates observed for those blends in particular.
Xanthan gum has a high affinity for water and is completely soluble (Fitzpatrick, 1995). 
Rapid hydration of the particles results in extensive swelling, causing them to come into 
contact and coalesce (Fitzpatrick, 1995; Dhopeshwarkar and Zatz, 1993). The 
formation of a continuous viscoelastic gel matrix stops the drug from dispersing into the 
reservoir quickly. It is probable that this also occurs following deposition of 
deaggregated particles in the modified stage 1 TSI, thus resulting in retardation of drug 
release. In conclusion, the modified stage 1 TSI apparatus was proven to be capable of 
discriminating between drug release rates from different model controlled release 
formulations for potential bronchial delivery.
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3.3 Modification of Stage 2
3.3.1 Rationale
Stage 2 deposition in the twin stage impinger (TSI), Apparatus A of the BP (1998), 
represents delivery to the alveolar region, or deep lung. It is from the large surface area 
of this region that most drugs, including proteins, are relatively well absorbed (Smith, 
1997; Niven, 1995; Patton, 1996) and as a result is targeted for systemic drug delivery 
via the pulmonary route. In vitro deposition patterns and release rates from potential 
controlled release formulations aimed for systemic delivery would clearly be both 
necessary and beneficial in terms of optimising these characteristics prior to in vivo 
studies.
The aim in modifying the stage 2 of the TSI was to develop an in vitro testing method 
that would be capable of distinguishing between release rates from different controlled 
release formulations, and in particular, from particles of < 5 /xm; the generally accepted 
aerodynamic particle size for pulmonary drug delivery is from 1 to 5 /xm (Gonda 1992; 
Newman, 1985).
3.3.2 Design Aspects
The stage 2 assembly of the standard TSI was modified as shown in Figure 3.9. In 
keeping with the design of the modified stage 1, it was decided that a reservoir would be 
added to the base of the stage 2 flask, with the fusion of an inert, synthetic support 
membrane between the base of the flask and the reservoir, upon which the deposited 
particles would be able to rest.
The pore size of the support membrane was required to be such that fine particles would 
be deposited on the surface and not pass straight through. In addition, it needed to be 
robust and washable for routine use in analytical procedures, and allow the passage of 
proteins through with minimal adsorption. A PI sintered disc (5 cm x 3 mm) (Aimer
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Products Ltd, London, UK) was chosen for this purpose. PI indicates a disc of porosity 
grade 1, which is equal to 160 /xm (range: 100-160 /xm). Sintered discs available from 
Aimer products Ltd. are graded in terms of porosity, where P0 = 250 /xm (range: 160- 
250 /xm) down to P5 = 1.6 /xm (range: 4-10 /xm).
A larger conical flask of 500 ml capacity was employed in preference to the standard 
250 ml conical flask. The larger flask allowed for a bigger reservoir to ensure sink 
conditions would be present, while still maintaining upright balance of the modified 
stage 2 assembly. The complete sinter disc was fused between the base of the large 
flask and the reservoir (University of Bath glass-blowing workshop, Bath, UK).
The ‘swan neck’ section of the coupling tube, which connects stage 1 and stage 2 of the 
TSI, was lengthened to account for the larger size of the lower impingement chamber. 
The complete vertical length to the top-most part of the modified coupling tube was 290 
mm, with the lower vertical section accounting for 43 mm of the total length. In 
addition, the lower jet assembly of the standard TSI was removed and replaced with a 
25 mm absolute filter holder (modified non-sterile Swinnex-25 filter holder, Millipore, 
Ireland). The modified lower jet assembly covered a larger surface area of the sintered 
disc, and prevented any water above the surface of the disc from being disrupted when 
the vacuum pump was operated. The filter holder could be removed, taken apart and 
washed thoroughly in between analyses. The inside protrusion on the underside was 
removed and the outside surface of the filter holder was smoothed down to an external 
diameter of 30 mm (University of Bath Workshop, Bath, UK), which enabled it to fit 
easily through the top of the 34/35 Quickfit™ 500 ml conical flask. The standard PTFE 
washer was kept in place to maintain a good seal between the two detachable parts of 
the filter holder, but a filter membrane was not required, as powder was intended to pass 
through the modified filter holder, onto the sinter glass.
Beneath the modified stage 2 assembly a magnetic stirrer (Heidolph™ MR3000, 
Heidolf Elektro GmbH & Co. KG, Kelheim, Germany) was set to a constant stir rate of 
500 rpm. This speed was chosen as the fastest without disturbing the particles on the 
top surface of the sinter
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Figure 3.9 Modified stage 2 of the TSI. Dimensions are detailed in Table 3.1; 
c) To vacuum pump.
f
Figure 3.10 Full assembly of the modified stage 2 TSI.
a) Silicone mouthpiece adapter; b) Throat adapter; c) Neck (modified stage 1 jet, with 5 
(im  cut-off); d) Stage 1 impingement chamber; e) Modified stage 2 coupling tube 
adapter; f) Modified stage 2 assembly; g) To vacuum pump; h) Modified stage 2 
impingement chamber; i) Modified Stage 2 jet, fitted with 25 mm absolute filter holder; 
j) 160 ml reservoir; k) PI sintered disc; 1) Sampling port.
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Table 3.1
Details o f the Modified Stage 2 o f the TSI.
Code Item Description Dimensions
(Fig-3.8) (mm)*
a Coupling tube Medium wall glass tubing 
ground glass cone 
Bent section and upper vertical section 
external diameter x  length (highest point) 
Lower vertical section 
external diameter x length
14/23 
13 x 247 
8 x4 3
b Screwthread, As BP (1998)
side-arm Plastic screw cap 28/13
adapter Silicone rubber ring 
PTFE washer
Glass screwhead, threadsize 






d Stage 2 impinge­ Conical flask 500 ml
ment chamber ground-glass inlet socket 34/35
e Stage 2 jet Modified Swinnex-25 filter holder,
assembly full height x external diameter, 
connected to lower vertical section of 
coupling tube by PTFE tubing
30x30
f Support PI sintered disc (Aimer Products Ltd., UK)
membrane diameter x  thickness 5 0 x 3




h Stage 2 
reservoir
Blown glass (University of Bath glass- 
blowing workshop, Bath, UK)
160 ml
i Magnetic Plain, PTFE encapsulated (Jencons
Follower (Scientific) Ltd., UK), length x  width 2 5 x 6
*Dimensions o f ground-glass sockets and cones are specified in terms o f suitable 
Quickfit™ apparatus.
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The TSI, Apparatus A of the BP (1998), with the standard stage 1 jet width of 14 mm 
and at the prescribed flow rate of 60 ± 5 lmin'1, has an effective aerodynamic cut-off 
diameter (ECD50; that is, the particle size for 50% retention of unit density spheres of 
equivalent settling rate in air) of 6.4 /xm (Hallworth and Westmoreland, 1987). The 
effect of changes in airflow rate or jet size on the ECD50 can be calculated using 
Equation 3.1, a simplified impaction equation developed by Hallworth and 
Westmoreland (1987):
ECDX =  X
Equation 3.1
Where F  is the flow rate (lmin'1), W is the jet diameter (cm) and X  is a constant with a 
value of 30 for the TSI.
For a better representation of deep lung deposition, and thus potential respirable 
particles, the internal diameter of the stage 1 jet of Apparatus A was modified to 11.6 
mm (University of Bath glass-blowing workshop, Bath, UK) to achieve an ECD50 of 
approximately 5 /xm (calculated 4.8 /xm) when operated at a flow rate of 60 ± 5 lmin'1, 
for use in conjunction with the modified stage 2 assembly. Both the upper section of 
the jet (between the throat cone joint and the stage 1 flask joint) and the length of the 
glass tube forming the jet were maintained as specified in the BP (1998).
Although no attempt was made to calibrate the modified TSI, the proof of principle was 
confirmed by mono-sized sphere calibration of comparable jets. The ECD50 of the 
modified stage 1 jet was measured as 5.3 ± 0.3 /xm by AEA Technology (Aerosol 
Science Centre, Oxfordshire, UK).
99
3.3.3 Validation of the Modified Stage 2 TSI
3.3.3.1 Deposition Characteristics
All TSI experiments were performed using an airflow rate of 60 ± 5 lmin'1. The current 
recommendation is that in vitro drug deposition from dry powder inhalers (DPIs) should 
be determined at an airflow rate equivalent to a 4 kPa pressure drop across the device 
(Ganderton, 1996). To achieve a 4 kPa pressure drop across the Monohaler® (Miat, 
Italy), which was the device used for the majority of investigations undertaken in this 
study, required a flow rate of 96 lm in1, as determined by the method outlined by 
Ganderton (1996).
A reduced flow rate (60 ± 5 lmin'1) was more appropriate for investigations using the 
modified stage 2 TSI as at the higher flow rate of 96 lmin'1 the turbulence caused within 
the apparatus disturbed the contents of the reservoir, causing water to be pulled through 
the sinter, from the reservoir into the impingement chamber. This was undesirable as 
the aim was to deposit particles onto the sinter to assess drug release profiles. 
Furthermore, it is the pressure drop developed by adult patients with respiratory disease 
when inhaling through a DPI at peak inspiratory flow rate that is typically in the region 
of 4 kPa, which will not necessarily correspond to that achieved by patients who may 
not have respiratory disease, in the case of insulin delivery by inhalation to treat 
diabetes, for example. The consistency of the flow rate used for in vitro investigations 
throughout this study was thus considered as more important, to enable comparisons 
between the formulations that were under investigation.
Deposition patterns of a conventional dry powder formulation (Ventolin® Rotacaps®, 
200 /xg, Allen & Hanburys, UK) obtained using the modified stage 2 TSI apparatus 
were compared with those obtained for the same formulation using the standard TSI, 
Apparatus A of the BP (1998), with a modified stage 1 jet to achieve an ECD50 of 5 /xm 
at 60 ± 5 lm in1 (see section 3.3.2 above), hereafter referred to as the standard TSI.
100
Standard TSI Experiments
The method used was based on the BP (1998) procedure for powder inhalers, Appendix 
XHF. 7 ml and 30 ml of distilled water was introduced into the upper (stage 1) and 
lower (stage 2) impingement chambers respectively. The airflow through the apparatus 
was adjusted to 60 ± 5 lmin'1 (SCR2 Flow Meter, Glass Precision Ltd., UK), without the 
inhaler in place, using an oil-less rotary vane pump model 1475 (Gast Manufacturing 
Company Limited, Buckinghamshire, UK). This was then repeated after placing the 
unprimed inhaler device in the mouthpiece adapter; the use of an additional glass 
adapter was required, to fit over the device and connect the mouthpiece adapter, at the 
inlet of the throat, to the airflow meter.
Two inhaler devices were used to perform two sets of analyses: (a) the Rotahaler® 
(GlaxoWellcome, Hertfordshire, UK), which is a low resistance device (Hindle et al., 
1994) and (b) the Monohaler®, a medium resistance device whose performance has been 
shown to be comparable to that of other dry powder devices (Pitcairn et al., 1997). The 
inhaler was prepared for use and a single Ventolin® Rotacap® was discharged into the 
TSI. The device and the components of stage 1 and stage 2 of the apparatus were 
washed into individual volumes of 50 ml with distilled water. Drug content deposited 
in each section was determined by spectrofluorimetric assay (section 2.5.2). Five 
capsules were analysed in this way, for each inhaler device.
Modified Stage 2 TSI Experiments
7 ml of distilled water was introduced into the stage 1 impingement chamber and 160 
ml into the stage 2 reservoir, so that the sinter was just wetted. The airflow through the 
apparatus was adjusted to 60 ± 5 lmin'1, without the inhaler in place, using the oil-less 
rotary vane pump and then repeated as before, with the unprimed inhaler placed in the 
mouthpiece. The inhaler was prepared for use and two Ventolin® Rotacaps® were 
discharged consecutively into the TSI. The device and the components of stage 1 of the 
apparatus were washed into individual volumes of 100 ml with distilled water. The 
components of the modified stage 2 were washed into a volume of 250 ml. Drug 
content deposited in each section was determined by spectrofluorimetric assay (section 
2.5.2). Five capsules were analysed in this way, for each inhaler. In addition, a second
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set of experiments were performed with the modified stage 2 using the Monohaler® in 
order to establish consistency.
Parameters Used to Describe Aerosol Performance
The performance of an aerosol during in vitro testing, using either the standard or the 
modified stage 2 TSI was described by three main parameters: the total recovered dose 
(RD), the total emitted dose (ED) and fine particle fraction (FPF). The ED refers to the 
amount of drug (mass or %) expelled from the device and recovered from the testing 
apparatus and the FPF is the portion of the ED that is potentially respirable (< 5 fim). 
Equations 3.2 -  3.4 were used to calculate the dry powder fractions described above.
Total amount o f drug detected (fig)
Total Recovered Dose (%) = x 100
Theoretical amount o f drug present (fig)
Equation 3.2
Total Emitted Dose (%) =
Amount of drug detected in stage 1 and stage 2 (fig)
x 100
Total amount of drug detected (fig)
Equation 3.3
Amount o f drug deposited in Stage 2 (%)
Fine Particle Fraction (%) =





The deposition patterns obtained using the standard TSI, Apparatus A, and those for the 
modified stage 2 TSI apparatus are detailed in Table 3.1. Dry powder fractions are 
detailed in Table 3.3.
Table 3.2
Deposition Data Obtained fo r  Ventolin® Rotacaps® Following Analysis Using a
Standard TSI and the Modified Stage 2 TSI, (Mean (%) ±SD; n = 5).




Modified Stage 2 TSI:
Monohaler®
Monohaler®*












*Second set o f experiments, where n=3.
Table 3.3
Dry Powder Fractions Obtained fo r  Ventolin® Rotacaps® Following Analysis Using a 





Modified Stage 2 TSI:
Monohaler®
Monohaler®*












*Second set o f experiments, where n=3.
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Discussion and Conclusions
The results obtained for the FPF using the Rotahaler® (14.5%) are misleading as the fine 
particle dose (FPD), represented by stage 2 deposition, was actually quite low, with a 
large proportion of the dose being retained in the device. The poor results obtained for 
Stage 2 deposition from the Rotahaler® were consistent with results obtained by 
Vidgren and co-workers (1988), illustrating its poor deaggregating capability as a result 
of the lack of turbulent airflow within the inhaler. Since it was the FPF that was of 
interest in this study, the Monohaler® was employed for all modified stage 2 
investigations performed during this study, in preference to the Rotahaler®.
The deposition data obtained using the Monohaler® was better in terms of drug 
deposition in both the standard and the modified stage 2 TSI. Though there was an 
apparent difference in the actual deposition data for the standard and modified TSI, 
these data were more comparable than the deposition data obtained for the Rotahaler® 
and Monohaler®, both using the standard TSI. It is probable that the new dimensions of 
the modified stage 2 TSI resulted in the decrease in stage 2 deposition and FPF that was 
observed when this apparatus was used. However, the results obtained from the second 
set of experiments which were performed using the modified stage 2 and the 
Monohaler® showed that deposition in the modified stage 2 from the Monohaler® was 
reproducible. A student’s t-test, performed using MicroCal® Origin v2.94, confirmed 
that there was no significant difference at the 0.05 level between the mean values 
obtained for stage 2 deposition (t = -0.67764, p = 0.52326) and for the FPF (t = - 
0.80825, p = 0.4498).
3.3.3.2 Drug Release Characteristics
3.3.3.2.1 Manufacture of Powder Blends
The same blends (prepared by wet granulation, section 2.3) were used to validate the 
modified stage 2 as had been used to validate the modified stage 1 (3.2.3), to enable a 
direct comparison. Formulation A, DEX:XG (75:25), contained 25% hydrogel; 
formulation B, DEX:XG (50:50), contained 50% hydrogel and formulation C, DEX:XG
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(25:75) contained 75% hydrogel. The control blend of salbutamol: lactose (SB:LAC) 
(1:100) was prepared in the same way as the test blends.
3.3.3.2.2 Diffusion Experiment Method
The modified TSI apparatus was set up as in Figure 3.11 (shown schematically in 
Figure 3.10), using the specifications set out in the BP (1998). The reservoir beneath 
the modified stage 2 assembly was filled with 160 ml distilled water. A magnetic 
follower was placed in the reservoir and stirred at a constant rate of 500 rpm using a 
magnetic stirrer (Heidolph™ MR3000, Heidolf Elektro GmbH & Co. KG, Kelheim, 
Germany) to ensure mixing throughout.
Content uniformity of the fine powder produced after particle size reduction of granules 
(section 2.3.2) was carried out by weighing ten samples of 50 mg of each of the blends 
and making up to 250 ml with distilled water before measuring the fluorescence of each. 
This method was adapted from the BP (1998) Uniformity of Content test applicable for 
unit-dose solid preparations for inhalation. The powder was then weighed into size 3 
hard gelatin capsules (Davcaps®, Herfordshire, UK), to a fill-weight of 25 ± 1 mg. 
Gelatin capsules were stored in a dessicator at 53-55% relative humidity (RH) 
(maintained using a saturated salt solution of magnesium nitrate), for at least 24 hours 
prior to use. This was to avoid brittle fracture of the capsules during piercing with the 
inhaler, which can occur if the RH of the surrounding environment falls below about 
40% at ambient temperature (Kontny and Mulski, 1989). A Monohaler® device (Miat, 
Italy) was used to discharge three gelatin capsules individually into the modified TSI at 
a rate of 60 ± 5 lmin'1 using an oil-less rotary vane pump model 1475 (Gast 
Manufacturing Company Limited, Buckinghamshire, UK). This gave a total dose 
weight of 75 mg with a total drug content of 750 /xg. Each capsule was fired for 4 
seconds giving an inhaled volume of 4 litres of air per capsule. After discharging all 
three capsules, the magnetic stirrer was switched on and 5 ml of distilled water was 
added to the reservoir using a 5 ml plastic syringe (B-D Plastipak, Becton Dickinson 
Company, NJ, USA) and needle (B-D PrecisionGlide® Needles 21G2, Becton Dickinson 
Company, NJ, USA).
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Figure 3.11 Full assembly of the modified stage 2 TSI.
1 0 6
Samples were taken manually, using a fresh syringe for each, over a period of 2 hours, 
at 5-minute intervals for the first hour, then at 10-minute intervals. Immediately after 
taking each 5 ml sample, the same volume was replaced with fresh distilled water. 
Samples were stored to one side for subsequent fluorescence analysis to determine the 
salbutamol concentration of each (section 2.5.2).
At the end of each experiment, the stage 1 section of the modified TSI was carefully 
removed and washed with distilled water into a 250 ml volume, sonicating in a water 
bath (Decon ultrasonic bath, UK) if necessary to ensure that all of the powder that had 
been deposited was collected. The device and modified stage 2 section were also 
washed, separately, into 250 ml volumes. From these washings, the RD, the ED and the 
FPF could be calculated (Equations 3.2-3.4). Each experiment was repeated at least 
three times to obtain concordance.
3.3.3.2.3 Results 
Particle Size Distributions
Results obtained for the particle size analysis of the three blends using the Malvern 
Mastersizer X (section 2.4.1) are shown in Table 3.4.
Content Uniformity
All of the blends were found to be uniform in drug content as determined by the BP 
(1998) definition that the preparation complies with the test if not more than one of the 
individual values thus obtained is outside the limits 85% to 115% o f the average value, 
and none is outside the limits 75% to 125 % o f the average value.
Mean drug content/mg obtained for each blend from the test for content uniformity was 
used to calculate the theoretical amount of drug present for each analysis, where actual 
capsule fill-weights had been recorded for this purpose.
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Dry Powder Fractions
Table 3.5 represents mean recovery and dry powder fractions obtained for each of the 
blends, following analysis using the modified stage 2 TSI. Equations 3.2-3.4 were used 
to calculate the dry powder fractions (section 3.3.3.1).
Drug Release Profiles
Figure 3.12 shows the release profile obtained for the control blend. Figures 3.13 to 
3.15 illustrate the release profiles obtained from each of the formulations of varying 
hydrogel concentration, tested using the modified stage 2 TSI.
Table 3.4
Average Particle Size Data fo r Three Blends Prepared by Wet Granulation with 
Drug:Excipient Ratios o f 1:100, as Determined by Dispersion in 0.1% (w/v) Lecithin in 
Cyclohexane (Malvern Mastersizer X) Following Sonication fo r  3 Minutes,
(Mean ±SD; n = 3).
Mean Equivalent Volume Diameter (pm)
d (0.1) d (0.5) d (0.9)
Control 1.07 ±0.021 3.19 ±0.091 7.93 ±0.326
Formulation A 0.86 ± 0.000 3.15 ±0.012 6.77 ±0.101
Formulation B 0.98 ±0.015 3.46 ± 0.042 7.88 ±0.076
Formulation C 1.02 ±0.012 3.78 ±0.071 9.12 ±0.670
Table 3.5
Average Dry Powder Fractions o f Each o f the Three Blends Following Analysis Using 
the Modified Stage 2 TSI, (Mean (%) ±SD; n —3).
RD ED FPF
Control 98.0 ± 7.642 82.6 ± 1.826 16.9 ±1.510
Formulation A 89.3 ± 9.675 83.3 ±0.160 16.4 ± 1.082
Formulation B 83.3 ± 1.450 90.1 ± 1.707 10.5 ±0.153
Formulation C 77.5 ±0.851 81.4 ± 12.80 18.7 ±1.800
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Figure 3.12 Release profiles for the control blend, SB:LAC (1:100). Run 1 (■), run 2 
(•)  and run 3 (▲) tested using the modified stage 2 TSI.
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Figure 3.13 Release profiles for formulation A, SB:DEX:XG (1:75:25). Run 1 (■), 
run 2 (•)  and run 3 (A) tested using the modified stage 2 TSI.
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Time (minutes)
Figure 3.14 Release profiles for formulation B, SB:DEX:XG (1:50:50). Run 1 (■), 
run 2 (• )  and run 3 (A) tested using the modified stage 2 TSI.
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Figure 3.15 Release profiles for formulation C, SB:DEX:XG (1:25:75). Run 1 (■), 
run 2 (•)  and run 3 (A) tested using the modified stage 2 TSI.
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3.3.3.2.4 Discussion and Conclusions
The entire drug from the control blend was released across the support membrane of the 
modified stage 2 within 9 minutes (Figure 3.12). By comparison, formulations A, B 
and C, containing increasing amounts of XG (the hydrogel polymer excipient), took 21 
minutes, 41 minutes and 63 minutes respectively to reach 100% drug release (Figures 
3.13-3.15).
These results are comparable to those obtained with the modified stage 1 (3.2.3.3), with 
the time to 100% drug release increasing with respect to the amount of XG present in 
the formulation; thus the rate of diffusion being determined by the concentration of XG 
in both instances. The sugar component (dextrose) present in these polymer 
formulations that were employed to validate the modified stage 1 TSI and the modified 
stage 2 TSI is known to have the effect of increasing the wetting properties, as a result 
of its higher solubility (Challinor, 1996). A faster release of drug is observed as the 
concentration of dextrose increases, in addition to the decrease in XG concentration, due 
to the sugar being dissolved by the water in the reservoir, and thus allowing faster 
hydration of the polymer.
The fact that the respective times to 100% drug release are much less when tested using 
the modified stage 2 than when tested using the modified stage 1 can be attributed to 
two main factors: a) the particle size of the powder from which drug release was being 
assessed and b) the mass of powder from which drug release was being assessed.
It would seem reasonable that the larger particle size (> 6.4 /xm) of the powder 
deposited in stage 1 would result in more extensive swelling as the particles hydrated, 
which would inevitably cause the large particles to come in to contact and coalesce 
more readily than the small particles deposited in stage 2 (< 5 /xm). Smaller particles 
also have a higher surface-to-volume ratio compared to macroscopic systems, and 
consequently diffusion-controlled drug release results in a more rapid release from the 
smaller microspheres (Franssen et al., 1999). In addition, the total mass of powder 
deposited in each stage requires consideration -  approximately 60% of the total dose 
was deposited in stage 1 compared with approximately 15% deposited in stage 2. A 
total of 100 mg of each blend was discharged during the modified stage 1
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investigations, with an estimated 60 mg reaching stage 1 compared to the 75 mg which 
was discharged during the stage 2 investigations, with an estimated 11.25 mg reaching 
stage 2, a percentage of which collects in the jets and glassware in each case. Thus, 
more than five times as much powder was deposited in stage 1, which would 
undoubtedly result in prolongation of drug release.
Unlike particles that were deposited in the modified stage 1, particles deposited on the 
support membrane of the modified stage 2 were not visible to the naked eye. Thus, 
there was no visual evidence that these small particles formed a hydrogel structure, 
which then caused retardation of drug release into the reservoir, however this would 
seem the likely explanation in view of the results obtained following both modified 
stage 1 TSI and modified stage 2 TSI investigations of the same blends.
Total recoveries obtained following modified stage 2 TSI testing gradually decreased as 
the XG component of the formulation increased (Table 3.5). This can be explained by 
losses occurring due to increased gel-formation upon wetting, as the amount of XG 
increased. Glassware was sonicated to maximise collection of deposited drug, however 
it is conceivable that at the higher concentrations of XG, this process did not achieve 
complete dissolution.
In conclusion, the modified stage 2 TSI apparatus was found capable of evaluating and 
distinguishing between drug release rates from different dry powder blend particles 
having an aerodynamic diameter of approximately 5 /tm or less. Dissolution profiles 
obtained from particles of this size range were found to be much faster than those 
obtained from larger particles of the same formulations, indicating the need to evaluate 




Development of an In Vitro Method for the Assessment 
of Potential Controlled Release Pulmonary Drug
Delivery Systems
The TSI was considered as a favourable analytical tool that could be modified for the 
purpose of this study. It has been shown that the TSI is a valuable tool for routine 
quality assessment of aerosols during product development, for stability testing and for 
the quality assurance and comparison of commercial products (Hallworth et al., 1978). 
It is true that the TSI is considered to have limitations in that the total sample is only 
divided into two size categories, and that the separation between these two categories is 
not perfectly sharp (El-Baseir et al., 1998), however, multistage devices are slow and 
tedious as chemical and physical quantification of collected particles is very time- 
consuming (El-Baseir et al., 1998). The TSI was originally developed to overcome this 
problem as a simpler but reproducible method for routine use (Hallworth et al., 1978; 
Timsina et al., 1994), as was required for this study.
3.2 Modification of Stage 1
3.2.1 Rationale
The aim of this initial work was to develop an in vitro testing method capable of 
discriminating between different controlled release formulations. Xanthan gum (XG), a 
hydrogel, was chosen as a model excipient for preliminary work due to its known ability 
as a controlled release excipient in tablet formulations (Challinor, 1996; Talukdar et al., 
1998). The principles established by studying stage 1 deposition of controlled release 
powders were subsequently used to develop an in vitro method for studying deposition 
and release from fine particles (section 3.3).
Stage 1 deposition represents delivery to the bronchiolar regions of the respiratory tract. 
Though this is not the conventional approach for pulmonary delivery (which is 
generally aimed at the large surface area of the alveolar region), there is scope for drug 
deposition to these parts for local therapy, for example with bronchodilators and anti­
inflammatory steroids, as it is the smooth muscle in this region which is the primary 
target site for these drugs (Ruffin et al., 1977). The obvious concern with such an
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approach is that particulate material deposited in the upper airways will be subjected to 
rapid mucociliary transport, resulting in a short duration of residence of both drug and 
carrier (Niven, 1992; Xeng et a l, 1995a), whereas for a sustained release carrier to be 
effective, it needs to be able to reside in the lung for a prolonged period of time so that 
the drug can be released and then absorbed. To overcome this, deposition should be 
directed to the deeper ciliated regions of the lung, the terminal bronchiole and 
respiratory bronchiole regions, as described by Weibel (1991), where the mucociliary 
escalator moves slower (Niven, 1992). In this instance, as the dose is carried up the 
mucociliary tract, the slow release of drug should occur within the vicinity of its site of 
action (Niven, 1992).
3.2.2 Design Aspects
Initial experiments were conducted using a standard twin stage impinger (TSI) 
(Apparatus A of the BP (1998); Figure 3.1), whereby potential sustained release dry 
powder formulations were fired into the TSI; the solvent from stage 1 was removed and 
diluted to a specific volume. From these studies, the amount of drug appearing in the 
solvent could be calculated and a release profile constructed based on the time elapsed 
between firing of the powder and removal of the solvent from stage 1. This technique 
proved unsatisfactory as the amount of drug detected was generally determined by the 
amount of powder impinging in stage 1, with no indication of how the drug was 
releasing from the gel that had formed. Subsequently, the stage 1 assembly was 
redesigned to provide information about the drug diffusion properties of sustained 
release dry powder blends with different excipient components. The basis for 
determining the effectiveness of a particular dry powder formulation in vitro was in 
terms of its release profile.
To construct release profiles of given powder blends, aspects which are known to 
influence apparent release rates in standard tablet dissolution procedures were 
investigated; namely, the dissolution volume and stirring rate. The round bottom flask 
of the stage 1 assembly was modified as shown in Figure 3.2 (University of Bath glass- 
blowing workshop, Bath, UK). A 300 ml reservoir was added to its base, providing a
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large enough volume for sink conditions to be present for in vitro release studies. Sink 
conditions are generally considered to be achieved when the saturated solubility of a 
drug in a medium is greater than ten times that of the maximum achievable 
concentration during the course of an experiment (Corbo et al., 1993). The solubility of 
salbutamol in water is 1 in 70 (Lund, 1994), thus even when the worst-case scenario is 
considered, whereby the complete dose (1000 pg) is deposited in stage 1, the solubility 
of salbutamol is over 4000 times the estimated maximum concentration.
A 1 mm brass mesh was fused between the reservoir and the round bottom flask. This 
size was chosen so that drug could easily diffuse across it without being restricted by 
the mesh size. Also the gel that formed was able to rest on the grid and not fall on to 
the stirrer situated at the bottom of the reservoir.
The standard ‘swan neck’ section of the coupling tube that connects stage 1 and stage 2 
of the TSI was lengthened by 20 cm (the lower jet assembly was unchanged). This 
enabled the magnetic stirrer and a laboratory jack to be placed under the modified stage 
1 assembly above the 250 ml conical flask of the stage 2 assembly. The flow rate, for 
the Rotahaler® device used, was set to 60 ± 5 lmin'1 to maintain an effective 
aerodynamic cut-off diameter (ECD50) of 6.4 pm.
Beneath the modified stage one assembly a magnetic stirrer (MR 3002, Heidolf Elektro 
GmbH & Co. KG, Kelheim, Germany) was set to a constant stir rate of 100 rpm. An 
increase or decrease in the stir rate resulted in a respective increase or decrease in 
release rate from the same powders; thus, this parameter was required to be constant in 
order to obtain comparable results for different powder formulations. It was important 
that this speed was not set too high as the development of a vortex disturbed the 
formation of the gel above.
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aFigure 3.2 Modified stage 1 of the TSI.
a) Connection for stage 1 jet; b) Stage 1 impingement chamber; c) To 
spectrophotofluorimeter; d) To stage 2; e) 1 mm brass mesh; f) From peristaltic pump; 
g) Sampling ports; h) 300 ml water reservoir; i) Magnetic follower. Specifications: a) 
Quickfit™ 24/29 joint; b) Height 65.6 x width 65.3 mm; d) Quickfit™ 14/23 joint + 22 
mm side arm; e) External diameter 50 mm; h) Height 74 x width 83 mm; i) Length 20 x 
width 7 mm.
Figure 3.3 Full assembly of the modified stage 1 TSI apparatus, 
a) Silicone mouthpiece adapter; b) Throat adapter; c) Neck adapter (stage 1 jet); d) 
Modified stage 1 assembly; e) Stage 1 impingement chamber; f) 300 ml reservoir; g) 
Lengthened stage 2 coupling tube adapter; h) Stage 2 jet; i) Stage 2 impingement 
chamber; j) To vacuum pump.
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3.2.3 Validation of the Modified Stage 1 TSI
3.2.3.1 Manufacture of Powder Blends
The powder blends used to test the modified stage 1 were prepared by wet granulation 
as detailed in section 2.3. Salbutamol base (SB) was used as a model drug, and blends 
were prepared at drug:excipient ratios of 1:100 using dextrose (DEX) and xanthan gum 
(XG). The ratio of excipients was varied to produce three blends with differing 
characteristics. Formulation A, DEX:XG (75:25), contained 25% hydrogel; formulation 
B, DEX:XG (50:50), contained 50% hydrogel and formulation C, DEX:XG (25:75) 
contained 75% hydrogel. A control blend of salbutamol: lactose (SB:LAC) (1:100) was 
prepared in the same way as the test blends.
3.2.3.2 Diffusion Experiment Method
The F-2000 spectrofluorimeter was set up for automated sampling (see section 2.5.2.2).
The modified TSI apparatus was set up as in Figure 3.4 (shown schematically in Figure 
3.3), using the specifications set out in the BP (1998). The reservoir beneath the 
modified stage 1 assembly was filled with 300 ml of distilled water. A magnetic 
follower was placed in the reservoir and stirred at a constant rate of 100 rpm using a 
magnetic stirrer (Heidloph™ MR 3002, Heidolf Elektro GmbH & Co. KG, Kelheim, 
Germany) to ensure mixing throughout. A continuous loop of water was set up with the 
300 ml reservoir of the modified stage 1 and the flow-through cell. The fluorimeter was 
blanked and the magnetic stirrer was switched off.
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The fine powder produced after particle size reduction of granules (section 2.3.2) was 
weighed into size 3 hard gelatin capsules (Davcaps®, Herfordshire, UK), to a fill-weight 
of 20 ± 1 mg. A Rotahaler® device (GlaxoWellcome, Hertfordshire, UK) was used to 
discharge the contents of five gelatin capsules individually into the modified TSI at a 
rate of 60 ± 5 lmin'1 using an oil-less rotary vane pump model 1475 (Gast 
Manufacturing Company Limited, Buckinghamshire, UK). Each capsule was fired for 
4 seconds giving an inhaled volume of 4 litres of air per capsule. This gave a total dose 
weight of 100 mg, with a total drug content of 1000 /xg.
After discharging all five capsules, the magnetic stirrer was switched on and the timing 
device was activated. Data points were collected at the set interval previously 
programmed into the timing device, to obtain the release profile of the powder blend in 




Figure 3.5 shows the release profile obtained for the control blend of 1:100 SB:LAC, 
and Figures 3.6 to 3.8 illustrate the release profiles obtained for each of the hydrogel- 
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Figure 3.5 Release profile for the control blend, SB:LAC (1:100), performed using 
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Figure 3.6 Release profiles for formulation A, SB:DEX:XG (1:75:25). Run 1 (■), 
and run 2 ( • )  performed using the modified stage 1 TSI.
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Figure 3.7 Release profiles for formulation B, SB:DEX:XG (1:50:50). Run 1 (■), 
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Figure 3.8 Release profiles for formulation C, SB:DEX:XG (1:25:75). Run 1 (■), 
and run 2 ( • )  performed using the modified stage 1 TSI.
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3.2.3.4 Discussion and Conclusions
Upon comparison of the results obtained from the different formulations tested, a wide 
variation in release profiles were obtained that could be distinguished between using the 
novel modified stage 1 of the TSI.
After firing 100 mg of the control blend into the modified stage 1, the powder was seen 
to pass through the 1 mm wire mesh and into the 300 ml reservoir as large aggregated 
particles. These quickly dispersed and began to dissolve. The modified TSI diffusion 
data for the SB:LAC (1:100) control blend indicated a quick diffusion rate across the 
sinter. With no polymer-based excipient in this particular formulation, total release of 
the SB occurred in 6 to 7 minutes, Figure 3.5.
Release rates for formulations A, B and C, each containing increasing amounts XG (the 
hydrogel component) can be seen to vary with respect to how much XG was present in 
the formulation, as would be expected. Formulation A (25% hydrogel, Figure 3.6) took 
30 to 35 minutes and Formulation B (50% hydrogel, Figure 3.7) took 180 minutes to 
reach 100% drug-release. Formulation C (75% hydrogel, Figure 3.8) did not achieve 
100% release of SB even after 400 minutes. After firing of the test blends, the powder 
could be seen on the surface of the 300 ml reservoir. Over time, the powder was seen to 
expand and form a hydrogel structure that rested on the top of the wire mesh above the 
reservoir. This was more visually apparent for formulations B and C, and was reflected 
in the release rates observed for those blends in particular.
Xanthan gum has a high affinity for water and is completely soluble (Fitzpatrick, 1995). 
Rapid hydration of the particles results in extensive swelling, causing them to come into 
contact and coalesce (Fitzpatrick, 1995; Dhopeshwarkar and Zatz, 1993). The 
formation of a continuous viscoelastic gel matrix stops the drug from dispersing into the 
reservoir quickly. It is probable that this also occurs following deposition of 
deaggregated particles in the modified stage 1 TSI, thus resulting in retardation of drug 
release. In conclusion, the modified stage 1 TSI apparatus was proven to be capable of 
discriminating between drug release rates from different model controlled release 
formulations for potential bronchial delivery.
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3.3 Modification of Stage 2
3.3.1 Rationale
Stage 2 deposition in the twin stage impinger (TSI), Apparatus A of the BP (1998), 
represents delivery to the alveolar region, or deep lung. It is from the large surface area 
of this region that most drugs, including proteins, are relatively well absorbed (Smith, 
1997; Niven, 1995; Patton, 1996) and as a result is targeted for systemic drug delivery 
via the pulmonary route. In vitro deposition patterns and release rates from potential 
controlled release formulations aimed for systemic delivery would clearly be both 
necessary and beneficial in terms of optimising these characteristics prior to in vivo 
studies.
The aim in modifying the stage 2 of the TSI was to develop an in vitro testing method 
that would be capable of distinguishing between release rates from different controlled 
release formulations, and in particular, from particles of < 5 jLtm; the generally accepted 
aerodynamic particle size for pulmonary drug delivery is from 1 to 5 [im (Gonda 1992; 
Newman, 1985).
3.3.2 Design Aspects
The stage 2 assembly of the standard TSI was modified as shown in Figure 3.9. In 
keeping with the design of the modified stage 1, it was decided that a reservoir would be 
added to the base of the stage 2 flask, with the fusion of an inert, synthetic support 
membrane between the base of the flask and the reservoir, upon which the deposited 
particles would be able to rest.
The pore size of the support membrane was required to be such that fine particles would 
be deposited on the surface and not pass straight through. In addition, it needed to be 
robust and washable for routine use in analytical procedures, and allow the passage of 
proteins through with minimal adsorption. A PI sintered disc (5 cm x 3 mm) (Aimer
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Products Ltd, London, UK) was chosen for this purpose. PI indicates a disc of porosity 
grade 1, which is equal to 160 /xm (range: 100-160 /xm). Sintered discs available from 
Aimer products Ltd. are graded in terms of porosity, where P0 = 250 /xm (range: 160- 
250 /xm) down to P5 = 1.6 /xm (range: 4-10 /xm).
A larger conical flask of 500 ml capacity was employed in preference to the standard 
250 ml conical flask. The larger flask allowed for a bigger reservoir to ensure sink 
conditions would be present, while still maintaining upright balance of the modified 
stage 2 assembly. The complete sinter disc was fused between the base of the large 
flask and the reservoir (University of Bath glass-blowing workshop, Bath, UK).
The ‘swan neck’ section of the coupling tube, which connects stage 1 and stage 2 of the 
TSI, was lengthened to account for the larger size of the lower impingement chamber. 
The complete vertical length to the top-most part of the modified coupling tube was 290 
mm, with the lower vertical section accounting for 43 mm of the total length. In 
addition, the lower jet assembly of the standard TSI was removed and replaced with a 
25 mm absolute filter holder (modified non-sterile Swinnex-25 filter holder, Millipore, 
Ireland). The modified lower jet assembly covered a larger surface area of the sintered 
disc, and prevented any water above the surface of the disc from being disrupted when 
the vacuum pump was operated. The filter holder could be removed, taken apart and 
washed thoroughly in between analyses. The inside protrusion on the underside was 
removed and the outside surface of the filter holder was smoothed down to an external 
diameter of 30 mm (University of Bath Workshop, Bath, UK), which enabled it to fit 
easily through the top of the 34/35 Quickfit™ 500 ml conical flask. The standard PTFE 
washer was kept in place to maintain a good seal between the two detachable parts of 
the filter holder, but a filter membrane was not required, as powder was intended to pass 
through the modified filter holder, onto the sinter glass.
Beneath the modified stage 2 assembly a magnetic stirrer (Heidolph™ MR3000, 
Heidolf Elektro GmbH & Co. KG, Kelheim, Germany) was set to a constant stir rate of 
500 rpm. This speed was chosen as the fastest without disturbing the particles on the 







Figure 3.9 Modified stage 2 of the TSI. Dimensions are detailed in Table 3.1; 
c) To vacuum pump.
f
Figure 3.10 Full assembly of the modified stage 2 TSI.
a) Silicone mouthpiece adapter; b) Throat adapter; c) Neck (modified stage 1 jet, with 5 
fim  cut-off); d) Stage 1 impingement chamber; e) Modified stage 2 coupling tube 
adapter; f) Modified stage 2 assembly; g) To vacuum pump; h) Modified stage 2 
impingement chamber; i) Modified Stage 2 jet, fitted with 25 mm absolute filter holder; 
j) 160 ml reservoir; k) PI sintered disc; 1) Sampling port.
Table 3.1
Details o f the Modified Stage 2 o f the TSI.
Code Item Description Dimensions
(Fig-3.8) (mm)*
a Coupling tube Medium wall glass tubing 
ground glass cone 
Bent section and upper vertical section 
external diameter x  length (highest point) 
Lower vertical section 
external diameter x  length
14/23 
13 x 247 
8 x43
b Screwthread, As BP (1998)
side-arm Plastic screw cap 28/13
adapter Silicone rubber ring 
PTFE washer
Glass screwhead, threadsize 






d Stage 2 impinge­ Conical flask 500 ml
ment chamber ground-glass inlet socket 34/35
e Stage 2 jet Modified Swinnex-25 filter holder,
assembly full height x external diameter, 
connected to lower vertical section of 
coupling tube by PTFE tubing
30x30
f Support PI sintered disc (Aimer Products Ltd., UK)
membrane diameter x thickness 5 0 x3




h Stage 2 
reservoir
Blown glass (University of Bath glass- 
blowing workshop, Bath, UK)
160 ml
i Magnetic Plain, PTFE encapsulated (Jencons
Follower (Scientific) Ltd., UK), length x  width 2 5 x 6
*Dimensions o f ground-glass sockets and cones are specified in terms of suitable 
Quickfit™ apparatus.
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The TSI, Apparatus A of the BP (1998), with the standard stage 1 jet width of 14 mm 
and at the prescribed flow rate of 60 ± 5 lmin'1, has an effective aerodynamic cut-off 
diameter (ECD50; that is, the particle size for 50% retention of unit density spheres of 
equivalent settling rate in air) of 6.4 /xm (Hallworth and Westmoreland, 1987). The 
effect of changes in airflow rate or jet size on the ECD50 can be calculated using 
Equation 3.1, a simplified impaction equation developed by Hallworth and 
Westmoreland (1987):
e c d 5Q = X w
Equation 3.1
Where F  is the flow rate (lmin"1), W  is the jet diameter (cm) and X is a constant with a 
value of 30 for the TSI.
For a better representation of deep lung deposition, and thus potential respirable 
particles, the internal diameter of the stage 1 jet of Apparatus A was modified to 11.6 
mm (University of Bath glass-blowing workshop, Bath, UK) to achieve an ECD50 of 
approximately 5 fim (calculated 4.8 /xm) when operated at a flow rate of 60 ± 5 lmin"1, 
for use in conjunction with the modified stage 2 assembly. Both the upper section of 
the jet (between the throat cone joint and the stage 1 flask joint) and the length of the 
glass tube forming the jet were maintained as specified in the BP (1998).
Although no attempt was made to calibrate the modified TSI, the proof of principle was 
confirmed by mono-sized sphere calibration of comparable jets. The ECD50 of the 
modified stage 1 jet was measured as 5.3 ± 0.3 /xm by AEA Technology (Aerosol 
Science Centre, Oxfordshire, UK).
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3.3.3 Validation of the Modified Stage 2 TSI
3.3.3.1 Deposition Characteristics
All TSI experiments were performed using an airflow rate of 60 ± 5 lmin'1. The current 
recommendation is that in vitro drug deposition from dry powder inhalers (DPIs) should 
be determined at an airflow rate equivalent to a 4 kPa pressure drop across the device 
(Ganderton, 1996). To achieve a 4 kPa pressure drop across the Monohaler® (Miat, 
Italy), which was the device used for the majority of investigations undertaken in this 
study, required a flow rate of 96 lmin'1, as determined by the method outlined by 
Ganderton (1996).
A reduced flow rate (60 ± 5 lmin'1) was more appropriate for investigations using the 
modified stage 2 TSI as at the higher flow rate of 96 lmin'1 the turbulence caused within 
the apparatus disturbed the contents of the reservoir, causing water to be pulled through 
the sinter, from the reservoir into the impingement chamber. This was undesirable as 
the aim was to deposit particles onto the sinter to assess drug release profiles. 
Furthermore, it is the pressure drop developed by adult patients with respiratory disease 
when inhaling through a DPI at peak inspiratory flow rate that is typically in the region 
of 4 kPa, which will not necessarily correspond to that achieved by patients who may 
not have respiratory disease, in the case of insulin delivery by inhalation to treat 
diabetes, for example. The consistency of the flow rate used for in vitro investigations 
throughout this study was thus considered as more important, to enable comparisons 
between the formulations that were under investigation.
Deposition patterns of a conventional dry powder formulation (Ventolin® Rotacaps®, 
200 /xg, Allen & Hanburys, UK) obtained using the modified stage 2 TSI apparatus 
were compared with those obtained for the same formulation using the standard TSI, 
Apparatus A of the BP (1998), with a modified stage 1 jet to achieve an ECD50 of 5 /xm 
at 60 ± 5 lmin'1 (see section 3.3.2 above), hereafter referred to as the standard TSI.
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Standard TSI Experiments
The method used was based on the BP (1998) procedure for powder inhalers, Appendix 
XIIF. 7 ml and 30 ml of distilled water was introduced into the upper (stage 1) and 
lower (stage 2) impingement chambers respectively. The airflow through the apparatus 
was adjusted to 60 ± 5 lmin"1 (SCR2 Flow Meter, Glass Precision Ltd., UK), without the 
inhaler in place, using an oil-less rotary vane pump model 1475 (Gast Manufacturing 
Company Limited, Buckinghamshire, UK). This was then repeated after placing the 
unprimed inhaler device in the mouthpiece adapter; the use of an additional glass 
adapter was required, to fit over the device and connect the mouthpiece adapter, at the 
inlet of the throat, to the airflow meter.
Two inhaler devices were used to perform two sets of analyses: (a) the Rotahaler® 
(GlaxoWellcome, Hertfordshire, UK), which is a low resistance device (Hindle et al., 
1994) and (b) the Monohaler®, a medium resistance device whose performance has been 
shown to be comparable to that of other dry powder devices (Pitcairn et al., 1997). The 
inhaler was prepared for use and a single Ventolin® Rotacap® was discharged into the 
TSI. The device and the components of stage 1 and stage 2 of the apparatus were 
washed into individual volumes of 50 ml with distilled water. Drug content deposited 
in each section was determined by spectrofluorimetric assay (section 2.5.2). Five 
capsules were analysed in this way, for each inhaler device.
Modified Stage 2 TSI Experiments
7 ml of distilled water was introduced into the stage 1 impingement chamber and 160 
ml into the stage 2 reservoir, so that the sinter was just wetted. The airflow through the 
apparatus was adjusted to 60 ± 5 lmin"1, without the inhaler in place, using the oil-less 
rotary vane pump and then repeated as before, with the unprimed inhaler placed in the 
mouthpiece. The inhaler was prepared for use and two Ventolin® Rotacaps® were 
discharged consecutively into the TSI. The device and the components of stage 1 of the 
apparatus were washed into individual volumes of 100 ml with distilled water. The 
components of the modified stage 2 were washed into a volume of 250 ml. Drug 
content deposited in each section was determined by spectrofluorimetric assay (section 
2.5.2). Five capsules were analysed in this way, for each inhaler. In addition, a second
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set of experiments were performed with the modified stage 2 using the Monohaler® in 
order to establish consistency.
Parameters Used to Describe Aerosol Performance
The performance of an aerosol during in vitro testing, using either the standard or the 
modified stage 2 TSI was described by three main parameters: the total recovered dose 
(RD), the total emitted dose (ED) and fine particle fraction (FPF). The ED refers to the 
amount of drug (mass or %) expelled from the device and recovered from the testing 
apparatus and the FPF is the portion of the ED that is potentially respirable (< 5 /xm). 
Equations 3.2 -  3.4 were used to calculate the dry powder fractions described above.
Total amount o f drug detected (fig)
Total Recovered Dose (%) = x 100
Theoretical amount o f drug present (fig)
Equation 3.2
Total Emitted Dose (%) =
Amount of drug detected in stage 1 and stage 2 (fig)
x 100
Total amount of drug detected (fig)
Equation 3.3
Amount o f drug deposited in Stage 2 (%)
Fine Particle Fraction (%) = x 100




The deposition patterns obtained using the standard TSI, Apparatus A, and those for the 
modified stage 2 TSI apparatus are detailed in Table 3.1. Dry powder fractions are 
detailed in Table 3.3.
Table 3.2
Deposition Data Obtained fo r  Ventolin® Rotacaps® Following Analysis Using a
Standard TSI and the Modified Stage 2 TSI, (Mean (%) ±SD; n = 5).




Modified Stage 2 TSI:
Monohaler®
Monohaler®*












*Second set o f experiments, where n-3.
Table 3.3
Dry Powder Fractions Obtained fo r  Ventolin® Rotacaps® Following Analysis Using a 





Modified Stage 2 TSI:
Monohaler®
Monohaler®*








14.5 ± 1.628 
23.2 ± 1.719
16.6 ± 1.125 
16.0 ± 0.565
*Second set o f experiments, where n=3.
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Discussion and Conclusions
The results obtained for the FPF using the Rotahaler® (14.5%) are misleading as the fine 
particle dose (FPD), represented by stage 2 deposition, was actually quite low, with a 
large proportion of the dose being retained in the device. The poor results obtained for 
Stage 2 deposition from the Rotahaler® were consistent with results obtained by 
Vidgren and co-workers (1988), illustrating its poor deaggregating capability as a result 
of the lack of turbulent airflow within the inhaler. Since it was the FPF that was of 
interest in this study, the Monohaler® was employed for all modified stage 2 
investigations performed during this study, in preference to the Rotahaler®.
The deposition data obtained using the Monohaler® was better in terms of drug 
deposition in both the standard and the modified stage 2 TSI. Though there was an 
apparent difference in the actual deposition data for the standard and modified TSI, 
these data were more comparable than the deposition data obtained for the Rotahaler® 
and Monohaler®, both using the standard TSI. It is probable that the new dimensions of 
the modified stage 2 TSI resulted in the decrease in stage 2 deposition and FPF that was 
observed when this apparatus was used. However, the results obtained from the second 
set of experiments which were performed using the modified stage 2 and the 
Monohaler® showed that deposition in the modified stage 2 from the Monohaler® was 
reproducible. A student’s t-test, performed using MicroCal® Origin v2.94, confirmed 
that there was no significant difference at the 0.05 level between the mean values 
obtained for stage 2 deposition (t = -0.67764, p = 0.52326) and for the FPF (t = - 
0.80825, p = 0.4498).
3.3.3.2 Drug Release Characteristics
3.3.3.2.1 Manufacture of Powder Blends
The same blends (prepared by wet granulation, section 2.3) were used to validate the 
modified stage 2 as had been used to validate the modified stage 1 (3.2.3), to enable a 
direct comparison. Formulation A, DEX:XG (75:25), contained 25% hydrogel; 
formulation B, DEX:XG (50:50), contained 50% hydrogel and formulation C, DEX:XG
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(25:75) contained 75% hydrogel. The control blend of salbutamol: lactose (SB:LAC) 
(1:100) was prepared in the same way as the test blends.
3.3.3.2.2 Diffusion Experiment Method
The modified TSI apparatus was set up as in Figure 3.11 (shown schematically in 
Figure 3.10), using the specifications set out in the BP (1998). The reservoir beneath 
the modified stage 2 assembly was filled with 160 ml distilled water. A magnetic 
follower was placed in the reservoir and stirred at a constant rate of 500 rpm using a 
magnetic stirrer (Heidolph™ MR3000, Heidolf Elektro GmbH & Co. KG, Kelheim, 
Germany) to ensure mixing throughout.
Content uniformity of the fine powder produced after particle size reduction of granules 
(section 2.3.2) was carried out by weighing ten samples of 50 mg of each of the blends 
and making up to 250 ml with distilled water before measuring the fluorescence of each. 
This method was adapted from the BP (1998) Uniformity of Content test applicable for 
unit-dose solid preparations for inhalation. The powder was then weighed into size 3 
hard gelatin capsules (Davcaps®, Herfordshire, UK), to a fill-weight of 25 ± 1 mg. 
Gelatin capsules were stored in a dessicator at 53-55% relative humidity (RH) 
(maintained using a saturated salt solution of magnesium nitrate), for at least 24 hours 
prior to use. This was to avoid brittle fracture of the capsules during piercing with the 
inhaler, which can occur if the RH of the surrounding environment falls below about 
40% at ambient temperature (Kontny and Mulski, 1989). A Monohaler® device (Miat, 
Italy) was used to discharge three gelatin capsules individually into the modified TSI at 
a rate of 60 ± 5 lmin'1 using an oil-less rotary vane pump model 1475 (Gast 
Manufacturing Company Limited, Buckinghamshire, UK). This gave a total dose 
weight of 75 mg with a total drug content of 750 /xg. Each capsule was fired for 4 
seconds giving an inhaled volume of 4 litres of air per capsule. After discharging all 
three capsules, the magnetic stirrer was switched on and 5 ml of distilled water was 
added to the reservoir using a 5 ml plastic syringe (B-D Plastipak, Becton Dickinson 
Company, NJ, USA) and needle (B-D PrecisionGlide® Needles 21G2, Becton Dickinson 
Company, NJ, USA).
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Figure 3.11 Full assembly of the modified stage 2 TSI.
106
Samples were taken manually, using a fresh syringe for each, over a period of 2 hours, 
at 5-minute intervals for the first hour, then at 10-minute intervals. Immediately after 
taking each 5 ml sample, the same volume was replaced with fresh distilled water. 
Samples were stored to one side for subsequent fluorescence analysis to determine the 
salbutamol concentration of each (section 2.5.2).
At the end of each experiment, the stage 1 section of the modified TSI was carefully 
removed and washed with distilled water into a 250 ml volume, sonicating in a water 
bath (Decon® ultrasonic bath, UK) if necessary to ensure that all of the powder that had 
been deposited was collected. The device and modified stage 2 section were also 
washed, separately, into 250 ml volumes. From these washings, the RD, the ED and the 
FPF could be calculated (Equations 3.2-3.4). Each experiment was repeated at least 
three times to obtain concordance.
3.3.3.2.3 Results
Particle Size Distributions
Results obtained for the particle size analysis of the three blends using the Malvern 
Mastersizer X (section 2.4.1) are shown in Table 3.4.
Content Uniformity
All of the blends were found to be uniform in drug content as determined by the BP 
(1998) definition that the preparation complies with the test if  not more than one o f the 
individual values thus obtained is outside the limits 85% to 115% o f the average value, 
and none is outside the limits 75% to 125 % o f the average value.
Mean drug content/mg obtained for each blend from the test for content uniformity was 
used to calculate the theoretical amount of drug present for each analysis, where actual 
capsule fill-weights had been recorded for this purpose.
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Dry Powder Fractions
Table 3.5 represents mean recovery and dry powder fractions obtained for each of the 
blends, following analysis using the modified stage 2 TSI. Equations 3.2-3.4 were used 
to calculate the dry powder fractions (section 3.3.3.1).
Drug Release Profiles
Figure 3.12 shows the release profile obtained for the control blend. Figures 3.13 to 
3.15 illustrate the release profiles obtained from each of the formulations of varying 
hydrogel concentration, tested using the modified stage 2 TSI.
Table 3.4
Average Particle Size Data fo r  Three Blends Prepared by Wet Granulation with 
Drug:Excipient Ratios o f 1:100, as Determined by Dispersion in 0.1% (w/v) Lecithin in 
Cyclohexane (Malvern Mastersizer X) Following Sonication fo r  3 Minutes,
(Mean ±SD; n = 3).
Mean Equivalent Volume Diameter (pm)
d (0.1) d (0.5) d (0.9)
Control 1.07 ±0.021 3.19 ±0.091 7.93 ± 0.326
Formulation A 0.86 ± 0.000 3.15 ±0.012 6.77 ±0.101
Formulation B 0.98 ±0.015 3.46 ± 0.042 7.88 ± 0.076
Formulation C 1.02 ±0.012 3.78 ±0.071 9.12 ±0.670
Table 3.5
Average Dry Powder Fractions o f Each o f the Three Blends Following Analysis Using 
the Modified Stage 2 TSI, (Mean (%) ±SD; n -  3).
RD ED FPF
Control 98.0 ± 7.642 82.6 ± 1.826 16.9 ±1.510
Formulation A 89.3 ± 9.675 83.3 ±0.160 16.4 ± 1.082
Formulation B 83.3 ± 1.450 90.1 ± 1.707 10.5 ±0.153
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Figure 3.12 Release profiles for the control blend, SB:LAC (1:100). Run 1 (■), run 2 
(•)  and run 3 (A) tested using the modified stage 2 TSI.
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Figure 3.13 Release profiles for formulation A, SB:DEX:XG (1:75:25). Run 1 (■), 
run 2 (•)  and run 3 (A) tested using the modified stage 2 TSI.
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Figure 3.14 Release profiles for formulation B, SB:DEX:XG (1:50:50). Run 1 (■), 
run 2 (•)  and run 3 (A) tested using the modified stage 2 TSI.
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Figure 3.15 Release profiles for formulation C, SB:DEX:XG (1:25:75). Run 1 (■), 
run 2 (• )  and run 3 (A) tested using the modified stage 2 TSI.
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3.3.3.2.4 Discussion and Conclusions
The entire drug from the control blend was released across the support membrane of the 
modified stage 2 within 9 minutes (Figure 3.12). By comparison, formulations A, B 
and C, containing increasing amounts of XG (the hydrogel polymer excipient), took 21 
minutes, 41 minutes and 63 minutes respectively to reach 100% drug release (Figures 
3.13-3.15).
These results are comparable to those obtained with the modified stage 1 (3.2.3.3), with 
the time to 100% drug release increasing with respect to the amount of XG present in 
the formulation; thus the rate of diffusion being determined by the concentration of XG 
in both instances. The sugar component (dextrose) present in these polymer 
formulations that were employed to validate the modified stage 1 TSI and the modified 
stage 2 TSI is known to have the effect of increasing the wetting properties, as a result 
of its higher solubility (Challinor, 1996). A faster release of drug is observed as the 
concentration of dextrose increases, in addition to the decrease in XG concentration, due 
to the sugar being dissolved by the water in the reservoir, and thus allowing faster 
hydration of the polymer.
The fact that the respective times to 100% drug release are much less when tested using 
the modified stage 2 than when tested using the modified stage 1 can be attributed to 
two main factors: a) the particle size of the powder from which drug release was being 
assessed and b) the mass of powder from which drug release was being assessed.
It would seem reasonable that the larger particle size (> 6.4 fim) of the powder 
deposited in stage 1 would result in more extensive swelling as the particles hydrated, 
which would inevitably cause the large particles to come in to contact and coalesce 
more readily than the small particles deposited in stage 2 (< 5 /-im). Smaller particles 
also have a higher surface-to-volume ratio compared to macroscopic systems, and 
consequently diffusion-controlled drug release results in a more rapid release from the 
smaller microspheres (Franssen et al., 1999). In addition, the total mass of powder 
deposited in each stage requires consideration -  approximately 60% of the total dose 
was deposited in stage 1 compared with approximately 15% deposited in stage 2. A 
total of 100 mg of each blend was discharged during the modified stage 1
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investigations, with an estimated 60 mg reaching stage 1 compared to the 75 mg which 
was discharged during the stage 2 investigations, with an estimated 11.25 mg reaching 
stage 2, a percentage of which collects in the jets and glassware in each case. Thus, 
more than five times as much powder was deposited in stage 1, which would 
undoubtedly result in prolongation of drug release.
Unlike particles that were deposited in the modified stage 1, particles deposited on the 
support membrane of the modified stage 2 were not visible to the naked eye. Thus, 
there was no visual evidence that these small particles formed a hydrogel structure, 
which then caused retardation of drug release into the reservoir, however this would 
seem the likely explanation in view of the results obtained following both modified 
stage 1 TSI and modified stage 2 TSI investigations of the same blends.
Total recoveries obtained following modified stage 2 TSI testing gradually decreased as 
the XG component of the formulation increased (Table 3.5). This can be explained by 
losses occurring due to increased gel-formation upon wetting, as the amount of XG 
increased. Glassware was sonicated to maximise collection of deposited drug, however 
it is conceivable that at the higher concentrations of XG, this process did not achieve 
complete dissolution.
In conclusion, the modified stage 2 TSI apparatus was found capable of evaluating and 
distinguishing between drug release rates from different dry powder blend particles 
having an aerodynamic diameter of approximately 5 f im or less. Dissolution profiles 
obtained from particles of this size range were found to be much faster than those 
obtained from larger particles of the same formulations, indicating the need to evaluate 




Manufacture of Model Controlled Release Pulmonary 
Drug Delivery Systems by Spray Drying
4.1 Introduction
Two popular methods for processing for processing powders in the respirable range for 
use in aerosol formulations are jet milling and spray drying (Adjei and Gupta, 1997). 
Previously, powders manufactured using the technique of wet granulation followed by 
milling were used to validate the modified stage 1 TSI and modified stage 2 TSI 
apparatus (Chapter 3). Spray drying has been employed by several workers (Broadhead 
et al., 1994; Foster et al., 1995; Maa et al., 1996; Mumenthaler et al., 1994), and is a 
more suitable technique for the manufacture of fine particles of proteins and peptides as 
the processes of wet granulation and milling may induce chemical and physical 
instability reactions of such drugs, rendering them inactive (Sacchetti and Van Oort, 
1996). The potential of spray drying in protein formulations lies in its ability to produce 
particles of controlled size and shape, critical to the development of dry powders for 
inhalation and microparticulates for controlled drug delivery (Broadhead et al., 1994).
The process of spray drying has been described earlier (Chapter 1). This chapter details 
the results obtained from various investigations performed during this study, utilising 
spray drying technology to produce respirable particles. Properties of spray dried 
powders, such as particle size and size distribution, morphology, bulk density, porosity, 
moisture content, flowability, stability etc. can be altered by modifying the spray drying 
process (Masters, 1985; Newton, 1966), but are also dependent on the type of raw 
material (Crosby and Marshall 1958), and properties such as viscosity, surface tension 
and density (Sacchetti and Van Oort, 1996). Thus, the effects of the spray drying 
process on the final product characteristics of a range of pharmaceutical excipients were 
first investigated, using a bench-scale spray dryer. Following on from this initial work, 
model excipients were chosen for co-spray drying with a model drug (salbutamol). The 
excipients were chosen with their potential to afford controlled release in mind, for 
subsequent analysis using the modified stage 2 TSI apparatus.
Finally, the scale-up process, from bench-scale to pilot-scale, was considered for the 
production of model respirable particles. Potential problems have arisen with this scale- 
up process (Foster and Leatherman, 1995), with properties of powders produced by
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different capacity spray dryers having been found to be substantially different. Pilot- 
scale formulations were manufactured with the aim to investigate the effect of small 
variations in drug content on release rate of model controlled release respirable 
particles, and to determine whether the modified stage 2 TSI apparatus could be used as 
a tool to distinguish between such release rates in vitro.
4.2 Characterisation of Various Spray Dried Excipients
The chosen pharmaceutical excipients (lactose, trehalose, mannitol, hetastarch, 
maltodextrin, polyvinylpyrrolidone (PVP), xanthan gum (XG) and locust bean gum 
(LBG)) were spray dried individually using a bench-scale spray dryer (Buchi Mini 
Spray Dryer, Model B-191, Buchi Labortechnik AG, Switzerland) as detailed in section 
2.2.1.1. The results obtained for the various investigations (particle size analysis, 
morphology and moisture content) carried out on the resultant spray dried powders 
follow, in sections 4.2.2 to 4.2.4.
4.2.1 Choice of Excipients
The choice of excipients was based on a number of factors. With the ultimate aim of 
producing respirable peptides and proteins using this technology, it was reasonable to 
begin with looking at excipients that have been successfully used in combinations with 
proteins, as stabilizers or protectants, during either spray drying or freeze drying. 
Sugars such as lactose, trehalose, sucrose and mannitol have been used extensively, 
both successfully and unsuccessfully, for this purpose (Andya, et al., 1999; Broadhead 
et al., 1994; Carpenter et al., 1989; Costantino et al., 1998; Naini et al., 1996).
Maltodextrins, partially hydrolysed starches, have been evaluated as potential 
lyoprotectants in the freeze drying of lactate dehydrogenase (Corveleyn and Remon, 
1996), with lyoprotection obtained being dependent on the dextrose equivalent (DE)
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value and also the concentration used. The DE value is a measure of the extent of starch 
polymer hydrolysis and is defined as the reducing power of a substance expressed in 
grams of D-glucose per 100 g of the dry substance (Wade and Weller, 1994). Different 
grades of maltodextrins have different physical properties, such as solubility and 
viscosity, depending upon their DE value.
Polymers such as hetastarch, polyethylene glycol (PEG) and gelatin have been shown to 
be effective inhibitors of heat-induced aggregation of low molecular weight urokinase 
(Vrkljan, et al., 1994), though in the same study, PVP was found to have either no effect 
or a detrimental effect, depending upon concentration. However, PVP has been shown 
to be an effective lyoprotectant (Townsend and DeLuca, 1988) and stabilizer (Coombes 
et al., 1998), and was chosen for use in this study due to its pharmaceutical applications 
as a controlled drug release agent, in addition to many other applications, in parenteral, 
topical and oral formulations (ISP Products for Pharmaceuticals Reference Guide). 
PVP is a synthetic polymer of various molecular weights and is characterised by its 
viscosity in aqueous solution relative to that of water, expressed as a K-value, ranging 
from 10-120 (Wade and Weller, 1994).
XG is a high molecular weight, semi-synthetic bacterial polysaccharide (Wade and 
Weller, 1994) with an established use as a hydrophilic matrix for controlled release 
tablet formulations (Dhopeshwarkar and Zatz, 1993; Fitzpatrick, 1995; Talukdar and 
Plaizier-Vercammen, 1993). The unique, synergistic, gel-forming reaction of XG with 
LBG (Kovacs, 1973; Rocks, 1971) has also been investigated as a controlled release 
matrix (Challinor, 1996). Formulations containing varying concentrations of one or 
both of these polysaccharides were previously used for validating the modified TSI 
apparatuses for their use as tools to distinguish between release rates of controlled 
release formulations for inhalation delivery, and were found to be successful in 
achieving this purpose (Chapter 3). Thus, though not necessarily suitable for delivery to 
the lungs, these gums were spray dried as model excipients, capable of achieving 
controlled release from particles within the respirable range.
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4.2.2 Particle Size Analysis
Spray dried excipient particles were sized using the Mastersizer X (Malvern Instruments 
Ltd., UK) as described in section 2.4.1.
Results
The results obtained for the particle size analysis of the spray dried excipients are 
detailed in Table 4.1.
Discussion
Particle size distributions of the spray dried powders were narrow, and essentially 
similar for those excipients spray dried under exactly the same process conditions. XG 
and LBG powders demonstrated a wider particle size distribution; this is likely to be as 
a result of the high viscosity of the initial feed solutions (Sacchetti and Van Oort, 1996), 
despite their lower total solids content. Droplet formation and size is affected by feed 
properties such as viscosity, surface tension and density, whereby an increase in any of 
these parameters results in the formation of larger droplets (Sacchetti and Van Oort, 
1996). It can be seen from the particle size results obtained for spray dried LBG, spray 
dried XG and spray dried XG:LBG (1:1) that as the viscosity of the feed solution 
increased noticeably, in that order, due to the synergistic interaction between XG and 
LBG (Rocks, 1971), the particle size distribution of the spray dried powders became 
wider.
The effects of viscosity on the PVP powders produced is not very pronounced as very 
dilute solutions were spray dried. However, the distribution of spray dried Plasdone K- 
90 (having the highest viscosity) is marginally wider than that of the other spray dried 
PVP powders; the K-value (section 4.2.1) of the PVP determines its viscosity and the 
most significantly different K-value was that of the K-90 (K = 85-95), compared to K= 
29-32 for both Plasdone C-15 and K-29/32, and K = 16-18 for Plasdone C-15.
The viscosity of maltodextrins in aqueous solution is affected by the DE value (section 
4.2.1) such that the viscosity decreases as the DE increases.
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Table 4.1
Average Particle Size Data fo r  Excipients Spray Dried as 1% (w/w) Solutions (Buchi B- 
191) at an Tiniet o f 120°C (Toutiet = 80 ± 2 ° C) Unless Otherwise Stated. Other Spray 
Parameters were Constant: Airflow = 600 l/hr, Aspirator = 100%, Feed Flow Rate = 
5 ml/min. Particle Size Determined by Dispersion in 0.1% (w/v) Lecithin in Cyclohexane 
(Malvern Mastersizer X) Following Sonication fo r  2 Minutes, (Mean ±SD; n - 3).
Product Mean Equivalent Volume Diameter (pm)
yield (%) d(0.1) d(0.5) d(0.9)
Lactose ' 2 0.81 ±0.025 1.39 ±0.138 3.65 ±0.255
Lactose 12.5% (w/w);
Tujet = 185°C; Tout]et = 106°C
32 0.99 ± 0.023 2.65 ± 0.068 8.34 ±0.503
Trehalose 3 0.73 ± 0.006 1.67 ±0.061 3.72 ±0.296
Trehalose 12.5% (w/w);
T ^ t = 185°C; Touuet = 106°C
39 1.03 ± 0.045 2.62 ±0.146 7.21 ±0.910
Mannitol 69 0.78 ±0.012 2.08 ± 0.044 3.77 ±0.038
Hetastarch R096JK3 56 0.86 ± 0.023 2.17 ±0.087 4.05 ±0.199
Hetastarch R024LB2 59 0.83 ± 0.017 2.15 ±0.057 4.14 ±0.059
Hetastarch 61913 58 0.76 ± 0.015 2.18 ±0.012 4.24 ±0.021
Maltodextrin C*Pur 01908 42 0.94 ±0.025 2.23 ± 0.044 4.27 ±0.191
Maltodextrin C*Pur 01910 43 0.97 ± 0.029 1.94 ±0.071 3.49 ±0.120
Maltodextrin C*Pur 01925 54 1.03 ±0.010 2.12 ±0.119 3.98 ±0.551
Plasdone C-15 67 1.10 ±0.025 2.33 ±0.012 4.28 ±0.078
Plasdone C-30 60 0.94 ± 0.021 2.17 ±0.040 3.95 ±0.044
Plasdone K-29/32 68 0.99 ± 0.015 2.31 ±0.036 4.53 ±0.040
Plasdone K-90 43 0.92 ± 0.006 2.32 ± 0.061 5.31 ±0.298
LBG 0.25% (w/w);
Feed flow rate = 10 ml/min; 
Toutiet = 57°C
11 0.79 ± 0.001 1.56 ±0.010 7.92 ±1.071
XG 0.25% (w/w); Feed flow 
rate=10 ml/min; Touuet= 61°C
15 1.37 ±0.049 1.88 ±0.017 9.33 ±0.562
XG:LBG (1:1) 0.25% (w/w); 
Feed flow rate =15 ml/min; 
Toutiet = 48°C
1.17 ±0.040 1.88 ±0.021 13.1 ±2.060
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The DE values for the maltodextrins C*Pur 01908, C*Pur 01910 and C*Pur 01925 are 
8-10, 14 and 22-25 respectively. Viscosity differences at the dilute solutions spray 
dried during this study do not appear to have an effect on the particle size distribution of 
the resultant spray dried powders, which are very similar.
The three batches of hetastarch have very similar particle size distribution, indicating 
reproducibility of the bench-scale spray drying process used in terms of the particle size 
distribution of the resultant powders.
The effect on particle size distribution of spray dried powders caused by increased feed 
solids concentration is demonstrated clearly by the results obtained for lactose and 
trehalose when spray dried at a total solids concentration of 12.5% (w/w) compared to 
1% (w/w). The particle size distribution increases with the increase in feed concentration 
despite the higher operation temperatures that were employed in both instances.
Spray drying of lactose and trehalose under the standard conditions employed for the 
other excipients (section 2.2.1.2) was not favourable, resulting in very poor recoveries 
of 2% and 3% respectively. The materials were not dried efficiently and were mostly 
deposited on the walls of the apparatus. The small amount of product that was obtained 
was agglomerated and ‘sticky’. Such a phenomenon has been previously experienced in 
the case of trehalose (Maa et al., 1997), and low product yield as a result of particle 
adhesion to the walls of the apparatus is a common problem that is known to be affected 
by the nature of the spray dried materials and spray drying conditions employed (Maa et 
al., 1998a). Spray dried lactose is widely used in pharmaceutical tablet preparations and 
is thus commercially available (Lund, 1994), implying that, under the right process 
conditions, it can be prepared efficiently by this method. In an attempt to save time and 
still produce some spray dried powders of lactose and trehalose, a cited method was 
used (Sebhatu et al., 1994) in preference to a trial and error approach to achieve such 
process conditions.
It is noteworthy that the increased total solids feed concentration (from 1% to 12.5% 
(w/w)) resulted in an increase in product yield for both lactose and trehalose. This is 
most likely to have been caused by the decrease in the particle size of powders prepared 
from low initial feed concentrations (Sacchetti and Van Oort, 1996), thus leading to a
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greater loss of powder, which may have been too fine to be collected efficiently by the 
cyclone, to the filter bag. A similar observation was made by Broadhead and co­
workers (1994), who concluded that as high a total solids content as possible should be 
used, as this would also reduce the time required to dry a given amount of material. As 
mentioned, the particle size distribution of both spray dried lactose and spray dried 
trehalose increased as a result of the increase in feed concentration that was performed 
as part of this study, which is not a desired outcome for the preparation of powders for 
inhalation delivery; this effect would presumably be lessened by a less dramatic 
increase in the total solid content to be spray dried. Higher feed concentrations may 
enable easier scalability of the spray drying process, and thus the effect of changing this 
parameter should be investigated to achieve optimal properties of the final powder 
following processing from the highest possible initial total solids content.
Product yield has also been demonstrated to be affected by temperature and spray dried 
volume. For example, Labrude and co-workers (1989) observed a significant increase 
in yield when higher inlet temperatures were used, and an optimum volume at which the 
yield was the greatest. The yield was found to increase up to a certain spray dried 
volume, after which there was a considerable loss of solution and product along the 
walls of the apparatus, with an effective decrease in recovery. The spray drying 
temperatures employed for the preparation of lactose and trehalose powders from 12.5% 
(w/w) total solids were significantly higher (T in iet = 185°C and T outiet = 106°C) than those 
employed at 1% (w/w) feed concentration ( T ^ e t  = 120°C and T outiet = 80°C), and the 
spray dried volume was greater for the latter. In addition, the feed flow rate was 
approximately doubled when the 12.5% (w/w) solutions were spray dried; thus it is likely 
that the modulation of several factors which can affect recovery of product during the 
spray drying process, and not just one factor, led to the increased product yield, and 
improved quality that was observed when the cited method was used.
The relatively low yields obtained for XG and LBG are likely to be as a result of both 
the low total solids content of the respective feed solutions that were spray dried and a 
function of the viscous nature of these feeds. Atomising viscous solutions results in the 
formation of large droplets that dry inadequately (Sacchetti and Van Oort, 1996), 




Spray dried excipient particles were viewed under a scanning electron microscope 
(SEM) (Jeol JSM-T330, Japanese Electron Optics Ltd.), as described in section 2.4.2.
Results
Figures 4.1 to 4.12 show scanning electron photomicrographs of excipients spray dried 
as 1% (w/w) solutions, at an Tiniet of 120°C (Toutiet = 80 ± 2°C) unless otherwise stated, 
with other bench-scale process conditions kept constant: airflow = 600 1/hr, aspirator = 
100% and feed flow rate = 5 ml/min.
Discussion
Spray dried particles can exhibit poor flow characteristics due to shattering and 
collapsing of the spray dried particles, but also due to the presence of electrostatic 
charge, and low bulk density due to internal voidage (Foster and Leatherman, 1995). 
Particle shape and texture can influence flow properties of a powder, which is important 
in dry powder aerosol formulation for both the filling of capsules, blisters or devices, 
and for subsequent aerosolisation of the drug from the inhaler (Chawla et al., 1994). In 
general, it is thought that more spherical particles tend to have better flow properties 
than more irregular particles of a similar size (Staniforth, 1994). In contrast, however, 
asperities or rough particle surfaces can lead to decreased adhesive forces compared to 
smooth particles (Hontanon et al., 2000), as the true area of contact is less than the 
apparent area of contact when surface contact exists only at a few asperities (Podczeck 
and Newton, 1996). It is evident that a balance is needed whereby agglomerates of drug 
and carrier excipient leave the device, which subsequently aerosolise into separated 
particles.
Lactose (Figure 4.1), trehalose (Figure 4.2) and especially mannitol, were very difficult 
to view using the SEM at high magnification without causing the particles to melt and 
coalesce. The particles were spherical with a smooth surface appearance. SEM images 
of the three different batches of hetastarch revealed particles of very similar 
morphology: smooth surfaces with significant indentations where the walls of the 
particles had collapsed inwards (Figures 4.3 to 4.5).
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Figure 4.1 SEM image of bench-scale spray dried lactose. 12.5% (w/w) solution, 
Ti„,et = 185°C and T outlet = 106°C.
Figure 4.2 SEM image of bench-scale spray dried trehalose. 12.5% (w/w) solution, 
Tjniet = 185°C and T outiet = 106°C.
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Figure 4.3 SEM image of bench-scale spray dried hetastarch, batch R096JK3.
Figure 4.4 SEM image of bench-scale spray dried hetastarch, batch R024LB2.
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Figure 4.5 SEM image of bench-scale spray dried hetastarch, batch 61913.
Figure 4.6 SEM image of bench-scale spray dried maltodextrin, C*Pur 01908.
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Figure 4.7 SEM image of bench-scale spray dried maltodextrin, C*Pur 01910.
1 0 KU X 3 * 5 0 0
Figure 4.8 SEM image of bench-scale spray dried maltodextrin, C*Pur 01925.
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Figure 4.9 SEM image of bench-scale spray dried PVP, Plasdone C-15.
Figure 4.10 SEM image of bench-scale spray dried PVP, Plasdone K-90.
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Figure 4.11 SEM image of bench-scale spray dried LBG. 0.25% (w/w) solution, feed 
flow rate = 34%, Tinjet = 1 2 0 °C and Toutiet = 61°C.
Figure 4.12 SEM image of bench-scale spray dried XG. 0.25% (w/w) solution in 
Milli-Q water; feed flow rate = 34%, Tiniet = 120°C and Toutiet = 57°C.
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In contrast, the morphologies of spray dried particles of the three different types of 
maltodextrins were different from one another (Figures 4.6 to 4.8). The spray dried 
maltodextrin with the lowest DE value, C*Pur 01908, (Figure 4.6) had a surface 
morphology similar to that of the spray dried hetastarch. However, as the DE increased, 
the particles appeared more spherical in shape as the indentations in the surfaces of the 
particles were much less pronounced, though perhaps greater in number (Figures 4.7 
and 4.8).
Spray dried LBG particles (Figure 4.11) were similar in appearance to spray dried 
hetastarch, but spray dried XG particles (Figure 4.12) had a more deformed appearance, 
with some indentations being not as well-defined as others.
Both of the pyrogen-free PVP powders (Plasdone C-15 and C-30) had a similar 
morphology after spray drying, as did both of the regular excipient grade PVPs 
(Plasdone K-29/32 and K-90). There were, however, differences in the surface 
morphology of the two types of PVP in that the spray dried powders of the pyrogen-free 
excipients (Figure 4.9) had a more shrivelled appearance than the spray dried powders 
of the regular PVP (Figure 4.10), caused by a greater number of surface indentations on 
each particle. According to the manufacturer of Plasdone PVP powders (ISP 
Technologies Inc.), there is no difference in the method of manufacture of the pyrogen- 
free and regular excipient grades; the only difference being that the C-grade has been 
tested by the USP procedure and proven to be ‘free of pyrogens’ at the time of 
shipment. Molecular weight of the raw material is not thought to be a contributing 
factor to the differences in spray dried particle morphology as both Plasdone C-30 and 
Plasdone K-29/32 have the same average molecular weight (K-value of 29-32). 
Interestingly, the pyrogen-free spray dried PVP powders were found to have less 
residual moisture than the K-grade spray dried PVP powders (section 4.2.4). Drier 
particles of the same material would perhaps be expected to have more surface 
indentations as a greater proportion of water is evaporated during the drying process, or 
alternatively, more hygroscopic particles might appear to have fewer indentations as a 
result of having absorbed a greater amount of moisture from the environment.
The drying of a wet droplet proceeds in two phases: an initial period where the drying 
rate is constant followed by a period of steadily decreasing drying rate (Masters, 1985).
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Rapid drying rates have been attributed to the production of spray dried particles with 
deformed shapes such as dimples, donut-like holes, and raisin-like wrinkles (Maa et al., 
1997). The temperature at the droplet surface is maintained at the wet bulb temperature, 
corresponding to 1 0 0 % relative humidity, during the initial period of constant drying 
rate. A dry crust can form, at the droplet surface, and cause the temperature to rise 
above the wet bulb temperature if the drying rate is rapid compared to the diffusion of 
water to the particle surface. Thus, when the crust can no longer withhold the interior 
vapour pressure, the droplet bursts or collapses (Maa et al., 1997). It has also been 
suggested that the collapsing of particles at the end of the drying cycle might be caused 
by sub-atmospheric pressures within the particles, as a result of the capillary action of 
the dried surfaces drawing liquid and solids outward uniformly around the drop (Crosby 
and Marshall, 1958).
Although SEM has been extensively used to investigate morphology of spray dried 
particles, it should be considered that the sample preparation involved with this 
technique (section 2.4.2) may have the potential to contribute to the particle deformation 
that is observed. Samples were coated under vacuum, and thus it seems possible that 
some surface indentation of the particles may have been caused as a result of being 
subjected to this procedure, after collection from the spray dryer.
4.2.3 Moisture Content
Moisture loss on drying of bench-scale spray dried excipient powders was determined 
as detailed in section 2.4.3. The initial moisture content, of the raw material, was also 
determined in the same manner to enable comparison, before and after spray drying.
Results
Results obtained for moisture loss on drying of the raw materials and spray dried 
materials are illustrated in Figure 4.13.
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Figure 4.13 Moisture loss on drying of various pharmaceutical excipients obtained 
from the raw material and after spray drying. Excipients spray dried as 1% (w/w) 
solutions, at an Tiniet of 120°C (Touuet = 80 ± 2 °C) with other bench-scale process 
conditions kept constant: airflow = 600 1/hr, aspirator = 100% and feed rate = 5 ml/min. 
*Lactose and trehalose spray dried as 12.5% (w/w) at an Tiniet of 185°C (Toutiet = 106°C).
Discussion
Only one determination of moisture content was performed for each sample due to the 
small amounts of powders that were prepared for this initial investigative study on spray 
dried excipient properties, thus it is difficult to draw any conclusions from the results 
obtained. However, there is much emphasis in the literature on the importance of water 
content of pharmaceutical powders, especially those incorporating biotherapeutic 
agents.
From a manufacturing and subsequent inhalation delivery perspective, moisture content 
of dry powders is of great importance, influencing factors such as crystallisation, 
agglomeration and flowability. Changes in such physicomechanical properties can have 
a direct impact on the physical stability of the formulation or an indirect impact on the 
stability of the protein (Hageman, 1992). Generally, the chemical stability of a protein
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decreases with increasing moisture in the solid state; increased water content can result 
in changes in dynamic activity or conformational stability of the protein, or the water 
may serve as a reactant and/or as a medium for mobilisation of reactants (Hageman, 
1988). Optimal water levels are required to produce stable formulations of 
biotherapeutic agents; over-drying can result in physical instability as water pays a key 
role in maintaining the higher, non-covalent structure of proteins and under-drying can 
result in biological instability (Hageman, 1992).
In general, the moisture content of the spray dried excipient powder was greater than 
that of the raw material, with the exception of trehalose, one of the batches of hetastarch 
and maltodextrin C*Pur 01925. A probable explanation for the spray dried powders 
having high moisture contents is that spray drying often leads to the formation of 
amorphous particles (Vidgren et al., 1987), the implications of which are discussed in 
more detail below. Those powders that retain less moisture upon spray drying are 
obviously more suitable candidates as potential excipients for dry powder inhalation 
systems.
Spray dried carbohydrates, with the exception of maltodextrin C*Pur 01908, had lower 
moisture contents than the spray dried synthetic polymer, PVP. In addition, the 
difference in the moisture content of the raw material and corresponding spray dried 
material was observed as being greater for the PVP powders compared to all of the 
other excipient powders before and after spray drying. The C-grade (pyrogen-free) 
spray dried PVP powders appear to be less hygroscopic than the K-grade spray dried 
PVP powders, perhaps accounting for the differences in the morphology of the 
respective powders, as noted in section 4.2.3. The moisture contents of the respective 
raw materials were very similar, suggesting that this difference observed is likely to be a 
consequence of the spray drying process.
Amorphous character is common in pharmaceutical powders due to their large size 
(especially polymeric materials, peptides and proteins), or as a result of high-energy 
processing, such as milling or spray drying (Hancock and Zografi, 1994; Hancock and 
Zografi, 1997). Many amorphous solids are hygroscopic and spontaneously absorb 
water from their surrounding environment, which subsequently has a plasticizing effect 
on the system and lowers the glass transition temperature (Tg). The Tg of an
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amorphous solid determines its chemical stability, physical stability and viscoelastic 
properties, and it usually becomes a critical parameter when the processing temperature 
approaches or exceeds its value (Hancock and Zografi, 1994). The transition, at Tg, 
from a glassy to a viscoelastic (rubbery) state can result in significant changes in 
apparent viscosity and mobility within the system. Greater macroscopic mobility, at 
temperatures above Tg, is likely to adversely affect stability by enhancing reactions 
dependent upon the mobility of the water or the protein (Ahlneck and Zografi, 1990).
However, the use of appropriate amorphous diluents (those with Tg’s higher than the 
existing system) may provide a means to increase the overall Tg and minimise the 
mobility of the system at a given temperature (Pikal, 1990). Furthermore, the use of 
amorphous excipients may in fact lead to a more reproducible formulation, attributable 
to their hygroscopic nature, which can protect the protein from small changes in 
moisture thereby maintaining Tg above the storage temperature. Formulations with 
excipients that absorb very little moisture and contain a low ratio of protein to excipient 
have an increased sensitivity to small differences in water content, whereby a small 
change in overall moisture content may result in large differences in the amount of 
water associated with the protein (Hageman, 1992). Another foreseeable concern 
associated with amorphous powders, however, is the occurrence of hygroscopic growth 
following delivery to the warm, humid environment of the respiratory tract (Hiller et al., 
1980), leading to an increase in particle size, thus affecting lung deposition patterns 
(Broadhead et al., 1996; Hickey and Martonen, 1993).
Residual moisture contents of spray dried powders have been found to be lower when 
processed at higher temperatures (Adler and Lee, 1999; Labrude et al., 1989; Maa et al., 
1998c), and resultant powders prepared at higher temperatures also appear to have 
greater stability on storage (Labrude et al., 1989). Alternative processing temperatures 
for the preparation of spray dried excipient powders were not investigated as part of this 
initial study, with the exception of lactose and trehalose as they did not yield any 
significant amount of product (section 4.2.2) when spray dried under the standard 
conditions which were employed for the other excipients (section 2.2.1.2). Spray dried 
lactose and spray dried trehalose did have lower moisture contents than most of the 
other spray dried excipients. It cannot be concluded that this is due to the higher spray 
drying temperatures that were used to process these materials, as other parameters too
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were different, and such a comparison can only be made when comparing the same 
materials. In support of this, it should be noted that both spray dried mannitol and spray 
dried maltodextrin C*Pur 01925 powders had lower moisture contents than spray dried 
lactose and spray dried trehalose powders, despite the higher processing temperatures 
employed to prepare the latter two.
Relative humidity during processing and storage is an important consideration as spray 
dried powders tend to equilibrate with subsequent processing and storage environments 
regardless of the manufacturing conditions (Maa, et al., 1998c), and thus lead to 
moisture-induced re-crystallisation of susceptible formulation excipients resulting in 
poor physical stability and a potential loss of product performance (Clark et al., 1996). 
Morphological changes and interparticulate agglomeration that may occur as a result of 
crystal growth cannot be reversed and thus will affect characteristics such as flowability 
and redispersibilty (Chan and Gonda, 1998). Furthermore, protein destabilisation is 
likely during re-crystallisation of such excipients as the protein component is expelled 
from the crystal lattice. Ambient relative humidity was not measured during the 
experiments carried out as part of this study and would thus be a consideration in the 
future as day to day variations are very likely to be encountered in the laboratory.
4.3 Bench-Scale Co-Spray Drying of Salbutamol with Model
Controlled Release Excipients
Salbutamol was co-spray dried with PVP, mucin (MUC), XG and XG:LBG, using a 
bench-scale spray dryer (Buchi Mini Spray Dryer, Model B-191, Buchi Labortechnik 
AG, Switzerland) as detailed in section 2.2.1.1. These excipients were further 
investigated in this part of the study due to their potential to afford controlled release. 
Mucin had not been included in the previous study (section 4.2); however it was 
considered that its potential bioadhesive nature, in combination with its natural 
occurrence in the lung, might render it as a suitable excipient for controlled release
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pulmonary delivery. The results obtained for the various investigations carried out on 
the resultant co-spray dried powders follow.
4.3.1 Particle Size Analysis
Spray dried salbutamol:excipient(s) particles were sized using the Mastersizer X 
(Malvern Instruments Ltd., UK) as described in section 2.4.1.
Results
The results for the particle size analysis for spray dried salbutamol:excipient(s) powders 
are detailed in Table 4.2.
Discussion
There was no apparent difference in the particle size distribution of the SB:PVP co­
spray dried powders compared to that obtained when PVP (Plasdone K-90) was spray 
dried alone. However, the particle size distributions of SB:XG and SB:XG:LBG co­
spray dried powders were considerably narrower when compared to the spray dried 
excipients alone (Table 4.1).
Total solids concentration of the gum formulations (XG and XG:LBG) was maintained 
at 0.25 % (w/w), previously when spray dried alone and also when spray dried with 
salbutamol, at ratios of salbutamol:excipient(s) of 1:10. Thus, the inclusion of 
salbutamol into the gum formulations to be spray dried resulted in there being a lower 
concentration of the gum component(s) compared to when they had been spray dried 
alone, in the absence of drug. This in turn suggests that the viscosity of the feeds 
containing salbutamol would have been lower than feeds containing gum(s) alone, and 
hence the presence of dug may have resulted in the formation of smaller droplets when 
spray dried. Presumably the same effect was not observed for the SB:PVP powders as 
the viscosity of the dilute solutions which were spray dried was not as significant a 




Average Particle Size Data fo r  Initial Powders Spray Dried Under Various Process Conditions (Biichi B-191; Aspirator = 100%, 
Airflow = 600 l/hr), as Determined by Dispersion in 0.1% Lecithin in Cyclohexane (Malvern Mastersizer X) Following Sonication fo r
2 Minutes, (Mean +SD; n — 3).
Bench-Scale Spray Conditions
Feed Cone.
% ( w/w )
Tiniet Toutiet Feed Rate Product 
(°C) (°C) (ml/min) yield (%)
Mean Equivalent Volume 
Diameter (pm)
d(0 .1 ) d(0.5) d(0.9)
SB:PVP K-90 (2:3) 1 .0 1 2 0 78 5 40 0.92 ±0.012 1.94 ±0.026 4.41 ± 0.061
SB:PVPK-90 (1:100) 1 .0 1 2 0 80 5 36
SB:PVP K-90 (1:200) 1 .0 1 2 0 80 5 37
SB:MUC (1:10) 1 .0 1 1 0 70 5 14 1.26 ± 0.049 2.45 ±0.052 5.95 ±0.096
SB:MUC (1:100) 1 .0 1 2 0 80 5 14
SB:XG (2:3) 0.42 150 1 0 2 5 16 0.93 ± 0.000 1.89 ±0.015 3.94 ±0.132
SB:XG (1:10) 0.25 1 1 0 70 5 18 0.85 ±0.006 1.64 ±0.012 2.95 ±0.035
SB:XG:LBG (1:5:5) 0.25 130 6 8 1 0 1 0 1.18 ±0.079 1.63 ±0.027 2.69 ±0.156
U>
4.3.2 Morphology
Spray dried salbutamol:excipient(s) particles were viewed under a scanning electron 
microscope (SEM) (Jeol JSM-T330, Japanese Electron Optics Ltd.), as described in 
section 2.4.2.
Results
Figures 4.14 to 4.17 show scanning electron photomicrographs of 
salbutamol:excipient(s) powders spray dried under bench-scale process conditions: 
airflow = 600 1/hr, aspirator = 100% and feed flow rate = 5 ml/min.
Discussion
Spray dried SB:PVP particles were the most spherical (Figure 4.14), with fewer and less 
pronounced surface indentations than spray dried PVP alone (Figure 4.10). Smaller 
SB:PVP particles appeared to have a smoother surface morphology than larger particles 
of the same powder. Some spray dried SB:MUC particles appeared irregular and 
collapsed, whereas other SB:MUC particles were smooth and spherical (Figure 4.15), 
suggesting that droplets were drying at different rates. In contrast, spray dried SB:XG 
(Figure 4.16) and spray dried SB:XG:LBG (Figure 4.17) particles all appeared fairly 
irregular in shape, owing to the indentations caused by the inward collapse of the 
particle wall.
Interestingly, the surface morphology of SB:XG and SB:XG:LBG particles was very 
similar, whereas when XG and LBG were spray dried separately, the particles had been 
different in their appearance (section 4.2.3). A possible explanation for such an 
observation might be that the XG, being more soluble than the LBG, is on the surface of 
the particles, thus resulting in particles of the same morphology as when XG was spray 
dried alone. Migration of certain components to the surface of the droplet during the 
spray drying process is not an uncommon observation. For example, inclusion of a 
surfactant in the formulation of the feed solution has been shown to improve sphericity 
and smoothness of the resultant particles (Adler and Lee, 1999; Maa et al., 1997). In 
this case, since surfactants are attracted to air-liquid interfaces, it is thought that they 
occupy the droplet surface, thus modifying the liquid interfacial properties.
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In contrast, the morphologies of spray dried particles of the three different types of 
maltodextrins were different from one another (Figures 4.6 to 4.8). The spray dried 
maltodextrin with the lowest DE value, C*Pur 01908, (Figure 4.6) had a surface 
morphology similar to that of the spray dried hetastarch. However, as the DE increased, 
the particles appeared more spherical in shape as the indentations in the surfaces of the 
particles were much less pronounced, though perhaps greater in number (Figures 4.7 
and 4.8).
Spray dried LBG particles (Figure 4.11) were similar in appearance to spray dried 
hetastarch, but spray dried XG particles (Figure 4.12) had a more deformed appearance, 
with some indentations being not as well-defined as others.
Both of the pyrogen-free PVP powders (Plasdone C-15 and C-30) had a similar 
morphology after spray drying, as did both of the regular excipient grade PVPs 
(Plasdone K-29/32 and K-90). There were, however, differences in the surface 
morphology of the two types of PVP in that the spray dried powders of the pyrogen-free 
excipients (Figure 4.9) had a more shrivelled appearance than the spray dried powders 
of the regular PVP (Figure 4.10), caused by a greater number of surface indentations on 
each particle. According to the manufacturer of Plasdone PVP powders (ISP 
Technologies Inc.), there is no difference in the method of manufacture of the pyrogen- 
free and regular excipient grades; the only difference being that the C-grade has been 
tested by the USP procedure and proven to be ‘free of pyrogens’ at the time of 
shipment. Molecular weight of the raw material is not thought to be a contributing 
factor to the differences in spray dried particle morphology as both Plasdone C-30 and 
Plasdone K-29/32 have the same average molecular weight (K-value of 29-32). 
Interestingly, the pyrogen-free spray dried PVP powders were found to have less 
residual moisture than the K-grade spray dried PVP powders (section 4.2.4). Drier 
particles of the same material would perhaps be expected to have more surface 
indentations as a greater proportion of water is evaporated during the drying process, or 
alternatively, more hygroscopic particles might appear to have fewer indentations as a 
result of having absorbed a greater amount of moisture from the environment.
The drying of a wet droplet proceeds in two phases: an initial period where the drying 
rate is constant followed by a period of steadily decreasing drying rate (Masters, 1985).
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Rapid drying rates have been attributed to the production of spray dried particles with 
deformed shapes such as dimples, donut-like holes, and raisin-like wrinkles (Maa et ak, 
1997). The temperature at the droplet surface is maintained at the wet bulb temperature, 
corresponding to 1 0 0 % relative humidity, during the initial period of constant drying 
rate. A dry crust can form, at the droplet surface, and cause the temperature to rise 
above the wet bulb temperature if the drying rate is rapid compared to the diffusion of 
water to the particle surface. Thus, when the crust can no longer withhold the interior 
vapour pressure, the droplet bursts or collapses (Maa et al., 1997). It has also been 
suggested that the collapsing of particles at the end of the drying cycle might be caused 
by sub-atmospheric pressures within the particles, as a result of the capillary action of 
the dried surfaces drawing liquid and solids outward uniformly around the drop (Crosby 
and Marshall, 1958).
Although SEM has been extensively used to investigate morphology of spray dried 
particles, it should be considered that the sample preparation involved with this 
technique (section 2.4.2) may have the potential to contribute to the particle deformation 
that is observed. Samples were coated under vacuum, and thus it seems possible that 
some surface indentation of the particles may have been caused as a result of being 
subjected to this procedure, after collection from the spray dryer.
4.2.3 Moisture Content
Moisture loss on drying of bench-scale spray dried excipient powders was determined 
as detailed in section 2.4.3. The initial moisture content, of the raw material, was also 
determined in the same manner to enable comparison, before and after spray drying.
Results
Results obtained for moisture loss on drying of the raw materials and spray dried 
materials are illustrated in Figure 4.13.
129
Lactose* 1 m  Raw Material
Trehalose* ......
Mannitol 1
Hetastarch R096JK3 _____ JUUHI___ UmJUIiHII
Hetastarch RQ24LB2
Hetastarch 61913 • ................................  1
iVbltodextrin 01908 ..........  .........................z zz '...........WEE......... i
Nfcltodextrin 01910
Maltodextrin 01925
PlasdoneC-15 . . .
Plasdone C-30 1
Plasdone K-29/32 ......................  .......................... , I
Plasdone K-90
— I— I— .— I— I— I— I— I— I— I— I— I— I— I— I— I— I— I— I— I— I— I— i—
0 2 4 6 8 10 12
Moisture Loss ce Drying (%)
Figure 4.13 Moisture loss on drying of various pharmaceutical excipients obtained 
from the raw material and after spray drying. Excipients spray dried as 1% (w/w) 
solutions, at an Tiniet of 1 2 0 °C (Toutiet = 80 ± 2°C) with other bench-scale process 
conditions kept constant: airflow = 600 1/hr, aspirator = 100% and feed rate = 5 ml/min. 
*Lactose and trehalose spray dried as 12.5% (w/w) at an Tiniet of 185°C (Touuet = 106°C).
Discussion
Only one determination of moisture content was performed for each sample due to the 
small amounts of powders that were prepared for this initial investigative study on spray 
dried excipient properties, thus it is difficult to draw any conclusions from the results 
obtained. However, there is much emphasis in the literature on the importance of water 
content of pharmaceutical powders, especially those incorporating biotherapeutic 
agents.
From a manufacturing and subsequent inhalation delivery perspective, moisture content 
of dry powders is of great importance, influencing factors such as crystallisation, 
agglomeration and flowability. Changes in such physicomechanical properties can have 
a direct impact on the physical stability of the formulation or an indirect impact on the 
stability of the protein (Hageman, 1992). Generally, the chemical stability of a protein
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decreases with increasing moisture in the solid state; increased water content can result 
in changes in dynamic activity or conformational stability of the protein, or the water 
may serve as a reactant and/or as a medium for mobilisation of reactants (Hageman, 
1988). Optimal water levels are required to produce stable formulations of 
biotherapeutic agents; over-drying can result in physical instability as water pays a key 
role in maintaining the higher, non-covalent structure of proteins and under-drying can 
result in biological instability (Hageman, 1992).
In general, the moisture content of the spray dried excipient powder was greater than 
that of the raw material, with the exception of trehalose, one of the batches of hetastarch 
and maltodextrin C*Pur 01925. A probable explanation for the spray dried powders 
having high moisture contents is that spray drying often leads to the formation of 
amorphous particles (Vidgren et al., 1987), the implications of which are discussed in 
more detail below. Those powders that retain less moisture upon spray drying are 
obviously more suitable candidates as potential excipients for dry powder inhalation 
systems.
Spray dried carbohydrates, with the exception of maltodextrin C*Pur 01908, had lower 
moisture contents than the spray dried synthetic polymer, PVP. In addition, the 
difference in the moisture content of the raw material and corresponding spray dried 
material was observed as being greater for the PVP powders compared to all of the 
other excipient powders before and after spray drying. The C-grade (pyrogen-free) 
spray dried PVP powders appear to be less hygroscopic than the K-grade spray dried 
PVP powders, perhaps accounting for the differences in the morphology of the 
respective powders, as noted in section 4.2.3. The moisture contents of the respective 
raw materials were very similar, suggesting that this difference observed is likely to be a 
consequence of the spray drying process.
Amorphous character is common in pharmaceutical powders due to their large size 
(especially polymeric materials, peptides and proteins), or as a result of high-energy 
processing, such as milling or spray drying (Hancock and Zografi, 1994; Hancock and 
Zografi, 1997). Many amorphous solids are hygroscopic and spontaneously absorb 
water from their surrounding environment, which subsequently has a plasticizing effect 
on the system and lowers the glass transition temperature (Tg). The Tg of an
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amorphous solid determines its chemical stability, physical stability and viscoelastic 
properties, and it usually becomes a critical parameter when the processing temperature 
approaches or exceeds its value (Hancock and Zografi, 1994). The transition, at Tg, 
from a glassy to a viscoelastic (rubbery) state can result in significant changes in 
apparent viscosity and mobility within the system. Greater macroscopic mobility, at 
temperatures above Tg, is likely to adversely affect stability by enhancing reactions 
dependent upon the mobility of the water or the protein (Ahlneck and Zografi, 1990).
However, the use of appropriate amorphous diluents (those with Tg’s higher than the 
existing system) may provide a means to increase the overall Tg and minimise the 
mobility of the system at a given temperature (Pikal, 1990). Furthermore, the use of 
amorphous excipients may in fact lead to a more reproducible formulation, attributable 
to their hygroscopic nature, which can protect the protein from small changes in 
moisture thereby maintaining Tg above the storage temperature. Formulations with 
excipients that absorb very little moisture and contain a low ratio of protein to excipient 
have an increased sensitivity to small differences in water content, whereby a small 
change in overall moisture content may result in large differences in the amount of 
water associated with the protein (Hageman, 1992). Another foreseeable concern 
associated with amorphous powders, however, is the occurrence of hygroscopic growth 
following delivery to the warm, humid environment of the respiratory tract (Hiller et al., 
1980), leading to an increase in particle size, thus affecting lung deposition patterns 
(Broadhead et al., 1996; Hickey and Martonen, 1993).
Residual moisture contents of spray dried powders have been found to be lower when 
processed at higher temperatures (Adler and Lee, 1999; Labrude et al., 1989; Maa et al., 
1998c), and resultant powders prepared at higher temperatures also appear to have 
greater stability on storage (Labrude et al., 1989). Alternative processing temperatures 
for the preparation of spray dried excipient powders were not investigated as part of this 
initial study, with the exception of lactose and trehalose as they did not yield any 
significant amount of product (section 4.2.2) when spray dried under the standard 
conditions which were employed for the other excipients (section 2.2.1.2). Spray dried 
lactose and spray dried trehalose did have lower moisture contents than most of the 
other spray dried excipients. It cannot be concluded that this is due to the higher spray 
drying temperatures that were used to process these materials, as other parameters too
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were different, and such a comparison can only be made when comparing the same 
materials. In support of this, it should be noted that both spray dried mannitol and spray 
dried maltodextrin C*Pur 01925 powders had lower moisture contents than spray dried 
lactose and spray dried trehalose powders, despite the higher processing temperatures 
employed to prepare the latter two.
Relative humidity during processing and storage is an important consideration as spray 
dried powders tend to equilibrate with subsequent processing and storage environments 
regardless of the manufacturing conditions (Maa, et al., 1998c), and thus lead to 
moisture-induced re-crystallisation of susceptible formulation excipients resulting in 
poor physical stability and a potential loss of product performance (Clark et al., 1996). 
Morphological changes and interparticulate agglomeration that may occur as a result of 
crystal growth cannot be reversed and thus will affect characteristics such as flowability 
and redispersibilty (Chan and Gonda, 1998). Furthermore, protein destabilisation is 
likely during re-crystallisation of such excipients as the protein component is expelled 
from the crystal lattice. Ambient relative humidity was not measured during the 
experiments carried out as part of this study and would thus be a consideration in the 
future as day to day variations are very likely to be encountered in the laboratory.
4.3 Bench-Scale Co-Spray Drying of Salbutamol with Model
Controlled Release Excipients
Salbutamol was co-spray dried with PVP, mucin (MUC), XG and XG:LBG, using a 
bench-scale spray dryer (Btichi Mini Spray Dryer, Model B-191, Biichi Labortechnik 
AG, Switzerland) as detailed in section 2.2.1.1. These excipients were further 
investigated in this part of the study due to their potential to afford controlled release. 
Mucin had not been included in the previous study (section 4.2); however it was 
considered that its potential bioadhesive nature, in combination with its natural 
occurrence in the lung, might render it as a suitable excipient for controlled release
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pulmonary delivery. The results obtained for the various investigations carried out on 
the resultant co-spray dried powders follow.
4.3.1 Particle Size Analysis
Spray dried salbutamol:excipient(s) particles were sized using the Mastersizer X 
(Malvern Instruments Ltd., UK) as described in section 2.4.1.
Results
The results for the particle size analysis for spray dried salbutamol:excipient(s) powders 
are detailed in Table 4.2.
Discussion
There was no apparent difference in the particle size distribution of the SB:PVP co­
spray dried powders compared to that obtained when PVP (Plasdone K-90) was spray 
dried alone. However, the particle size distributions of SB:XG and SB:XG:LBG co­
spray dried powders were considerably narrower when compared to the spray dried 
excipients alone (Table 4.1).
Total solids concentration of the gum formulations (XG and XG:LBG) was maintained 
at 0.25 % f / w), previously when spray dried alone and also when spray dried with 
salbutamol, at ratios of salbutamol:excipient(s) of 1:10. Thus, the inclusion of 
salbutamol into the gum formulations to be spray dried resulted in there being a lower 
concentration of the gum component(s) compared to when they had been spray dried 
alone, in the absence of drug. This in turn suggests that the viscosity of the feeds 
containing salbutamol would have been lower than feeds containing gum(s) alone, and 
hence the presence of dug may have resulted in the formation of smaller droplets when 
spray dried. Presumably the same effect was not observed for the SB:PVP powders as 
the viscosity of the dilute solutions which were spray dried was not as significant a 




Average Particle Size Data fo r  Initial Powders Spray Dried Under Various Process Conditions (Btichi B-191; Aspirator = 100%, 
Airflow = 600 l/hr), as Determined by Dispersion in 0.1% Lecithin in Cyclohexane (Malvern Mastersizer X) Following Sonication fo r
2 Minutes, (Mean ±SD; n = 3).
Bench-Scale Spray Conditions
Feed Cone.
% ( W/w )
Tiniet Toudet Feed Rate Product 
(°C) (°C) (ml/min) yield (%)
Mean Equivalent Volume 
Diameter (pm)
d(0 .1) d(0.5) d(0.9)
SB:PVP K-90 (2:3) 1 .0 1 2 0 78 5 40 0.92 ±0.012 1.94 ±0.026 4.41 ±0.061
SB:PVP K-90 (1:100) 1 .0 1 2 0 80 5 36
SB:PVP K-90 (1:200) 1 .0 1 2 0 80 5 37
SB:MUC (1:10) 1 .0 1 1 0 70 5 14 1.26 ± 0.049 2.45 ±0.052 5.95 ±0.096
SB:MUC (1:100) 1 .0 1 2 0 80 5 14
SB:XG (2:3) 0.42 150 1 0 2 5 16 0.93 ±0.000 1.89 ±0.015 3.94 ±0.132
SB:XG (1:10) 0.25 1 1 0 70 5 18 0.85 ±0.006 1.64 ±0.012 2.95 ±0.035
SB:XG:LBG (1:5:5) 0.25 130 6 8 1 0 1 0 1.18 ±0.079 1.63 ± 0.027 2.69 ±0.156
4.3.2 Morphology
Spray dried salbutamol:excipient(s) particles were viewed under a scanning electron 
microscope (SEM) (Jeol JSM-T330, Japanese Electron Optics Ltd.), as described in 
section 2.4.2.
Results
Figures 4.14 to 4.17 show scanning electron photomicrographs of 
salbutamol:excipient(s) powders spray dried under bench-scale process conditions: 
airflow = 600 1/hr, aspirator = 100% and feed flow rate = 5 ml/min.
Discussion
Spray dried SB:PVP particles were the most spherical (Figure 4.14), with fewer and less 
pronounced surface indentations than spray dried PVP alone (Figure 4.10). Smaller 
SB:PVP particles appeared to have a smoother surface morphology than larger particles 
of the same powder. Some spray dried SB:MUC particles appeared irregular and 
collapsed, whereas other SB:MUC particles were smooth and spherical (Figure 4.15), 
suggesting that droplets were drying at different rates. In contrast, spray dried SB:XG 
(Figure 4.16) and spray dried SB:XG:LBG (Figure 4.17) particles all appeared fairly 
irregular in shape, owing to the indentations caused by the inward collapse of the 
particle wall.
Interestingly, the surface morphology of SB:XG and SB:XG:LBG particles was very 
similar, whereas when XG and LBG were spray dried separately, the particles had been 
different in their appearance (section 4.2.3). A possible explanation for such an 
observation might be that the XG, being more soluble than the LBG, is on the surface of 
the particles, thus resulting in particles of the same morphology as when XG was spray 
dried alone. Migration of certain components to the surface of the droplet during the 
spray drying process is not an uncommon observation. For example, inclusion of a 
surfactant in the formulation of the feed solution has been shown to improve sphericity 
and smoothness of the resultant particles (Adler and Lee, 1999; Maa et al., 1997). In 
this case, since surfactants are attracted to air-liquid interfaces, it is thought that they 
occupy the droplet surface, thus modifying the liquid interfacial properties.
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Figure 4.14 SEM image of bench-scale spray dried SB:PVP K-90 (2:3). 1% (w/w) 
solution, Tiniet = 120°C, Toutiet = 80°C and feed flow rate = 16%.
1 0 K U  X 5 , 0 0 0  5 M- m 0 4 2 9 6 7
Figure 4.15 SEM image of bench-scale spray dried SB:MUC (1:10). 1% (w/w)
solution, T^iet = 110°C, Toudet = 70°C and feed flow rate = 16%.
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Figure 4.16 SEM image of bench-scale spray dried SB:XG (1:10). 0.25% (w/w)
solution, Tiniet = 110°C, Toutiet = 70°C and feed flow rate = 16%.
Figure 4.17 SEM image of bench-scale spray dried SB:XG:LBG (1:5:5). 0.25% 
(w/w) solution, Tiniet = 130°C, Toutiet = 68°C and feed flow rate = 34%.
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4.3.3 Drug Incorporation
Drug incorporation efficiency of bench-scale co-spray dried powders was determined as 
detailed in section 2.4.4.
Results
The results for the drug incorporation efficiency obtained for the co-spray dried 
powders are summarised in Table 4.3.
Discussion
Very high drug incorporation efficiencies were obtained under the spray drying 
conditions employed. Spray drying, as a method of manufacture of microparticles, has 
been shown to be more efficient at incorporating or encapsulating drug into excipients 
than other methods such as solvent evaporation and solvent extraction (Pavanetto et al., 
1992), or emulsification procedures (Haghpanah et al., 1994). Incorporation 
efficiencies as low as 10% (Falk et al., 1997), and even 3.7% and 0.73% (Bodmeir et 
al., 1995) have been reported using supercritical carbon dioxide to precipitate 
microparticles. The nature of the polymer and the drug are thought to influence drug 
incorporation efficiency of such particles, for example hydrophobic drugs are partially 
soluble in supercritical carbon dioxide and thus will not precipitate until their solubility 
limit is reached (Bodmeier et al., 1995; Falk et al., 1997).
The gel-forming nature of the excipients used in this study is likely to have been 
advantageous for the entrapment of the salbutamol. An excess number of drug particles 
might be captured in the molecular network of the swollen polymers, as hypothesised 
by Lin and Pemg (1992) in a study that looked at the adsorption behaviour of a drug on 
chitosan-acetate gel powder. They concluded that adsorption and encapsulation 
phenomena might be occurring simultaneously, leading to a larger adsorbed amount of 
drug on chitosan-acetate gel powder compared to chitosan powder.
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Table 4.3
Actual Salbutamol Content (Mean ±SD; n = 5) and Incorporation Efficiencies for  
Salbutamol:Excipient Powders Spray Dried (Btichi B-191) Under Various Process
Conditions as Detailed in Table 4.2.
SB Content (%(w/w)) Actual Ratio of Incorporation
Theoretical Actual SB:Excipient(s) Efficiency(%)
SB:PVP K-90 (2:3) 40.0 36.0 ±0.029 2:3.6 90.0
SB:PVP K-90 (1:100) 0.99 0.91 ±0.930 1:109 91.9
SB:PVP K-90 (1:200) 0.50 0.49 ± 2.061 1:205 98.0
SB:MUC (1:10) 9.09 7.82 ± 1.032 1 :1 2 8 6 .0
SB:MUC (1:100) 0.99 0.81 ± 1.006 1 : 1 2 2 81.8
SB:XG (2:3) 40.0 30.3 ±0.138 2:4.6 75.8
SB:XG (1:10) 9.09 8.02 ± 1.004 1 :1 2 8 8 .2
SB:XG:LBG (1:5:5) 9.09 7.44 ± 7.440 1 :1 2 81.8
Table 4.4
Average Dry Powder Fractions Obtained fo r  Each o f the Bench-Scale Spray Dried 
Formulations Tested Using the Modified Stage 2 TSI with the Manual Sampling 
Technique, (Mean (%) ±SD; n = 3).
RD ED FPF
SB:PVP K-90 (2:3) 84.0 ±6.612 69.6 ±4.216 29.7 ± 4.042
SB:PVP K-90 (1:100) 80.7 ± 2.987 49.4 ± 9.629 39.1 ±11.47
SB:PVP K-90 (1:200) 82.3 ± 2.524 63.1 ±7.200 29.8 ± 5.419
SB:MUC (1:10) 71.9 ±1.877 74.2 ±4.168 25.4 ± 3.454
SB:MUC (1:100) 72.7 ± 3.202 61.8 ±7.160 24.5 ± 10.71
SB:XG (2:3) 80.6 ± 1.637 83.5 ± 0.872 46.4 ± 1.246
SB:XG (1:10) 60.0 ± 10.58 69.5 ±3.109 67.8 ± 4.875
SB:XG:LBG (1:5:5) 78.0 ±0.667 48.1 ± 16.32 49.1 ± 12.49
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4.3.4 Modified Stage 2 TSI Experiments
4.3.4.1 Method
The diffusion experiment method detailed in section 3.3.3.2.2 was followed, with the 
exception that only one gelatin capsule, containing 25 ± 1 mg of spray dried 
salbutamol:excipient(s) powder was discharged during each individual experiment.
4.3.4.2 Results 
Dry Powder Fractions
Dry powder fractions (Table 4.4) were calculated using equations 3.2 to 3.4 (section 
3.3.3.1).
Drug Release Profiles
Figures 4.18 to 4.20 illustrate the average release profiles obtained for each of the 
salbutamol:excipient(s) powders following deposition in the modified stage 2  apparatus.
4.3.4.3 Discussion and Conclusions
Release profiles obtained for the bench-scale formulations of salbutamol with potential 
controlled release excipients illustrate that only very small differences were detected 
with PVP and mucin (Figures 4.18 and 4.19, respectively). However this can be 
concluded to be a function of the formulations and not a limitation of the modified stage 
2 TSI apparatus as formulations of SB:XG showed marked differences in the release 
profiles obtained (Figure 4.20). Figure 4.21 illustrates the mean time to 100% 
salbutamol release of the different formulations tested. SB:XG (2:3), containing 60% 
hydrogel, took 59 minutes to achieve 100% salbutamol detection compared to 8 6  
minutes for SB:XG (1:10), containing 91% hydrogel.
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Figure 4.18 Average release profiles for SB:PVP (2:3) (■), SB:PVP (1:100) (•) and 
SB:PVP (1:200) (▲), following deposition in the modified stage 2 TSI apparatus, using 
the manual sampling technique (n = 3). Powders spray dried under the bench-scale 





Figure 4.19 Average release profiles for SB:MUC (1:10) (■) and SB:MUC (1:100) 
(•), following deposition in the modified stage 2 TSI apparatus, using the manual 
sampling technique (n = 3). Powders spray dried under the bench-scale process 
conditions detailed in Table 4.2.
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Figure 4.20 Average release profiles for SB:XG (2:3) (■), SB:XG (1:10) (•)  and 
SB:XG:LBG (1:5:5) (A), following deposition in the modified stage 2 TSI apparatus, 
using the manual sampling technique (n = 3). Powders spray dried under the bench- 
scale process conditions detailed in Table 4.2.
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Figure 4.21 Summary of the mean time taken to achieve 100% detection of 
salbutamol across the modified stage 2 TSI sinter following discharge of 1 x 25 mg 
capsule of powders produced by the bench-scale co-spray drying of salbutamol with 
excipient(s), as detailed in Table 4.2 (n = 3).
The initial burst of drug, which can be seen from the release profiles obtained, is a 
commonly observed feature of hydrophilic release systems (Fitzpatrick, 1995). Initially 
drug is rapidly released, in the period during which hydration of the particles takes 
place, and the release then slows progressively after the gel has formed.
The release profile for SB:XG:LBG (1:10) was markedly different, indicating a faster 
overall release rate from this formulation compared to the SB:XG (1:10) formulation. 
This was a surprising result as we might expect the synergistic interaction between the 
XG and LBG to lead to the formation of a gel, and retard drug release to a greater extent 
(Challinor, 1996). This observation was further investigated with powders 
manufactured using a pilot-scale spray dryer, and is discussed fully in section 4.4.6.3.
Dry powder fractions obtained for bench-scale spray dried powders indicated that stage 
2  deposition of these powders was greater than conventional formulations, and those 
formulations prepared by wet granulation which were used in the initial validation of 
the modified TSI (section 3.3.3.1). This is likely to be the result of the small and 
narrow particle size distributions of these powders (Table 4.2), enabling better deep 
lung deposition.
4.3.5 Spray Drying of SB:XG (1:10)
The effect of feed concentration and flow rate on product yield and particle size of 
bench-scale spray dried SB:XG (1:10) was investigated as detailed in Table 4.4.
Results
Particle size analysis results for spray dried SB:XG (1:10) powders are shown in Table 
4.4. Figure 4.22 illustrates the mean VMD obtained for the above powders.
Discussion
There was a noticeable difference in the particle size distribution and VMD of the spray 
dried powders produced from a feed concentration of 0 .1 % (w/w) compared with higher
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concentrations. The differences between the particle size distributions obtained after 
small increases in feed concentration are not as marked, for example between 0.25% 
(w/w) and 0.5% (w/w), or between 0.5% (w/w) and 0.75% (w/w)- However, from these 
results it would appear that the feed concentration had a more marked effect on the 
particle size than changing either feed flow rate or spray drying temperature at a fixed 
feed concentration. The exception was seen with the feed concentration of 1% (w/w) 
where there was a marked increase in the particle size distribution when spray dried at a 
slo wer feed rate, resulting in a high Toutiet.
In general, product yields were slightly better for solutions spray dried at slower feed 
rates, and a greater loss was observed as a result of inefficient drying of solutions that 








Figure 4.22 Mean VMD (/im) of spray dried SB:XG (1:10) powders, under the 
bench-scale process conditions detailed in Table 4.4 {n = 3).
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Bench-Scale Spray Dried SB:XG (1:10) Fomxilation
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Table 4.5
Average Particle Size Data fo r  SB:XG (1:10) Powders (A-L) Spray Dried Under Various Process Conditions (Biichi B-191), as Determined by 
Dispersion in 0.1% Lecithin in Cyclohexane (Malvern Mastersizer X) Following Sonication fo r  2 Minutes, (Mean ±SD; n = 3).
Feed Bench-Scale Spray Conditions Mean Equivalent Volume
Cone. T iniet Toutiet Aspirator Airflow Feed Rate Product Diameter (pm)
% (w/w) (°C) ( ° C ) (%) rate (1/hr) (ml/min) yield (%) d(0 .1 ) d(0.5) d(0.9)
A 0 .1 1 1 0 48 1 0 0 800 1 0 2 0 0 .6 8  ± 0.006 1.18 ± 0 .0 0 1 2 .0 1  ± 0 .0 0 1
B 0.125 1 1 0 74 1 0 0 600 5 23 0.84 ± 0.027 1.58 ±0.061 6.71 ±3.283
C 0.25 1 1 0 70 1 0 0 600 5 18 0.85 ±0.006 1.64 ±0.012 2.95 ±0.035
D 0.5 1 1 0 74 1 0 0 600 5 16 0.87 ±0.055 2.04 ±0.155 4.49 ± 0.402
E 0.5 1 2 0 6 6 1 0 0 600 1 0 1 2 0.80 ± 0.032 1.82 ±0.052 3.82 ±0.081
F 0.75 1 1 0 49 1 0 0 600 2 0 1 0 1.53 ±0.006 1.89 ±0.001 5.04 ±0.150
G 0.75 1 2 0 62 1 0 0 600 15 11 1.53 ±0.010 1.93 ±0.006 5.47 ±0.647
H 0.75 1 2 0 61 1 0 0 600 2 0 1 2 1.50 ±0.021 1 .8 8  ± 0 .0 1 0 5.62 ±0.369
I 0.75 140 71 1 0 0 600 15 11 1.52 ±0.006 1.92 ±0.006 5.52 ±0.076
J 0.75 140 65 1 0 0 600 2 0 13 1.53 ±0.006 1.94 ±0.021 6.50 ± 1.416
K 1 .0 1 1 0 58 1 0 0 600 1 0 1 0 0.83 ±0.191 1.95 ±0.160 5.65 ± 1.309
L 1 .0 130 95 1 0 0 600 5 5 0.86 ±0.055 2.94 ±0.300 7.59 ± 1.294
4.4 Pilot-Scale Spray Drying of Salbutamol with Model 
Controlled Release Excipients
Salbutamol was co-spray dried with XG and XG:LBG, as potential controlled release 
excipients, using a pilot-scale spray dryer (Niro Production Minor, Serial No. 9019, 
Niro Atomiser, Copenhagen, Denmark) as detailed in section 2.2.2.
Two immediately apparent differences were noted in the bulk appearance of the pilot- 
scale spray dried powders compared to the equivalent bench-scale spray dried powders: 
a) the pilot-scale powders were a pale yellow colour in appearance and b) the 
‘contamination’ of the final product caused by the probable build-up of the material at 
the at the air inlet, inside the chamber. It is stated in the technical manual that though 
this problem is uncommon, on occasions the turbulence of the drying air at the inlet 
could cause a ‘hot-spot’ around the perimeter of the opening. As a result, if the 
atomised droplets come in to contact with that area, they will stick and continue to build 
up. These deposits might then disrupt the airflow inside the chamber, discolour the 
powder, or drop off, creating lumps in the dried powder.
The majority of these lumps could be separated from the final product easily as they 
tended to accumulate together in the centre of the base of the collection pail. Scanning 
electron photomicrographs are shown in section 4.4.4, Figures 4.33 and 4.34.
4.4.1 Investigation of Yellowing Phenomenon
The powders manufactured in the pilot-scale spray dryer were a pale yellow colour in 
appearance, with the intensity of the colour being the greatest for the 
salbutamol:excipient(s) ratio of 1:10, becoming less apparent in the 1:50 formulations 
and even less in the 1:100 formulations. Two possible explanations for the observation 
of this pale yellow colouration were considered to be a) Maillard reaction between the 
carbohydrate and salbutamol, or b) decomposition of salbutamol. The latter was 
considered to be the most likely cause, however both phenomena are discussed below.
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4.4.1.1 Maillard Reaction
Maillard reactions are responsible for the ‘browning’ process seen most often in the 
food industry when foods are cooked. They commonly occur when carbohydrates are 
heated together with proteins (amines), and occur most readily at higher temperatures, 
under alkaline conditions and at high moisture contents (Hurrell, 1980). Only reducing 
sugars, containing carbonyl groups with which the amines react, take part in Maillard 
reactions; however, non-reducing carbohydrates can be hydrolysed to yield reducing 
sugars that may then react in this manner.
Although there is greater evidence of this reaction occurring between primary amines 
and reducing carbohydrate excipients (Duvall et al., 1965; George et al., 1994), the 
reaction has also been shown to occur with secondary amines (Wirth et al., 1998). 
Thus, since salbutamol is a secondary amine, it seemed possible that its interaction with 
a carbohydrate such as xanthan gum might result in discolouration due to the Maillard 
reaction. Xanthan gum was considered a potential substrate for the Maillard reaction as 
each repeat unit of the polymer is composed of five sugar residues: two glucose, two 
mannose and one glucuronic acid (Lund, 1994), and glucose is a reducing sugar (Wirth 
et al., 1998).
If such a reaction between the carbohydrate and amine group of the salbutamol was 
responsible for the yellow colour of the pilot-scale spray dried powders, it would also be 
expected to occur in the bench-scale spray dried powders. However, no such colour 
was visible for the bench-scale spray dried powders of SB:XG (2:3 and 1:10) or 
SB:XG:LBG (1:5:5). It may be possible that the reaction between the carbohydrate and 
salbutamol was more pronounced or accelerated due to the high temperatures that the 
pilot-scale spray dried powders had been exposed. Alternatively, the discolouration 
might be attributable purely to the decomposition of salbutamol as a result of the high 
processing temperatures.
Yellow discolouration, attributable to the Maillard reaction, of a tablet formulation upon 
aging, and in the presence of moisture at elevated temperatures, has been demonstrated 
as having no significant loss of potency on assay and was thus considered as being 
mostly an issue of aesthetics (George et al., 1994).
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4.4.1.2 Decomposition of Salbutamol
Salbutamol base is known to melt at 155°C, with decomposition (BP, 1998), thus it 
seemed likely that the colour had developed as a result of heat-induced decomposition 
of the salbutamol during the spray drying process.
The extent of decomposition and subsequent effect of this on the analytical procedure 
employed during this study were investigated using infrared (IR) absorption 
spectrophotometry (section 2.5.6.1), nuclear magnetic resonance (NMR) spectroscopy 
(section 2.5.6.2), high performance liquid chromatography (HPLC) (section 2.5.6.3) and 
finally, the fluorescence spectra of decomposed salbutamol base were compared with 
those of the raw material and that spray dried at a low temperature (section 2.5.6.4).
IR Spectra
The IR spectra of micronised SB (raw material) and spray dried SB (Biichi B-191, 
section 2.2.1.1) at T^et = 110°C, resulting in white powder and at Tiniet = 220°C, 
resulting in a yellow powder are shown in Appendix B. All of the spectra obtained 
were identical to each other and to that of the reference spectrum contained in the BP 
(1998). From these spectra it was inferred that there was either no change in the 
functional group composition of the yellow SB powder, or that the degree of 
decomposition was too small to detect by IR spectroscopy.
NMR Spectra
The NMR spectra obtained are shown in Appendix C. The spectra suggest that the 
structures of all of the samples tested were the same. The only indication of 
decomposition was in the SB:XG (1:10) pilot-scale spray dried sample, where there was 
an extra peak detected in the aromatic region of the spectrum, thus indicating the 
presence of a chromophore. Once again, this technique was not sensitive enough to 
detect very small amounts of decomposition or contamination in the samples.
HPLC Chromatograms
HPLC chromatograms are shown in Appendix D. When the sensitivity was increased 
from 0.1 to 0.01 AUFS, extra peaks (probable degradation peaks) were observed in the 
chromatograms of the spray dried powders when compared to the raw material.
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Fluorescence Spectra
Both the excitation (Figure 4.23) and emission spectra (Figure 4.24) of SB spray dried 
at Tjniet = 110°C and at Tiniet = 220°C were essentially identical to those obtained for the 
micronised raw material, when overlaid, with peaks and valleys observed at exactly the 
same wavelengths for all three samples.
Thus, it was considered that the method of assay by fluorescence was suitable for use 
for subsequent investigations performed using the discoloured powders that were 




Figure 4.23 Fluorescence excitation spectra overlaid for 2 /xg/ml SB raw material, 2 





Figure 4.24 Fluorescence emission spectra overlaid for 2 /ig/ml SB raw material, 2 
pg/ml SB spray dried at T ^ t = 110°C and 2 fig/ml SB  spray dried at T i^et = 220°C.
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4.4.2 Particle Size Analysis
Spray dried salbutamol:excipient(s) particles were sized using the Mastersizer X 
(Malvern Instruments Ltd., UK) as described in section 2.4.1.
Results
The results obtained for the particle size analysis of the pilot-scale spray dried powders 
are detailed in Table 4.6. VMD of the same powders are compared in Figure 4.25.
Table 4.6
Average Particle Size Data fo r  SB:XG and SB:XG:LBG Powders Spray Dried as 0.25% 
(w/w) Solutions (Niro 9019), at an Tiniet of240-250°C (Toutiet = 120-125°C) Unless 
Otherwise Stated. Other Spray Parameters were Constant: Airflow = 400 kg/hr, 
Atomiser Speed = 60 Hz (24000 rpm) and Pump = 6.5-8. Particle Size Determined by 
Dispersion in 0.1% (w/v) Lecithin in Cyclohexane (Malvern Mastersizer X) Following
Sonication for 2 Minutes, (Mean ±SD; n = 3)
Product Mean Equivalent Volume Diameter (/xm)
yield (%)* d(0 .1) d(0.5) d(0.9)
SB:XG (1:10) 
1.5% f/w) 0.96 ± 0.032 7.70 ± 0.545 20.8 ±4.390
0.5% (w/w) 0.90 ± 0.010 5.43 ±0.133 12.2 ± 0.549
0 .2 % (w/w) 0 .8 8  ± 0 .0 1 0 4.87 ±0.112 10.1 ±0.547
0 .1 % (w/w) 0.86 ± 0.015 4.99 ±0.153 1 0 .8  ±1.126
SB:XG (1:50) 40 0 .8 6  ± 0 .0 1 2 4.39 ±0.144 8 .6 8  ± 0.579
SB:XG (1:100) 35 0 .8 6  ±0.006 4.46 ± 0.042 8.93 ±0.086
SB:XG:LBG (1:5:5) 50 0.85 ± 0.006 3.96 ±0.068 7.81 ±0.224
SB:XG:LBG (1:25:25) 34 0.87 ±0.017 4.33 ± 0.057 8.59 ±0.569
SB:XG:LBG (1:50:50) 30 0 .8 8  ± 0.006 4.67 ± 0.036 8.83 ± 0.070
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Figure 4.25 Mean VMD (/xm) of SB:XG and SB:XG:LBG powders manufactured by 
pilot-scale spray drying of 0.25% (w/w) solutions (*SB:XG (1:10) spray dried as 0.2% 
(w/w) solution), (n = 3).
Discussion
The particle size distributions of the pilot-scale co-spray dried powders (Table 4.6) were 
larger than those obtained for bench-scale co-spray dried powders (Tables 4.4 and 4.5). 
However, the VMD of all of the pilot-scale formulations was less than 5 /xm (Figure 
4.25), and there did not appear to be any marked differences in the particle size of the 
different formulations that were spray dried under the same conditions.
Larger droplets are likely to have formed from the atomisation of the feed in the pilot- 
scale spray dryer, which incorporated a rotary atomiser, as compared to the 0.7 mm 
nozzle of the bench-scale spray dryer. The larger size of the pilot-scale drying chamber 
increases the amount of time for solvent evaporation from these larger liquid drops 
before the particles pass in to the cyclone (Foster and Leatherman, 1995).
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4.4.3 M oisture Content
Moisture loss on drying of pilot-scale spray dried salbutamol:excipient(s) powders was 
determined as detailed in section 2.4.3. Powders were equilibrated at room temperature 
in a dessicator following their transportation from Penwest Pharmaceutical Co., NY, 
USA, where they were manufactured.
Results
The results obtained for moisture loss on drying of pilot-scale spray dried powders are 
















Pilot-Scale Spray Dried Formulation
Figure 4.26 Moisture loss on drying (approx. 1 g to 100°C, for 60 minutes) SB:XG 
and SB:XG:LBG powders manufactured by pilot-scale spray drying of 0.25% (w/w) 
solutions (*SB:XG (1:10) spray dried as 0.2% (w/w) solution), (n = 3).
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Discussion
There were two observable trends in the moisture content of the pilot-scale spray dried 
powders: a) SB:XG powders retained a greater amount of moisture than did those 
containing LBG, and b) powders with a higher drug content appeared to retain less 
moisture than those of lower drug content.
The pilot-scale spray dried powders had been stored in a dessicator, thus they would be 
expected to have equilibrated with their environment (Maa et al., 1998), prior to 
determination of moisture content. The presence of LBG in the spray dried powders 
resulted in less hygroscopic particles than those of spray dried XG alone.
4.4.4 Morphology
Spray dried salbutamol:excipient(s) particles were viewed under a scanning electron 
microscope (SEM) (Jeol JSM-T330, Japanese Electron Optics Ltd.), as described in 
section 2.4.2.
Results
Figures 4.27 to 4.32 show scanning electron photomicrographs of pilot-scale spray dried 
SB:XG and SB:XG:LBG powders (T i^et = 240-250°C, Toutiet = 120-125°C, airflow = 
400 kg/hour, atomiser speed = 60 Hz, and pump = 6.5-8). SB:XG (1:10) shown was 
spray dried as a 0.2% (w/w) solution; all others were 0.25% (w/w).
Discussion
Figures 4.33 and 4.34 are scanning electron photomicrographs illustrating the 
‘contamination’ that was detected during the pilot-scale spray drying of these powders. 
Thread-like material as well as crystalline material (stalactite in appearance) was 
collected amongst most of the pilot-scale spray dried powders. This was most likely to 
be the result of built-up material at the air inlet which had subsequently broken way and 
been carried in the air stream, or alternatively, fibres may have formed as a result of 
insufficient forces present to break up the liquid filament into droplets (Bodemeier and 
Chen, 1988).
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Figure 4.27 SEM image if pilot-scale spray dried SB:XG (1:10).
Figure 4.28 SEM image of pilot-scale spray dried SB:XG (1:50).
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Figure 4.29 SEM image of pilot-scale spray dried SB:XG (1:100).
Figure 4.30 SEM image of pilot-scale spray dried SB:XG:LBG (1:5:5).
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Figure 4.31 SEM image of pilot-scale spray dried SB:XG:LBG (1:25:25).
Figure 4.32 SEM image of pilot-scale spray dried SB:XG:LBG (1:50:50).
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Figure 4.33 SEM image if pilot-scale spray dried SB:XG (1:10), showing 
contamination of the final powder caused by the build-up of material at the air inlet 
inside the chamber.
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Figure 4.34 SEM image if pilot-scale spray dried SB:XG (1:10), showing 
contamination of the final powder caused by the build-up of material at the air inlet 
inside the chamber.
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All of the pilot-scale spray dried powders appeared to have very similar surface 
morphology. The particles were generally fairly irregular in shape as a result of 
collapsed walls. Many of these surface indentations were not as clearly defined as 
others and some particles exhibited visible cracks (Figures 4.28, and 4.31). The 
formation of collapsed particles during spray drying is common and has been previously 
discussed (section 4.2.3).
Particle morphology did not appear to be affected by the variation in drug content of the 
different formulations.
4.4.5 Drug Incorporation
Drug incorporation efficiency of pilot-scale co-spray dried powders was determined as 
detailed in section 2.4.4.
Results
The results for the drug incorporation efficiencies obtained for pilot-scale spray dried 
powders are summarised in Table 4.7.
Discussion
Drug incorporation efficiencies obtained by pilot-scale spray drying are comparable to 
those obtained by bench-scale spray drying (section 4.3.3). The pilot-scale spray dried 
XG:LBG powders appear to be more efficient at incorporating salbutamol than the 
pilot-scale spray dried XG powders alone. This is not a surprising result when we 
consider that XG and LBG interact synergistically to form a gel structure (Kovacs, 
1973; Rocks, 1971), within which the salbutamol will be incorporated.
Greater incorporation efficiency of XG:LBG was not previously observed with the 
bench-scale spray dried powders, however only three bench-scale formulations 
containing XG or XG:LBG were prepared and thus such a trend may have been missed 
as a result of insufficient data.
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Table 4.7
Actual Salbutamol Content (Mean ±SD; n = 10) and Incorporation Efficiencies of 
SB:XG and SB:XG:LBG Powders Spray Dried as 0.25% (w/w) Solutions (Niro 9019), at 
an Tiniet of240-250°C (Toutiet = 120-125°C) Unless Otherwise Stated. Other Spray 
Parameters were Constant: Airflow = 400 kg/hr, Atomiser Speed = 60 Hz (24000 rpm)
and Pump = 6.5-8.
SB Content (%(w/w)) Actual Ratio of Incorporation
Theoretical Actual SB.'Excipient(s) Efficiency(%)
SB:XG
(1 :1 0 ) (0 .2 %) 9.09 5.69 ±2.616 1:17 62.6
SB:XG (1:50) 1.96 1.42 ±0.996 1:69 72.4
SB:XG (1:100) 0.99 0.79 ± 0.459 1:126 79.8
SB:XG:LBG (1:5:5) 9.09 6.82 ± 3.408 1:14 75.0
SB:XG:LBG (1:25:25) 1.96 1.94 ±0.915 1:51 99.0
SB:XG:LBG (1:50:50) 0.99 0.97 ± 0.429 1 : 1 0 2 98.0
4.4.6 Modified Stage 2 TSI Experiments
4.4.6.1 Method
The diffusion experiment method detailed in section 3.3.3.2.2 was followed, with the 
exception that only one gelatin capsule, containing 25 ± 1 mg of spray dried 
salbutamohexcipient powder was discharged during each individual experiment. 
Results were obtained using both the manual sampling technique (as used with all 
bench-scale processed powders) and the automated sampling technique (section 




Dry powder fractions (Tables 4.8 and 4.9) were calculated using equations 3.2 to 3.4 
(section 3.3.3.1).
Drug Release Across Modified Stage 2 TSI Sinter
Figures 4.35 and 4.36 illustrate the average time to release 50%, 75% and 100% 
salbutamol across the modified stage 2  sinter obtained for each of the 
salbutamol:excipient(s) powders following manual sampling and automated sampling, 
respectively.
4.4.6.3 Discussion and Conclusions
Though the trend in the results obtained for the different pilot-scale spray dried 
formulations is the same, there is a very marked difference in the apparent controlled 
release efficiency of the different formulations, as determined by diffusion across the 
modified stage 2 sinter, depending on the sampling technique used. Results obtained 
using automated sampling suggest that the time over which salbutamol is released is far 
greater, for each of the formulations, than when they were tested using manual 
sampling. The most likely explanation for this observation is the introduction of fresh 
distilled water after each sample is removed by the manual sampling technique used. 
This would undoubtedly serve to dilute the contents of the reservoir after each sample is 
taken, reducing the concentration gradient and thereby increasing the diffusion rate of 
the salbutamol from the powder into the reservoir. In contrast, there is no removal or 
addition of solvent during analysis with the automated sampling technique as the flow­
through cell enables constant re-circulation of the contents of the reservoir.
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Table 4.8
Average Dry Powder Fractions Obtained for Each o f the Pilot-Scale Spray Dried 
Formulations Tested Using the Modified Stage 2 TSI with the Manual Sampling 
Technique, (Mean (%) ±SD; n = 3).
RD ED FPF
SB:XG (1:10) 86.1 ±3.051 76.7 ±2.816 17.1 ±2.991
SB:XG (1:50) 81.6 ±1.845 79.2 ±1.778 19.5 ± 1.388
SB:XG (1:100) 77.5 ±4.290 76.1 ± 1.079 16.9 ± 1.990
SB:XG:LBG (1:5:5) 84.6 ±4.518 72.8 ±4.011 21.7 ±2.790
SB:XG:LBG (1:25:25) 79.8 ± 2.084 74.3 ±2.219 21.8 ± 1.546
















Pilot-Scale Spray Dried Fornulation
Figure 4.35 Mean time to 50%, 75% and 100% drug release of pilot-scale spray dried 




Average Dry Powder Fractions Obtained for Each of the Pilot-Scale Spray Dried 
Formulations Tested Using the Modified Stage 2 TSI with the Automated Sampling
Technique, (Mean (%) ±SD; n = 3).
RD ED FPF
SB:XG (1:10) 87.9 ± 1.457 77.7 ± 1.818 15.6 ±3.324
SB:XG (1:50) 84.7 ± 2.996 82.4 ±1.286 18.1 ±2.752
SB:XG (1:100) 78.2 ± 5.252 73.6 ±5.882 16.2 ± 2.223
SB:XG:LBG (1:5:5) 79.5 ±1.600 74.0 ± 2.790 20.3 ± 5.535
SB:XG:LBG (1:25:25) 78.5 ± 5.667 71.8 ±0.681 15.7 ±3.432



















Pilot-Scale Spray Dried Fornulation
Figure 4.36 Mean time to 50%, 75% and 100% drug release of pilot-scale spray dried 
powders tested using the modified stage 2 TSI with the automated sampling technique, 
(n = 3).
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Time to 100% release of salbutamol increased as the drug content decreased for the 
SB:XG formulations, though not necessarily reflected by corresponding times to 50% 
and 75% release. Although these times to 100% release are not markedly different for 
the SB:XG formulations, there is a noticeable trend when compared with the 
SB:XG:LBG formulations. Results obtained for the latter, using either technique, did 
not appear to reveal any differences in release rates observed, regardless of drug 
content.
The ability of XG to behave as a controlled release matrix for tablet formulations, both 
alone and in combination with LBG, has been established (Challinor, 1996). However, 
in such tablet formulations, the presence of LBG results in a more efficient controlled 
release system, and XG alone allows the drug to escape at a much faster rate. It is 
postulated that dissolution was slower from the combination owing to the formation of 
bonds between the two gums thus resulting in a firmer, resilient gel structure (Challinor, 
1996). From the results obtained following deaggregation and deposition in the 
modified stage 2 , it would appear that the formation of this gel does not take place in 
the same way as it does with tablet formulations. The individual particles are perhaps 
not in close enough contact as a result of being deaggregated and dispersed and owing 
to the small mass of powder deposited on the stage 2  sinter, as they would be in a tablet 
formulation. The small particle size of the spray dried powders may also be a 
contributing factor.
It is apparent that the properties of a tablet formulation will not necessarily be reflected 
when even the same excipients are formulated and delivered in a different way, thus 
demonstrating the need for accurate in vitro means of analysing these properties which 
reflects, as near as possible, the characteristics which will be achieved in vivo. The 
effect of a larger powder mass, in which particles would be in close contact, on the 
dissolution rate of salbutamol from each of the pilot-scale spray dried powders was 
investigated to assess the hypothesis that these factors affected drug release (section 
4.4.7 below).
Dry powder fractions obtained using the modified stage 2 TSI were reproducible 
(Tables 4.8 and 4.9). Total recovered dose values were lower than those obtained with 
conventional formulations, but this is not surprising due to the nature of the powder
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formulations tested here. When wetted, the powders formed gels that were difficult to 
dissociate from the glassware as they dissolved only very slowly. As a result, some 
salbutamol may have remained trapped in such deposits, resulting in lower recoveries 
than usual. Emitted doses are low due to a large proportion of powder being retained in 
the device; nevertheless, the values obtained were reproducible.
4.4.7 Bulk Powder Diffusion Experiments
Figure 4.37 illustrates the apparatus that was designed to assess the drug release from 
bulk powder samples across a PI sintered disc (University of Bath glass-blowing 
workshop, Bath, UK). The complete apparatus was placed on a magnetic stirrer 
(Heidolph™ MR3000, Heidolph Elektro GmbH & Co., KG, Kelheim, Germany) so that 
the contents of the reservoir could be stirred at a constant rate of 500 rpm.
Figure 4.37 Testing apparatus for assessment of drug release from bulk powder 
samples, a) Sampling port (inlet); b) Sampling port (outlet); c) Plain, PTFE 
encapsulated magnetic follower, 25 mm length x 6  mm width (Jencons (Scientific) Ltd., 




The apparatus (Figure 4.37) was connected to the spectrofluorimeter for automated 
sampling at 10-minute intervals (section 2.5.2.2). The reservoir held 195 ml of distilled 
water, with the sinter just wetted. 5 mg of the pilot-scale spray dried formulation being 
tested was placed in the centre of the top surface of the PI sintered disc, as a bulk 
powder sample, using a metal spatula. The magnetic stirrer and timer were then 
activated simultaneously. Each formulation was tested at least three times to obtain 
concordance.
4.4.7.2 Results
Figure 4.38 illustrates average drug release profiles obtained from bulk powder samples 
of pilot-scale spray dried SB:XG powders and Figure 4.39 illustrates those obtained 
from pilot-scale spray dried SB:XG:LBG powders.
4.4.7.3 Discussion and Conclusions
Figures 4.38 and 4.39 illustrate that when drug release characteristics were assessed 
from bulk pilot-scale spray dried powder samples, the differences in the formulations 
were more apparent than when these powders were previously tested using the modified 
stage 2 TSI apparatus (section 4.4.6).
If we consider that the 1:100 salbutamol:excipient(s) formulations contain 
approximately 1% drug, the 1:50 formulations contain approximately 2% drug and the 
1:10 approximately 9%, then the difference in drug release from the different 
formulations is represented clearly using this method to test bulk powder release 
characteristics. The 1:10 formulations release faster than the other two formulations, as 
would be expected, and the difference between the 1:50 and 1:100 formulations is not as 
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Figure 4.38 Average release profiles for 5 mg bulk powder samples of pilot-scale 
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Figure 4.39 Average release profiles for 5 mg bulk powder samples of pilot-scale 
spray dried SB:XG:LBG (1:5:5) (■), SB:XG:LBG (1:25:25) (•)  and SB:XG:LBG 
(1:50:50) (A), (n = 3).
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The release profiles are different for the SB:XG and SB:XG:LBG powders, and it 
would appear that the presence of LBG results in a slower release of salbutamol across 
the PI sinter. This difference is most pronounced for the 1:50 and 1:100 formulations 
which have released 27% and 23% respectively, after 500 minutes, when LBG was 
included in the formulations, compared to 41% and 38% when there was no LBG 
present. This suggests that gel-formation between the XG and the LBG may be taking 
place, causing the observed differences, with the bulk pilot-scale spray dried powders.
The distribution of the powder initially placed on the sintered disc was not investigated 
as part of this study. It is anticipated that different release profiles would have been 
obtained if the distribution had been varied, owing to differences in subsequent gel 
formation properties and changes in surface area available for drug release to occur. 
The results obtained for experiments performed with bulk powder samples in this study 
do, however, confirm that drug release characteristics will vary depending on the type 
of formulation and how it is delivered.
4.5 Conclusions
Properties of spray dried materials, such as particle size, morphology and residual 
moisture content have been shown to vary depending upon the nature of the material, 
and upon various spray drying parameters.
For example, bench-scale spray drying parameters that were suitable for processing 
most of the polymeric excipients investigated during this study were not suitable for 
lactose and trehalose, resulting in very poor recoveries due to losses on the walls of the 
apparatus. The latter materials can, however, be spray dried successfully when 
processed under favourable conditions for these materials; namely, by using higher 
temperatures and higher feed concentrations. Spray dried sugars resulted in far 
smoother and more spherical particles than those of spray dried polymers, which were 
generally observed, by SEM, as being of irregular shape due to indentations in the walls
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of the spray dried particles. Most of the excipients spray dried under the bench-scale 
conditions employed in this study exhibited higher residual moisture contents than the 
respective raw material. Those powders that retained less moisture may be more 
favourable candidates for use in dry powder formulations, both in terms of the physical 
stability of the powder, and the stability of the active ingredient, especially of peptide 
and protein drugs (Hageman, 1992).
Co-spray drying of salbutamol with model excipients resulted in high drug 
incorporation efficiencies with both the bench-scale and the pilot-scale spray dryer used 
in this study. However, differences in the properties of the two sets of powders were 
observed. The degradation of salbutamol as a result of the high processing 
temperatures, together with increased drying times encountered during pilot-scale scale 
spray drying, would suggest that sensitive materials, such as peptides and proteins, 
would also be likely to undergo thermal degradation if they were to be processed under 
the same conditions. Thus, scale-up procedures will require thorough investigation with 
regard to the manufacture of biotherapeutic agents by spray drying.
Model gel-forming excipient(s) have been processed by spray drying to prepare 
powders of an appropriate size for inhalation delivery. The resultant controlled release 
powders have been shown to have different release characteristics following 
aerosolisation, using the novel modified stage 2 TSI, when compared to the bulk 
formulation. This illustrates that differences in the behaviour of such formulations will 
be observed as a function of the method by which they are delivered, and thus the 
importance of accurate in vitro testing methods, which, as closely as possible, reflect 
likely in vivo characteristics.
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CHAPTER 5
Manufacture of Potential Biotherapeutic Pulmonary 
Drug Delivery Systems by Spray Drying
5.1 Introduction
The aim of the work presented in this chapter was to investigate the utilisation of spray 
drying technology to produce respirable protein particles.
Initial studies, performed using protein models, looked at the effect of spray drying at 
different temperatures. As an indicator of protein denaturation and degradation 
occurring due to increasing spray drying temperatures, change in enzyme activity was 
monitored using alkaline phosphatase (AP). Also, the extent of aggregation occurring 
as a result of spray drying at different temperatures was investigated using both AP and 
trypsin.
Enzymes are frequently used as model protein drugs due to the ease with which their 
activity can be determined. However, the extent of activity losses and degradation 
encountered during any process depends upon the protein itself, with some being more 
prone than others (Mumenthaler et al., 1994). Similarly, the protection afforded by 
excipients such as sugars, which are often used to protect proteins in the solid state, is 
dependent upon properties of the protein as well as those of the sugar; combining to 
determine the nature of the protein-excipient interaction which then may or may not 
result in increased stability (Forbes et al., 1998). These observations suggest that it may 
be more beneficial in the long-term to investigate the effects of formulation and 
processing conditions on potential therapeutic proteins rather than on model proteins, as 
each system will require individual characterisation to identify optimal conditions.
There is currently widespread interest in the pulmonary delivery of insulin for the 
treatment of diabetes mellitus (Berelowitz and Becker, 2000; Chetty and Chien, 1998; 
Patton, 1997; Patton and Platz, 1994; Patton et al., 1999; Trehan and Ali, 1998), 
demonstrating encouraging results with respect to fast-acting aerosols. There is still a 
need however, with these formulations, to combine the administration of a slow-acting 
subcutaneous injection in order to provide insulin basal levels (Patton et al., 1999). 
Thus the potential of producing respirable particles of insulin for (controlled release) 
pulmonary delivery by spray drying was investigated in the latter part of this study.
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5.2 Model Proteins
Model proteins, alkaline phosphatase (AP) and trypsin, were spray dried using a bench- 
scale spray dryer (Biichi Mini Spray Dryer, Model B-191, Biichi Labortechnik AG, 
Switzerland) as detailed in section 2.2.1.1. The results obtained for the various 
investigations carried out on the resultant spray dried powders follow.
5.2.1 Particle Size Analysis
Spray dried AP particles were sized using the Mastersizer X (Malvern Instruments Ltd., 
UK) as described in section 2.4.1.
Results
The results obtained for the particle size analysis of powders of AP spray dried at inlet 
temperatures (Tiniet) of 140°C and 180°C are detailed in Table 5.1.
Table 5.1
Average Particle Size Data fo r  AP Powders Spray Dried as 3% (w/w) Solutions in 
Milli-Q Water (Biichi, B-191) as Determined by Dispersion in 0.1% (w/v) Lecithin in 
Cyclohexane (Malvern Mastersizer X,) Following Sonicationfor 1 and 2 Minutes,
(Mean ±SD; n = 3).
T iniet Toutlet Product Mean Equivalent Volume Diameter (fim)
(°C) (°C) yield(%) d ( 0 .1) d (0.5) d (0.9)
1 minute:
2  minutes:
140 95 60 1.24 ±0.085 
0.76 ± 0.010
5.89 ± 0.111 
3.07 ±0.101












It appears that the particle size distribution of AP spray dried at the lower temperature 
(Tiniet= 140°C, Toutiet = 95°C) is smaller than that of AP spray dried at the higher 
temperature (Tiniet = 180°C, Toutiet = 125°C). These results are in agreement with 
findings by Etzel and co-workers (1996) who reported a decrease in volume median 
diameter (VMD) of AP powders spray dried at decreasing outlet temperatures.
The increased tendency to aggregate (section 5.2.4) and agglomerate (Broadhead et al., 
1994) exhibited by powders spray dried at the higher temperature is likely to be 
attributable, at least in part, to the observation that particle size increased as spray 
drying temperature was increased. However, the effect of temperature on particle size 
is generally dependent on the material being dried (Crosby and Marshall, 1958), thus 
this observation is likely to be material and formulation specific.
Particle size distributions obtained after sonicating samples for 1 minute and for 2 
minutes are shown in Table 5.1 to illustrate the difference in the results obtained. A 
sonication time of 2  minutes resulted in noticeably smaller particle size distributions 
than after 1 minute. The sonication process helps to disperse the powder and also aids 
in breaking up agglomerates of particles. It cannot be ruled out that the sonication 
process may also break up protein aggregates formed by the denaturation of the AP 
during the spray drying process, casting doubt on the suitability of this method for 
determining a true representation of the particle size distribution of spray dried powders 
of peptides and proteins; however, this has not been previously demonstrated.
5.2.3 Morphology
Particles were viewed under a scanning electron microscope (SEM) (Jeol JSM-T330, 
Japanese Electron Optics Ltd.), as described in section 2.4.2.
Results
Figures 5.1 and 5.2 show scanning electron photomicrographs of alkaline phosphatase 
before and after spray drying.
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Figure 5.1 SEM image of lyophilised AP -  raw material (LOT 72H70351) as 
supplied by Sigma Chemical Company, St. Louis, MO, USA.
1 0 K U
Figure 5.2 SEM image of bench-scale spray dried AP. 3% (w/w) solution in Milli-Q
water spray dried at Tjniet = 120°C and Toutiet= 80°C.
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Discussion
The walls of the spray dried particles (Figure 5.2) appear to have collapsed inward, most 
likely to have been caused by the rapid evaporation of solvent from the surface of the 
particles (Bittner and Kissel, 1999; Maa et al., 1997).
Etzel and co-workers (1996) have described particle morphologies exhibited by AP 
powders spray dried at different temperatures. They observed that the highest inlet 
temperature had the largest concentration of particles that appeared spherical, and that 
there was an increase in the number of particles that were caved-in and in the depth of 
the indentations in the particles as the outlet temperature decreased. They also noted 
evidence of broken and hollow particles at all temperatures.
All spray dried proteins do not exhibit the same morphologies as have been described 
above. For example, Maa and co-workers (1997) observed the opposite effect on 
morphology of spray dried proteins caused by changes in processing temperatures; that 
is, they noted a significant change in particle shape from irregular to spherical as the 
outlet temperature was decreased. In addition, they observed that while spray dried 
particles of recombinant human deoxyribonuclease (rhDNase) and recombinant-derived 
humanized anti-IgE monoclonal antibody (rhuMAb) had smooth surfaces, they 
exhibited different shapes -  the rhDNase particles were spherical and the rhuMAb 
particles were deformed. They also noted that spray dried bovine serum albumin (BSA) 
particles had a wrinkled, or raisin-like, surface morphology.
The differences which are observed in particle morphology of spray dried proteins 
implies the need to investigate how the morphology of specific protein drugs will be 
affected as a result of spray drying process conditions.
5.2.4 Protein Aggregation
The method used to investigate the degree of aggregation occurring as a result of spray 
drying proteins at different temperatures is detailed in section 2.5.4.
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Results
Results obtained for AP (Figure 5.3) and trypsin (Figure 5.4) are expressed as the mean 
OD/mg detected due to turbidity of reconstituted spray dried samples over the UV range 
340-360nm.
Discussion
Turbidity of both reconstituted AP and trypsin samples increased as the spray drying 
temperature was increased. This can be attributed to the increase in protein aggregation 
occurring as a result of protein degradation and denaturation caused by increasing spray 
drying temperatures investigated in this study. However, high temperature is often not 
the sole cause of protein degradation and surface denaturation at the air-liquid interface 
of the droplets in the spray may also be implicated in the formation of insoluble 
aggregates (Mumenthaler et al., 1994).
Formation of aggregates during spray drying in the case of AP does not imply a direct 
correlation with loss of activity. For example, although aggregate formation is observed 
when AP was spray dried at Tiniet = 140°C (Figure 5.3), the same sample was found to 
retain 100% activity (Figure 5.5). It is possible that aggregate formation may be 
reversible upon reconstitution and the losses in activity observed at the higher spray 
drying temperatures may thus be due to other non-reversible denaturation processes.
In such cases where aggregation is mainly induced by surface denaturation, the 
formation of aggregates can be significantly reduced by the addition of a surfactant to 
the formulation, which presumably migrates preferentially to the air-liquid interface of 
the droplets in the spray, thereby reducing the exposure of the protein (Mumenthaler et 
al., 1994).
It can be seen from these results that although the trend was the same for both models 
employed in this investigation, the degree of aggregation occurring was not identical, 
thus supporting the argument that the extent of degradation encountered during the 





Figure 5.3 Degree of protein aggregation observed as a result of bench-scale spray 
drying of 3% (w/w) solutions of AP in Milli-Q water at increasing inlet temperatures.
120 150
Inlet Temperature (°Q
Figure 5.4 Degree of protein aggregation observed as a result of bench-scale spray 
drying of 3% (w/w) solutions of trypsin in Milli-Q water at increasing inlet temperatures.
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5.2.5 Determination of Enzyme Activity
The Sigma Quality Control Test Procedure for the Enzymatic Assay of Alkaline 
Phosphatase (Glycine and Zinc Assay), as detailed in section 2.5.5.1 was used 
determine loss of activity of AP as a result of the spray drying process.
Results
The results obtained for the loss of activity of AP at different spray drying temperatures 
are illustrated in Figure 5.5.
Discussion
As all other spray drying parameters were kept constant, an increase in the Tiniet resulted 
in an increase in the T 0Uuet during these experiments. Figure 5.5 shows clearly that there 
was a greater loss of activity of AP observed as a result of spray drying at higher 
temperatures.
Inlet Temperature (°Q
Figure 5.5 Percentage activity loss of AP observed after bench-scale spray drying of 
3% (w/w) solutions of the enzyme in Milli-Q water, at increasing inlet temperatures.
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Similar effects have been demonstrated by Adler and Lee (1999) who found that low 
Tiniet produced the least measurable effect on lactate dehydrogenase (LDH) inactivation 
and by Labrude and co-workers (1989), who observed an increase in the formation of 
methaemoglobin as a consequence of increased Tiniet when they spray dried 
haemoglobin; thus it is recognised that spray drying temperature is an important 
consideration when producing particles for inhalation where activity should be retained.
The extent of activity loss seen here for AP, however, is specific to this enzyme under 
the spray drying conditions employed in this study and activity losses encountered by 
different proteins under the same process conditions are likely to vary, depending on the 
inherent thermo lability of the protein in question.
5.3 Insulin
Insulin was spray dried using a bench-scale spray dryer (The Biichi Mini Spray Dryer, 
Model B-191 (Biichi Labortechnik AG, Switzerland) as detailed in section 2.2.1.1. In 
addition, insulin was co-spray dried with lactose and with xanthan gum (XG) as 
insulimexcipient ratios of 1:10 and 1:100, as detailed in section 2.2.1.3. The results 
obtained for the various investigations carried out on the resultant spray dried powders 
follow.
5.3.4 Particle Size Analysis
Spray dried insulin particles and co-spray dried insulimexcipient particles were sized 
using the Mastersizer X (Malvern Instruments Ltd., UK) as described in section 2.4.1.
Results
The results for the particle size analysis of spray dried and co-spray dried insulin 
powders are detailed in Tables 5.2 and 5.3, respectively.
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Table 5.2
Average Particle Size Data fo r  Insulin Powders Spray Dried as 1% (w/w) Suspensions in 
Milli-Q Water (Biichi, B-191), as Determined by Dispersion in 0.1% (w/v) Lecithin in 
Cyclohexane (Malvern Mastersizer X) Following Sonication fo r  2 Minutes,
(Mean ±SD; n = 3).
T in iet Toutlet Product Mean Equivalent Volume Diameter (/im)
(°C) (°C) yield (%) d (0.1) d (0.5) d (0.9)
110 73 18 2.92 ± 0.074 11.5 ±0.199 19.3 ±1.189
140 97 23 2.87 ± 0.023 11.3 ±0.064 18.4 ±0.172
170 118 26 2.91 ±0.031 11.6 ±0.161 18.8 ±0.376
200 140 10 2.78 ± 0.056 11.3 ±0.541 18.1 ±2.188
Table 5.3
Average Particle Size Data fo r  Insulin:Excipient Powders Co-Spray Dried as 1% (w/w) 
Solutions in Milli-Q water (Biichi, B-191), as Determined by Dispersion in 0.1% (w/v) 
Lecithin in Cyclohexane Following Sonication fo r  2 Minutes, (Mean ±SD; n — 3).
T in iet Toutlet Product Mean Equivalent Volume Diameter (/im)
(°C) (°C) yield (%) d (0.1) d (0.5) d (0.9)
INS:LAC 110 73 27 1.53 ±0.021 3.98 ±0.157 12.3 ± 1.994
(1:10) 140 97 30 1.60 ±0.075 4.32 ±0.453 10.8 ±0.832
170 117 47 1.45 ±0.015 3.05 ± 0.036 7.59 ± 0.669
INS:LAC 110 73 13 1.41 ±0.035 4.39 ± 0.534 31.3 ±24.73
(1:100) 140 97 24 1.49 ± 0.042 4.80 ± 0.737 36.0 ±12.81
170* 117 25 32.6 ± 7.792 113 ±13.48 169 ±1.935
INS:XG 110 73 18 1.65 ±0.050 4.28 ± 0.329 28.5 ±20.41
(1:10) 140 97 24 1.62 ±0.025 4.30 ± 0.235 16.2 ±3.862
170 117 31 1.80 ±0.026 5.54 ± 0.069 15.8 ± 1.295
INS:XG 110 73 12 1.66 ±0.010 3.90 ±0.010 13.2 ±0.499
(1:100) 140 97 14 1.84 ±0.040 5.40 ±0.198 19.9 ± 3.094
170 117 21 2.93 ± 0.050 12.1 ±0.133 23.5 ±1.193
*Spray dried material solidified upon storage (desiccated using silica gel crystals at 2- 
8°C), and was not broken up following sonication fo r  3 and 5 minutes.
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Discussion
The presence of agglomerated spray dried particles may have skewed the particle size 
distributions that were obtained (Table 5.2). However, the suspected agglomerates were 
still present after sonicating samples for 3 and 5 minutes, suggesting that the particle 
size distributions of the spray dried insulin powders were in fact greater than AP and 
other materials spray dried during this study.
The particle size results obtained for the spray dried insulimexcipient powders (Table 
5.3) also indicated a wide particle size distribution of these powders, perhaps due to the 
presence of agglomerates which were not broken-up by the sonication process.
The particle size distributions and the VMD of the insulin excipient powders are 
generally smaller than those of the spray dried raw material alone. This might suggest 
that the wide distributions are the result of aggregates of insulin rather than 
agglomerates of particles, and that the presence of these aggregates is less due to 
stabilisation of the protein when spray dried with lactose or XG. Another explanation 
might be the fact that the insulin alone was spray dried from suspension, due to its poor 
water solubility, whereas the incorporation of excipients had resulted in a solution feed 
with lactose, and a very viscous gel-like feed with XG. The solubility and stability of 
insulin solutions can be influenced by the incorporation of additives, by agitation, 
temperature, pH, and insulin concentration (Quinn and Andrade, 1983). It is 
conceivable that the presence of excipients such as XG or lactose may lead to insulin- 
excipient interactions occurring, thereby minimising or preventing self-association and 
aggregation of the insulin molecules.
INS:LAC (1:100) powders spray dried at 170°C resulted in particle sizes which were 
very different when compared with the other powders. Unfortunately, these powders 
were not sized immediately after collection from the spray dryer. During storage 
(desiccated using silica gel crystals at 2-8°C) this formulation in particular formed large, 
solidified agglomerates which were crystalline in appearance.
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5.3.5 Morphology
Particles were viewed under a scanning electron microscope (Jeol JSM-T330, Japanese 
Electron Optics Ltd.), as described in section 2.4.2.
Results
Figures 5.6 to 5.9 show scanning electron photomicrographs of insulin before and after 
spray drying at different temperatures. Figures 5.10 to 5.13 show scanning electron 
photomicrographs of co-spray dried insulin, with lactose and XG.
Discussion
The SEM images of spray dried insulin powders (Figures 5.7 to 5.9) show particles of 
very similar morphology to the raw material (Figure 5.6). This is most likely due to the 
raw material being spray dried from a suspension and not from a solution (Wan et al., 
1992). The raw material used here is purified from an ethanol/phosphoric acid extract 
of bovine pancreas by multiple ammonium sulfate and isoelectric precipitations, and 
then crystallized without zinc, followed by crystallization with zinc. It is these crystals 
that are shown in the SEM images. Interestingly, in the sample spray dried at Tmiet = 
200°C, the presence of random, non-crystalline particles can be noted, which suggests 
that a small proportion of the feed may actually have been in solution when spray dried.
In contrast, particles of spray dried INS:LAC have a completely different appearance to 
insulin particles spray dried alone. In addition, there is a difference in morphology of 
INS:LAC particles spray dried at different temperatures. At lower temperatures, (Tiniet 
= 110°C, Figure 5.10) the particles are smooth and spherical, but at higher temperatures, 
(Tiniet = 170°C, Figure 5.11), many of the particles are totally collapsed with a shrivelled 
appearance and very irregular in shape, with only very few small particles that appear to 
be smooth and spherical. Spray dried INS:XG powders exhibited a wide distribution of 
particle sizes and morphologies (Figures 5.12 and 5.13). The larger particles appeared 
quite smooth and spherical, whereas smaller particles were more deformed with 
collapsed walls. The effect of spray drying at higher temperatures did not appear to be 
as noticeable when insulin was spray dried with XG compared to lactose.
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Figure 5.6 SEM image of insulin, from bovine pancreas. Raw material (LOT 
88H1307) as supplied by Sigma Chemical Company, St. Louis, MO, USA.
1 0 K U
Figure 5.7 SEM image of bench-scale spray dried insulin. 1% (w/w) suspension in
Milli-Q water spray dried at an T^et of 110°C.
Figure 5.8 SEM image of bench-scale spray dried insulin. 1% (w/w) suspension in 
Milli-Q water spray dried at an Tiniet of 170°C.
Figure 5.9 SEM image of bench-scale spray dried insulin. 1% (w/w) suspension in
Milli-Q water spray dried at an Tiniet of 200°C.
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Figure 5.10 SEM image of bench-scale spray dried INS:LAC (1:10). 1% (w/w) total 
solids concentration in Milli-Q water, spray dried at an Tiniet of 110°C.
Figure 5.11 SEM image of bench-scale spray dried INS:LAC (1:10). 1% (w/w) total
solids concentration in Milli-Q water, spray dried at an Tiniet of 170°C.
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Figure 5.12 SEM image of bench-scale spray dried INS:XG (1:10). 1% (w/w) total 
solids concentration in Milli-Q water, spray dried at an Tiniet of 110°C.
Figure 5.13 SEM image of bench-scale spray dried INS:XG (1:100). 1% (w/w) total
solids concentration in Milli-Q water, spray dried at an Tiniet of 110°C.
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5.3.6 Protein Aggregation
The method used to investigate the degree of aggregation occurring as a result of spray 
drying insulin is detailed in section 2.5.4.
Results
Figure 5.14 illustrates aggregation of insulin observed after spray drying at different 
temperatures. Results obtained are expressed as the mean OD/mg detected due to 
turbidity of reconstituted spray dried insulin samples, over the UV range 340-360nm.
Discussion
Figure 5.14 shows clearly that the degree of aggregation caused by increased inlet 
drying temperature is not as marked for insulin as was previously noted for both of the 
model proteins, AP and trypsin (Figures 5.4 and 5.5, respectively). It can be concluded 
once again, that the extent of protein aggregation occurring as a result of spray drying is 
dependent upon the nature of the protein itself, and that a true representation cannot be 
achieved with the use of protein models.
140 170
Inlet Temperature (°Q
Figure 5.14 Degree of protein aggregation observed as a result of spray-drying 
suspensions of 1% (w/w) insulin in Milli-Q water at increasing inlet temperatures.
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5.3.7 Activity Assay
Assessment of insulin activity was performed by the specific detection of 
phosphorylated protein(s), activated downstream of the insulin cell-signalling pathway, 
using the procedure of sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) as described in section 2.5.5.2.
Results
Figures 5.15 to 5.17 illustrate the results obtained for the activity assay of insulin 
performed after spray drying at increasing temperatures, and after co-spray drying with 
excipients (lactose or XG).
Discussion
This method of determining insulin activity is limiting in that the extent of activity loss 
occurring as a result of processing conditions cannot be determined, and the results are 
purely qualitative. However, it is suitable for initial determination in vitro as to whether 
or not the resultant spray dried insulin powders will be of any therapeutic value.
Most commonly used methods in the literature, for the assessment of biological activity 
retention of insulin powders prepared for inhalation, have been combined with its 
administration to the lungs and involve the monitoring of blood glucose levels in rats 
(Liu et al., 1993), rabbits (Colthorpe et al., 1992), or guinea pigs (Kawashima et al., 
1999), generally by direct intratracheal instillation or by aerosol administration of the 
insulin in some cases. The difficulties and inconsistencies encountered with such 
animal studies (Farr and Taylor, 1997; Patton et al., 1999), in addition to the 
unavoidable differences in size and aerodynamic properties of the human airways 
compared to those of an animal model (Zeng et al., 1995a), have resulted in there being 
more human data available than animal data with respect to insulin delivery by 
inhalation (Patton and Platz, 1994). This then exemplifies the need to determine 
whether or not the insulin has retained biological activity following any manufacturing 
method(s) that might have been employed, prior to its administration to human subjects. 
Denaturation resulting in an altered form of the insulin molecule is likely to carry a
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greater possibility of allergic response in individuals following administration to the 
lung as has been demonstrated with subcutaneous injection therapy (Ratner et al., 1990).
Insulin binds to the insulin receptor, thereby activating its intrinsic protein kinase 
function. This activation results in receptor autophosphorylation on several tyrosine 
residues, which in turn enhances the ability of the receptor to phosphorylate tyrosine 
residues on other target proteins (Stryer, 1988). This ability of insulin to induce 
tyrosine phosphorylation of proteins was assessed by immunoblotting with anti- 
phospho-tyrosine antibodies (Welhamet al., 1995). Thus, the bands seen in Figure 5.15 
are the result of immunoprecipitation of such tyrosine-phosphorylated proteins, 
indicative of active insulin having bound its receptor. Inactivated insulin would not be 
able to bind the receptor and hence there would be no observable response.
The bands seen in Figures 5.16 and 5.17 are the result of the immunoprecipitation of 
phosphorylated protein kinase B (PKB) by anti-phospho-PKB antibodies. Figure 5.18 
illustrates the importance of PKB activation (by phosphorylation; Cohen, 1999a; Cross 
et al., 1995) in the mediation of many of the metabolic effects of insulin, the principle 
ones being the regulation of nutrient uptake (glucose, amino acids, fatty acids) and the 
production of storage macromolecules (protein, glycogen, triglycerides) by muscle, liver 
and adipose tissue. Recognition of the insulin molecule by its receptor is essential for 
signal transmission (Kahn, 1997), and hence the subsequent manifestation of these 
metabolic effects.
Once again, inactivated insulin will not bind its receptor, hence the signal transduction 
pathway will not be initiated and the phosphorylation of PKB would not be observed. 
The complex molecular mechanisms thought to be involved in the insulin signalling 
pathway are beyond the scope of this study, but have recently been reviewed by Cohen 
(1999a) and by Taha and Klip (1999).
The bands obtained due to phosphorylated tyrosine residues (Figures 5.15) and the 
bands obtained due to phosphorylated PKB (Figure 5.16) in both instances are very 
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Figure 5.15 Induction of tyrosine phosphorylation in FD-6 myeloid cells by insulin 
as lyophilised raw material (control), and after spray drying 1% (w/w) solutions at inlet 
temperatures of 110°C and 200°C (Biichi B-191 Mini Spray Dryer; airflow = 6001/hr, 
aspirator = 100% and feed rate = 5 ml/min). D represents stimulation with a physically 
denatured sample of insulin (by heating in a water bath), and U represents untreated 
cells. All cells were treated with the respective insulin sample (at 0.1, 0.5 and 1.0 
/xg/ml) for 2 minutes following a 1-hour period of factor deprivation. All samples were 
separated by SDS-PAGE and immunoblotting was performed with 4G10 anti-phospho- 
tyrosine antibodies. Blots were developed for 1 minute (A) and 5 minutes (B). The 
position of molecular mass standards are shown and expressed in kDa.
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Figure 5.16 Induction of PKB phosphorylation in FD-6 myeloid cells by insulin as 
lyophilised raw material (control), and after spray drying 1% (w/w) solutions at inlet 
temperatures of 110°C and 200°C (Biichi B-191 Mini Spray Dryer; airflow = 6001/hr, 
aspirator = 100% and feed rate = 5 ml/min). D represents stimulation with a physically 
denatured sample of insulin (by heating in a water bath), and U represents untreated 
cells. All cells were treated with the respective insulin sample (at 0.1, 0.5 and 1.0 
/tg/ml) for 2 minutes following a 1-hour period of factor deprivation. All samples were 
separated by SDS-PAGE and immunoblotting was performed with 9270 anti-phospho- 
PKB antibodies. Blots were developed for 1 minute (A) and 5 minutes (B). The 
position of molecular mass standards are shown and expressed in kDa.
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Figure 5.17 Induction of PKB phosphorylation in FD-6 myeloid cells by insulin after 
co-spray drying 1% (w/w) solutions with lactose (A) and with XG (B), at inlet 
temperatures of 110°C, 140°C and 170°C (Biichi B-191 Mini Spray Dryer; airflow = 
6001/hr, aspirator = 100% and feed rate = 5 ml/min). All cells were treated with the 
respective insulin sample (at 0.5 and 1.0 /xg/ml) for 2 minutes following a 1-hour period 
of factor deprivation. All samples were separated by SDS-PAGE and immunoblotting 
was performed with 9270 anti-phospho-PKB antibodies. Blots were developed for 5 
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Figure 5.18 Schematic diagram illustrating how insulin controls cell metabolism 
(from Cohen, 1999b). Insulin binds to the insulin receptor, thereby activating its 
intrinsic protein kinase function, allowing it to phosphorylate itself. This enables it to 
bind to and phosphorylate the insulin receptor substrates (IRS), which, in turn, recruit 
the enzyme phosphatidylinositol 3-kinase (PI3K) to the cell membrane. PI3K converts 
the membrane lipid phosphatidylinositol (4,5) bisphosphate (PIP2) to 
phosphatidylinositol (3,4,5) trisphosphate (PIP3). PIP3 then binds to 3- 
phosphoinositide-dependent protein kinase-1 (PDK1) and protein kinase B (PKB), 
allowing PDK1 to switch on PKB and other protein kinases. These protein kinases then 
switch many other enzymes on or off, such as the protein kinase glycogen synthase 
kinase-3 (GSK3), and so mediate the effects of insulin on metabolism and gene 
expression; these effects are reversed by phosphatases that dephosphorylate each protein 
(not shown in diagram) and by PTEN, a phosphatase that reconverts PIP3 to PIP2.
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However, the bands obtained for insulin spray dried at an inlet temperature of 220°C are 
noticeably weaker, suggesting a decrease in activity resulting in decreased insulin- 
receptor binding. Nonetheless, these results are encouraging as activity appears to be 
unaffected when insulin was spray dried at 110°C, and even at 200°C there is evidence 
of some activity being retained when the cells were stimulated with the higher 
concentration of insulin. Furthermore, the quantifiable nature of method is 
demonstrated, with the intensity of the band corresponding to the degree of insulin 
activity retention.
The possibility that changes in the secondary structure of the hormone might have 
occurred, even at the lower processing temperatures, which were then reversible upon 
reconstitution cannot be precluded. Such an observation has been made by Yeo and co­
workers (1994) and also by Winters and co-workers (1996), following the precipitation 
of insulin in supercritical carbon dioxide. In these studies mentioned, Raman 
spectroscopy techniques were used to provide quantitative estimates of the secondary 
structure contents of both solid and solution phase protein samples. Despite extensive 
perturbations seen in the spectra, the insulin powders recovered essentially full 
biological activity upon reconstitution in normal saline, as determined by animal tests; 
blood glucose levels of rats was monitored by tail vein sampling using a commercial 
glucose meter (Yeo et al., 1993).
Figure 5.17 illustrates that INS:LAC and INS:XG powders spray dried at inlet 
temperatures of 110°C, 140°C and 170°C have all retained insulin activity. There is no 
apparent effect on this activity as a result of spray drying at the different temperatures 
and a strong signal for phosphorylated PKB is obtained from all the conditions, 
indicating that the active conformation of the insulin was retained upon reconstitution.
From the results presented here, it is difficult to conclusively determine whether the 
inclusion of the excipients in the formulations prior to spray drying did in fact have a 
stabilising effect on the insulin. However, as a reflection on the noticeably weak bands 
obtained when insulin alone was spray dried at Tiniet = 200°C (Figure 5.16), we might 
have expected weaker bands from the powders that were spray dried at Tiniet = 170°C 
(Figure 5.17), especially for the less concentrated 0.5 /xg/ml samples, due to insulin 
denaturation at this high temperature. Thus, it is possible that the presence of lactose or
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XG in the formulation may have helped to preserve insulin activity at high spray drying 
temperatures.
There is an existing debate as to the exact mechanism by which carbohydrates stabilise 
proteins in the solid state (Fox, 1995). The two major mechanisms which have been put 
forward are: a) the ‘water replacement hypothesis’, whereby it is believed that 
carbohydrates form hydrogen bonds with proteins in the solid state (Carpenter and 
Crowe, 1989) which replace the hydrogen bonds that existed between the protein and 
water molecules in the aqueous state that were serving to preserve the native structure of 
the protein; and b) the ‘vitrification’ hypothesis, which suggests that by maintaining the 
protein in an amorphous, glassy matrix, the physical hindrance encountered by the 
protein due to the rigidity of the matrix will prevent it from changing shape, thereby 
stabilising the protein (Franks et al., 1991). In addition, a third effect of adding an 
excipient is the ‘dilution’ effect; it has been shown that the presence of an excipient 
reduces the possibility of protein molecules interacting with one another to form 
aggregates in the solid state (Costantino et al., 1994a).
Recently, Tzannis and Prestrelski (1999) have demonstrated that high concentrations of 
sugar in a protein-sugar system can have a destabilising effect as a result of a phase 
separation within the formulation matrix; preferential sugar-sugar interactions (at high 
concentrations of sugar) form a sugar-rich phase with subsequent decrease in the 
amount of sugar available to interact with the protein. In contrast, at low concentrations 
of sugar, preferential protein-sugar hydrogen bonding interactions were dominant, 
resulting in protein stabilisation. From the results obtained in this study (Figure 5.17A), 
concentrations of lactose that were ten times and one hundred times higher than the 
concentration of insulin did not appear to destabilise the hormone.
Lactose, being a reducing sugar (Wirth et al., 1998), may be unsuitable to protect 
against chemical degradation however, as it has the potential to undergo the Maillard 
reaction (section 4.4.1.1) with proteins while in solution prior to and during drying 
(Naini et al., 1998). Although this type of reaction was not visible in the powders that 
were spray dried during this study, a brown discolouration may develop during storage 
(George et al., 1994), and should not be discounted. In this context, XG may also be a 
potential candidate for Maillard reactions with proteins, and discolouration might also
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be observed in the INS:XG powders upon aging, though not observed during this study. 
Trehalose has been proposed as a more suitable candidate for development of proteins 
for inhalation as it is non-reducing (Wirth et al., 1998). Moreover, trehalose has a high 
glass transition temperature in its dry state and the ability to retain relatively large 
amounts of water without recrystallising (Green and Angell, 1989).
The results obtained in this investigation suggest that the co-spray drying of insulin with 
XG does not have a deleterious effect on insulin activity (Figure 5.17B). There is, 
however, a concern that this might change over time in vivo when a hydrogel excipient 
is included in the formulation. The hydration of the hydrogel and that of the protein 
prior to dissolution and release, in combination with the in vivo temperature of 37°C, 
could result in an undesirable environment with respect to protein stability (Hageman et 
al., 1992). This is especially important for the delivery of insulin as the extent of 
aggregation of lyophilised insulin powders has been directly correlated with water 
uptake (Costantino et al., 1994b). Furthermore, Brown and co-workers (1986) have 
previously demonstrated the instability of insulin in a polymer matrix when exposed to 
elevated levels of temperature and moisture. Thus, the insulin activity of such 
controlled release formulations should ideally be assessed over a suitable time period 
following complete hydration of the hydrogel.
5.3.8 Insulin Release Across PI Sintered Disc
The movement of insulin across a PI sintered disc (as is employed in the modified stage 
2 TSI, section 3.3) and the release of insulin across this disc from co-spray dried 
insulin:excipient powders was investigated to assess the suitability of the modified stage 
2 apparatus for use in the in vitro analysis of protein formulations.
5.3.5.1 Method
The movement of insulin across a PI sintered disc was investigated using the apparatus 
previously described for the assessment of release characteristics from bulk powders
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(Figure 4.37, section 4.3.2.6). Samples were taken manually for determination of 
protein concentration.
5 mg of insulin raw material was placed on to the top surface of the PI sintered disc as a 
bulk powder sample and the magnetic stirrer was started. 5ml of 10 mM Tris buffer 
was added to the reservoir using a 5 ml plastic syringe (B-D Plastipak, Becton 
Dickinson Company, NJ, USA) and needle (B-D PrecisionGlide® Needles 21G2, Becton 
Dickinson Company, NJ, USA). Samples were taken manually, using a fresh syringe 
for each, over a period of 60 minutes, at 5-minute intervals. Immediately after taking 
each 5 ml sample, the same volume was replaced with fresh Tris buffer. Samples were 
stored to one side for subsequent determination of protein concentration using the Bio- 
Rad Protein Assay (section 2.5.3.2). Each experiment was repeated three times to 
obtain concordance. 5 mg of spray dried insulin (Tiniet = 110°C), and 50 mg of co-spray 
dried insulin with lactose and insulin with XG (both 1:10, Tiniet = 110°C) were all tested 
in the same way.
5.3.5.2 Results
Figures 5.19 and 5.20 illustrate the results obtained for the raw material and for spray 
dried insulin, respectively. Figures 5.21 and 5.22 illustrate the results obtained for co­
spray dried INS:LAC (1:10) and INS:XG (1:10), respectively.
5.3.5.3 Discussion and Conclusions
The mean times observed for 5 mg of insulin to cross the PI sintered disc were 30 
minutes for the raw material (Figure 5.19) and 26 minutes for the spray dried material 
(Figure 5.20). In contrast, 50 mg of spray dried INS:LAC (1:10) took 8 minutes (Figure 
5.21), and only approximately 30-35% of the total insulin was released from 50 mg of 
the spray dried INS:XG (1:10) formulation after 60 minutes (Figure 5.22). The 60- 
minute duration of these experiments did not allow for 100% release to be achieved 
from the INS:XG (1:10) formulation, which would have been considered to be at the 
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Figure 5.19 Movement of insulin raw material across a PI sintered disc. Run 1 (■), 
run 2 (•)  and run 3 (A) performed using 5 mg bulk powder samples.
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Figure 5.20 Movement of bench-scale spray dried insulin (Tiniet =110 °C) across a PI 
sintered disc. Run 1 (■), run 2 (•)  and run 3 (A) performed using 5 mg bulk powder 
samples.
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Figure 5.21 Release profiles for bench-scale spray dried INS:LAC (1:10, Tiniet = 
110°C), across a PI sintered disc. Run 1 (■), run 2 (• )  and run 3 (▲) performed using 







Figure 5.22 Release profiles for bench-scale spray dried INS:XG (1:10, T^et = 
110°C), across a PI sintered disc. Run 1 (■), run 2 (• )  and run 3 (A) performed using 
50 mg bulk powder samples.
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Lactose appeared to increase the solubility of insulin in water when formulated for co­
spray drying. This could be a factor as to why the time taken for 100% detection is less 
for INS:LAC (1:10) than for the raw material or spray dried insulin alone, although the 
solvent used for these analyses was Tris buffer, in which insulin was more soluble than 
in water.
The gel-forming property of XG upon hydration appears to retard the release of insulin 
in the same manner as has previously been described for salbutamol (sections 4.4.6 and 
4.4.7). The long term stability of a biotherapeutic agent such as insulin prior to release 
from the matrix of a hydrogel excipient will require further investigation; from the 
results obtained in this study, it is not known if the insulin which is detected after 60 
minutes, released from the INS:XG (1:10) formulation, is still biologically active.
Approximately 95-100% of the raw material and spray dried insulin weighed and placed 
onto the sintered disc was recovered, indicating that minimal loss was occurring if at all, 
as small amounts adsorbed to the disc, and/or to the plastic syringes that were used to 
collect samples.
The results obtained during this series of experiments indicate that the PI sintered disc 
is suitable for assessing insulin release from different formulations, with the view to 
compare release rates obtained from different formulations against each other. Thus, 
the modified stage 2 TSI apparatus would be suitable for use with insulin and perhaps 
other protein drugs, to assess the deep lung deposition characteristics and subsequent 
release profiles of potential controlled release formulations, when used in conjunction 
with an appropriate inhalation device.
The Monohaler® device, previously used during this study, is not a suitable device for in 
vitro testing of deposition characteristics of protein formulations owing to the fact that 
the formulation is discharged from gelatin capsules. Gelatin is affected by changes in 
humidity (Kontny and Mulski, 1989), which may in turn affect the stability of a protein 
formulation. The Diskhaler® may be a more suitable device, whereby the protein 
formulation can be individually dosed into the wells of the blistered-disks, and 
subsequently protected from moisture by heat-sealing with aluminium foil (Lucas et al., 
1998). Stability of a protein formulation to the heat-sealing process will, however,
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require investigation, in addition to long-term storage stability and suitability of the 
device, in terms of achieving efficient aerosolisation of a given formulation.
5.4 Conclusions
In summary, it has been demonstrated that the spray drying process yields powders of 
different properties, determined by the nature of the protein and the spray drying 
parameters that are employed, and thus that model proteins may not necessarily reflect 
the behaviour of other protein drugs.
AP, trypsin and insulin all showed an increase in aggregation as the spray drying 
temperature was increased, but to varying extents. In general, the activity of a protein 
drug can be maintained during spray drying if the spray drying parameters are 
favourable, or by the inclusion of excipients that may serve to protect the protein. 
Unnecessarily harsh processing conditions may be detrimental, as would be expected, 
and as was observed in this study when AP and insulin were spray dried at high 
temperatures.
The model gel-forming excipient, XG, used in this study would appear to have the 
potential to be co-spray dried with insulin, resulting in controlled release powders of a 
suitable size-range for inhalation delivery. Other materials may, however, be more 
suited for delivery to the lungs than XG; alternative excipients will require to be 
investigated individually to determine compatibility with insulin, and subsequent 
biocompatibility. Further, insulin:excipient(s) ratios will need investigation to optimise 
powder properties and to achieve therapeutic release of the hormone, over the desired 
period of time. The modified stage 2 TSI apparatus may be used, in conjunction with a 
suitable device, for preliminary investigations to screen potential excipients by 
comparing the release characteristics of different formulations.
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CHAPTER 6
General Discussion and Conclusions
General Discussion and Conclusions
A novel method for the in vitro evaluation of drug release rates from potential 
controlled release powders intended for inhalation delivery has been described. The 
modified stage 1 TSI apparatus has been tested and shown capable of distinguishing 
between release rates from different formulations that may be targeted for bronchial 
deposition, and the modified stage 2 TSI apparatus has been shown capable of 
distinguishing between release rates from different formulations intended for alveolar 
deposition.
The influence of particle size distribution on drug release rates, and thus the need to 
investigate release characteristics from formulations which differ in this respect, has 
been demonstrated; the increase in the surface area of finer particles being in contact 
with the dissolution medium results in faster dissolution, and hence an increase in 
cumulative drug release. Additionally, the feasibility of using gel-forming polymers to 
achieve controlled release inhalation delivery, as has been employed in some studies for 
nasal delivery, has been demonstrated. Biocompatibility and in situ stability of 
potential excipients, in addition to the impact on the stability of the drug product, and on 
the safety and performance of the drug product for the intended patient populations will 
eventually determine the acceptability of such delivery systems (Poochikian and Bertha, 
2000).
As with all in vitro models, the modified apparatuses are simplified representations that 
cannot take into full account the levels of branching of the airways in the human lung, 
or the tissue surfaces that will influence the impaction of any formulation (Tako, et al., 
1984). They can, however, be of valuable use as non-invasive research tools to 
compare and optimise drug release characteristics of potential controlled release 
inhalation therapeutics.
In vitro testing cannot always predict in vivo performance; validation of the final 
product accomplished by in vivo testing in human subjects remains the ultimate test for 
any dosage form (Talukdar et al, 1998). In vivo studies will thus be essential to
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evaluate clinical response, to assess the mode of deposition, the effect of mucociliary 
clearance and most importantly the safety of potential carriers.
Particles of an appropriate size for pulmonary delivery (aerodynamic diameter 1-5 /xm) 
(Gonda, 1992) have been manufactured by spray drying. Co-spray drying of a model 
drug with model gel-forming excipient(s) resulted in potential controlled release 
powders, also of an appropriate size for inhalation. Differences in release 
characteristics have been observed following aerosolisation of these powders when 
compared to the bulk spray dried formulation. These differences were most likely due 
to the small mass of powder and small particle size (< 5 /xm) deposited in stage 2 of the 
modified stage 2 TSI apparatus, and also due to the probable lack of formation of the 
stronger gel (by the interaction of XG and LBG, in this case) as a result of the 
individual particles not being in close enough contact following deaggregation during 
aerosolisation.
Properties such as particle size distribution, morphology and residual moisture content 
of spray dried powders have been shown to differ with respect to the nature of the 
material being spray dried, and with changes in processing parameters. This illustrates 
the need to fully characterise potential excipient properties, and also drug-excipient 
properties, as the use of model compounds will not necessarily reflect the properties 
obtained for all materials. This is especially true for proteins and peptides as some are 
clearly more robust than others and able to withstand more harsher processing 
conditions without any detrimental effect, while others are more sensitive. Optimisation 
of different process parameters for different materials will lead to the optimisation of 
spray drying as a method of manufacturing respirable particles for inhalation delivery.
Concerns with regards to the scale-up of the spray drying process have been 
exemplified by the decomposition of salbutamol that was encountered during pilot-scale 
spray drying in this study. This is in agreement with the findings of other workers 
(Foster and Leatherman, 1995) who have shown that changes in the capacity of the 
spray dryer can yield products with drastically different properties. Undoubtedly, this 
will bear significant consequences for the manufacture of peptides and proteins by spray 
drying, which are generally more likely to be susceptible to degradation and 
denaturation. In addition, product yields obtained after pilot-scale spray drying (30-
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50%), although twice those obtained after bench-scale spray drying of the same 
formulations, were still fairly low in terms of scalability and economic viability of the 
spray drying process. Different materials were shown to vary in terms of product yield 
after spray drying under the same bench-scale conditions, and thus it may be possible to 
achieve higher recoveries for pilot-scale spray drying than those obtained in this study. 
The need to optimise product yield is of greater concern when very low total solids are 
employed in the initial feed concentrations to be spray dried, as poor recoveries will 
result in the collection of only very small masses of powder for each batch that is spray 
dried.
Poor recoveries were a disadvantage of the bench-scale spray dryer under the conditions 
employed in this study, however, lower spray drying temperatures could be used that 
did not result in decomposition of salbutamol, and also maintained the biological 
activity of insulin powders. Furthermore, co-spray drying of insulin with gel-forming 
excipient(s) did not appear to have any detrimental effect on its biological activity; thus, 
this may be a feasible approach to the development of controlled release inhalation 
powders of insulin. A major consideration with such an approach, of course, will be to 
fully assess the safety and the effect on the integrity of lung tissue caused by such 
systems that swell upon hydration in situ.
For the treatment of diabetes mellitus, insulin is presently delivered as a solution, by 
subcutaneous injection, for fast response before meals, and as a suspension of its 
insoluble complex with zinc and/or protamine for long and intermediate action (Brown, 
1998). Despite recent developments in pulmonary delivery of insulin demonstrating 
encouraging results with respect to fast-acting aerosols, there is still a requirement, with 
such formulations, to combine the administration of a slow-acting subcutaneous 
injection in order to provide insulin basal levels (Patton et al., 1999), hence the 
development of a controlled release powder formulation, that may be inhaled to provide 
the insulin basal level in place of the present injection, would be of considerable value. 
Extended-release profiles (Elbert et al., 2000) and sustained insulin plasma levels 
(Patton et al., 1999) have recently been achieved following the administration of large, 
porous particles of insulin to rats.
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CHAPTER 7
Suggestions for Further Work
Suggestions for Further Work
The study presented has provided an insight into the feasibility of co-spray drying gel- 
forming excipients for potential controlled release pulmonary drug delivery, and how 
release profiles from such systems may be assessed in vitro. Thus it is now appropriate 
to consider improvements to and continuation of the various methodologies employed 
in this preliminary study.
To mimic the expected in vivo conditions as closely as possible, the modified TSI 
apparatuses should be used in conjunction with a dissolution medium whose pH has 
been adjusted to 7-7.4, as this will allow physiological comparability (El-Baseir et al., 
1998). Furthermore, the maintenance of this medium at 37°C should also be 
considered, which would involve further development of the modified TSI apparatuses 
to include some form of temperature-regulating mechanism. Temperature and pH can 
affect protein stability, and thus are important considerations for protein drugs, and 
especially those that are intended for controlled release, due to the extended exposure 
that will be encountered by such formulations. In addition, more complete validation of 
the modified TSI apparatuses may involve investigation of the view that different 
release profiles were obtained as a result of differences in the particle size and mass of 
powder deposited. The mass of powder deposited may be varied and subsequent release 
profiles compared and the segregation of particles (using a cascade impactor, for 
example) prior to testing may be attempted to obtain information on the effect of 
particle size of the powders on the release profiles obtained.
Correlation of the in vitro dissolution data with in vivo data for drug products will 
require consideration to determine the ultimate usefulness of the in vitro testing 
methods that have been developed during this study.
Dispersibility of the cohesive pure spray dried particles may be improved by blending 
with coarser carrier particles, and further by the addition of ternary components (Lucas 
et al., 1998). Such blending methods should be investigated as a means to increase 
stage 2 deposition and decrease the amount of spray dried material retained in the
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device and that deposited in stage 1. Lactose (Chan et al., 1997; Lucas et al., 1998), 
mannitol (Broadhead et al., 1996; Chan et al., 1997) or trehalose (Byron et al., 1996) 
may be used as potential carriers for dry powder systems. Of these, the latter two may 
be better in view of the long-term stability of biotherapeutic agents; ‘protected’ proteins, 
however, may not be in direct intimate contact with carrier particles and thus stability 
may not be compromised by the use of a reducing sugar such as lactose. Carrier type 
and drug:carrier ratio will require investigation to achieve optimal dispersibility.
The use of a suitable, non-capsule-based device may then enable the deposition and 
release characteristics of potential controlled release protein inhalation formulations to 
be investigated using the modified TSI apparatuses.
Other excipients should be investigated for potential of co-spray drying with insulin and 
other biotherapeutic agents, to prepare controlled release inhalation powders, as XG 
may not be suitable for delivery to the lungs, with or without LBG. Drug:excipient 
ratios of spray dried formulations will also require optimisation to achieve the desired 
release characteristics. More complete characterisation of resultant powders should be 
attempted where possible. For example, particle size distributions may be determined 
using a cascade impactor or other suitable apparatus that employs time of flight aerosol 
beam spectroscopy, for example. Moisture contents of spray dried powders may be 
more accurately determined by Karl Fischer (KF) titration or by thermogravimetric 
analysis (TGA) coupled with differential scanning calorimetry (DSC). In addition, prior 
to spray drying, the viscosity and surface tension of feeds should be determined, as 
these parameters are known to affect droplet formation during the spraying process 
(Sacchetti and Van Oort, 1996).
Toxicity, biocompatibility and stability of potential excipients, both in situ and during 
storage, will require thorough investigation, especially as many novel candidates may 







A student’s t-Test was used to determine whether the slopes of any given two graphs 
were significantly different in value at the 5% level of significance (i.e. p = 0.05).
In this instance,
with («i + 722 -  4) degrees of freedom,
where Slope\ is the gradient of the first line,
Slopei is the gradient of the second line,
SD\ is the standard deviation of the gradient o f the first line,
SD2 is the standard deviation of the gradient o f the second line,
7ii is the number of points on the first line and 
722 is the number of points on the second line.
To test the null hypothesis, Ho, that there is no significant difference between the two 
slopes at the 5% level, we must:
 ^slope
Slopel -  Slope2
Accept H0 if  t s i o p e  <  P ^ 0.05
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C/f/-Squared Test
To determine the equality of more than two estimates of a parameter (P), the Bartlett 
(C/zz-Squared) Test was used (Richardson, 1973):
A* slo p e  *  2
(7
where <x2 is given by:
a 2 =
nxSDx + 2^*SZ^ 2 
nx + n 2 +
where SDu SD2, etc. are the standard deviations associated with the estimates Pi, P2, 
etc. and ni and n2 are the number of observations used in determining the estimates.
If the estimates all come from the same normal distribution,
Y t f - P ) 2 2
— — -5 ------  will have a x  distribution with N-l degrees of freedom,
a
where N is the number of estimates.
To test the null hypothesis, Ho, that there is no significant difference between the slopes 
at the 5% level, we must:
Accept H0 if  Z siope <  Z d f  at p = 0.05
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Figure B2 IR spectrum of micronised SB (raw material), obtained 
section 2.5.6.1.











Nuclear Magnetic Resonance (NMR) Spectra
Figure C l NMR spectrum of micronised SB (raw material), obtained as detailed in 
section 2.5.6.2
Figure C2 NMR spectrum of bench-scale spray dried SB at Tjniet = 220°C, obtained 
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Figure C3 NMR spectrum of bench-scale spray dried SB :XG (1:10) at Tiniet=l 10°C, 
obtained as detailed in section 2.5.62
JlL.
Figure C4 NMR spectrum o f pilot-scale spray dried SB:XG (1:10) at Tjniet = 250°C, 
obtained as detailed in section 2.5.6.2.
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APPENDIX D
High Performance Liquid Chromatography (HPLC) 
Chromatograms
A  B
Figure D1 HPLC Chromatograms of micronised SB (raw material), obtained at (A) 




Figure D2 HPLC Chromatograms of bench-scale spray dried SB at Tjniet = 110°C, 





Figure D3 HPLC Chromatograms of bench-scale spray dried SB at Tjniet = 220°C, 





Figure D4 HPLC Chromatograms of brown crystals collected from cyclone 
following bench-scale spray dried SB at Tjniet= 220°C, obtained at (A) low (0.1 AUFS) 
and (B) high (0.01 AUFS) sensitivity, as detailed in section 2.5.6.3.
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A B
Figure D5 HPLC Chromatograms of bench-scale spray dried SBXG (1:10) at Tin|et 
= 110°C, obtained at (A) low (0.1 AUFS) and (B) high (0.01 AUFS) sensitivity, as 
detailed in section 2.5.6.3.
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A B
Figure D6 HPLC Chromatograms of pilot-scale spray dried SB:XG (1:10) at Tjn]et = 
250°C, obtained at (A) low (0.1 AUFS) and (B) high (0.01 AUFS) sensitivity, as 
detailed in section 2.5.6.3.
2 2 1
A B
Figure D7 HPLC Chromatograms of 1 mg/ml XG, obtained at (A) low (0.1 AUFS) 
and (B) high (0.01 AUFS) sensitivity, as detailed in section 2.5.6.3.
2 2 2
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